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Abstract	Lysine	 acetylation	 is	 a	 dynamic	 post-translational	 modification	 occurring	ubiquitously	 in	 cells.	 	Histone	deacetylases	 (HDACs)	catalyze	 the	enzymatic	hydrolysis	of	acetyllysine.	 	 There	 are	 18	 HDACs,	 tasked	with	 the	 negative	 regulation	 of	 acetylation	 of	thousands	of	proteins.		It	is	therefore	critical	to	understand	the	reactivity	and	specificity	of	these	enzymes.			To	probe	the	substrate	specificity	of	HDAC	isozymes,	we	developed	and	optimized	a	real-time	enzyme-coupled	assay	 that	measures	deacetylation	via	 the	 formation	of	acetate	and	 two	 mass	 spectrometric	 assays	 that	 measure	 the	 mass	 change	 associated	 with	deacetylation.	 	These	assays	were	used	 to	measure	 the	 reactivity	of	HDAC8	and	HDAC11	with	 a	 variety	 of	 acetylated	 peptides	 and	 inhibitors,	 providing	 insight	 into	 the	 substrate	selectivity.		To	characterize	HDAC11,	we	recombinantly	expressed	a	SUMO-HDAC11	fusion	protein	in	E.	coli	 in	the	presence	of	the	molecular	chaperone	trigger	factor.	 	 Interestingly,	HDAC11	 expressed	 in	 bacteria	 is	 inactive,	 in	 contrast	 to	 the	 catalytically	 active	 HDAC11	expressed	and	purified	from	eukaryotic	cells.		HDAC11	purified	from	insect	cells	catalyzes	deacetylation	 of	 unlabeled	 peptide	 substrates	 and	 demonstrate	 unique	 selectivity	 that	differs	from	HDAC8.		To	identify	protein	substrates,	we	introduced	a	chip-based	proteomics	method	 to	 screen	 the	 reactivity	 of	 HDAC	 isozymes	with	 thousands	 of	 full-length	 human	proteins.	 	 This	 work	 identified	 44	 and	 25	 potential	 HDAC8	 and	 HDAC11	 substrates,	respectively.		These	substrates	were	then	validated	using	peptide	mimics	with	the	enzyme-coupled	 and	 mass	 spectrometric	 assays	 mentioned	 above,	 determining	 rate	 constants	spanning	 three	orders	of	magnitude.	 	Based	on	 these	 results,	 isocitrate	dehydrogenase	1	(IDH1)	 variants	 containing	 single,	 biologically	 relevant	 acetyllysine	 side	 chains	 were	expressed	 and	 purified.	 	 HDAC8	 catalyzes	 the	 deacetylation	 of	 these	 full-length	 protein	substrates	 in	 vitro	 with	 high	 efficiency.	 	 Furthermore,	 the	 acetyllysine	 modifications	decrease	 the	 catalytic	 activity	 of	 IDH1.	 	 Finally,	 the	 first	 HDAC	 prodrug,	 SAHA-TAP,	 is	shown	 to	 covalently	 modify	 a	 conserved	 cysteine	 residue,	 Cys153	 in	 HDAC8,	 leading	 to	irreversible	 inactivation	 and	 simultaneous	 release	 of	 the	 competitive	 inhibitor	 SAHA.		Overall,	 this	work	provides	new	methods	 for	 the	characterization	of	HDAC	reactivity,	 the	identification	 of	 novel	 HDAC8	 and	 HDAC11	 substrates,	 and	 analysis	 of	 HDAC-inhibition.		This	work	provides	a	foundation	for	understanding	disease	states	that	arise	from	aberrant	acetylation	and	deacetylation.	
	 1	
Chapter	1	
Histone	Deacetylases1,2	
Overview	While	the	human	genome	has	roughly	20,000	protein	coding	regions,	the	complexity	of	the	human	proteome	is	much	greater.		This	is	due,	in	part,	to	the	ability	of	cells	to	modify	proteins	after	translation.		These	post-translational	modifications	(PTMs)	are	a	diverse	set	of	chemical	changes	that	alter	protein	structure	and	function.		Many	of	these	modifications	are	 dynamic	 and	 reversible.	 	 PTMs	 include	methylation,	 phosphorylation,	 ubiquitination,	acetylation	and	biotinylation,	among	others.		Some	of	these	PTMs,	such	as	acetylation	and	methylation,	were	originally	identified	as	modifications	on	the	tail	regions	of	core	histone	proteins	where	 they	 function	 to	regulate	access	 to	DNA	through	alterations	 to	chromatin	structure	 (1).	 	 Lysine	acetylation	has	garnered	 increasing	 interest	 in	 recent	years,	with	a	trend	in	publication	rate	that	rivals	that	of	phosphorylation	(2).	A	major	 advance	 in	 the	 acetylation	 field	 has	 been	 the	 transition	 from	 analysis	 of	acetylation	 (hyper-	 and	 hypoacetylation)	 of	 specific	 sites	 in	 histone	 tails	 to	 defining	 and	understanding	 the	 numerous	 proteins	 that	 are	 modified	 through	 acetylation	 events.		Acetylation	 has	 been	 shown	 to	 compete	 and	 cooperate	 with	 other	 PTMs,	 such	 as	ubiquitination	 (3),	 and	 affect	 specific	 protein-protein	 interactions,	 protein	 stability	 and	protein-DNA	 interactions	 (4).	 	 Identifying	 these	 interactions	 will	 lead	 to	 a	 better																																																									1	Reproduced,	in	part,	from	Lopez,	J.		E.,	Sullivan,	E.		D.,	and	Fierke,	C.		A.,	(2016)	Metal-dependent	Deacetylases:	Cancer	and	Epigenetic	Regulators.		ACS	Chem.		Bio.		11,	706-16.			2	Original	text	written	by	Jeffrey	E.		Lopez	and	Eric	D.		Sullivan.		Updated	and	revised	by	Eric	D.		Sullivan.	
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understanding	 of	 the	 acetylome,	 the	 collection	 of	 proteins	 that	 undergo	acetylation/deacetylation,	 and	 the	 role	 of	 acetylation	 in	 cell	 regulation,	 growth	 and	homeostasis	(Figure	1).		
	
Figure	1.1:	Acetylation	is	critical	for	regulation	and	proper	cellular	function.			Lysine	acetyltransferases	(KATs)	and	histone	deacetylases	(HDACs)	maintain	acetylation	at	an	optimal	level.		KATs	 and	 HDACs	 regulate	 essential	 processes	 such	 as	 DNA	 repair,	 chromatin	 and	 actin	 remodeling,	 and	proteins	that	serve	as	checkpoints	during	the	cell	cycle.		Acetylation	 is	 an	 enzymatically-catalyzed	 and	 reversible	 PTM	 in	 which	 an	 acetyl	group	is	added	at	the	Nε-position	of	a	lysine	side	chain.		This	reaction	is	catalyzed	by	lysine	acetyltransferases	(KATs),	using	acetyl-CoA	as	a	cofactor.		The	reverse	reaction,	hydrolysis	of	 acetyllysine,	 is	 catalyzed	 by	 histone	 deacetylases	 (HDACs),	 and	 results	 in	 regenerated	lysine	 and	 free	 acetate.	 	 Traditionally,	 HDACs	 have	 been	 described	 as	 transcriptional	repressors	due	to	their	effect	on	the	recruitment	and	intramolecular	interactions	of	many	proteins,	 including	 bromodomain-containing	 proteins,	 MEF2-binding	 proteins	 and	domains,	 and	 histone	 tails.	 	 They	 also	 aid	 in	 local	 chromatin	 compaction	 (1).	 	 However,	
FDA for the treatment of T-cell lymphomas, and a fourth
inhibitor, Panobinostat (hydroxamic acid), has recently been
approved for multiple myeloma treatment.13
Studies have recently demonstrated that pan-HDACi can
also be used to increase the effectiveness of anticancer
immunotherapy treatments. In one mechanism, T-cell survival
is enhanced due to prevention of activation-induced cell death
by lymphocytes.14,15 However, these effects vary significantly
and can produce a variety of nondesirable side effects as a
consequence. Additionally, HDACi’s have been used to
enhance vaccine strategies; namely, mice vaccinated with
melanoma cells that have been pretreated with trichostatin A
(TSA) show an increase in immune response toward additional
tumors, effectively enhancing their tumor specific immunity
mechanisms.16,17
HDACs are divided into four different classes based on their
sequence homology to yeast orthologs.18 Class I, which shares
homology with Rpd3, consists of HDACs 1, 2, 3, and 8. Class
II, with homology to Hda1, can be divided into two
subclassesIIa (HDACs 4, 7 and 9) and IIb (HDACs 6 and
10). Class III, with homology to the Sir2 family, is known as the
sirtuins and utilizes NAD+ as a cofactor. Class IV, which shares
homology with both class I and class II, consists of HDAC11.
Classes I, II, and IV are metal-dependent HDACs that use a
metal−water as the nucleophile during catalysis, which is
activated via a general acid−base mechanism (Figure 2).19 In
Figure 1. Acetylation, critical for regulation and proper cellular function. Lysine acetyltransferases (KATs) and histone deacetylases (HDACs)
maintain acetylation at an optimal level. HATs and HDACs regulate essential processes such as DNA repair, chromatin and actin remodeling, and
proteins that serve as checkpoints during the cell cycle.
Figure 2. General acid/base mechanism of catalysis utilized by metal-dependent deacetylases.19 The conserved Asp−Asp−His triad coordinates a
divalent metal ion that coordinates the metal−water nucleophile. His143 acts as both a general acid and a general base, while Tyr306 and His142
stabilize the oxyanion intermediate.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b01067
ACS Chem. Biol. 2016, 11, 706−716
707
	 3	
acetylation	and	deacetylation	has	now	been	observed	on	many	non-histone	proteins,	and	is	not	limited	to	the	nucleus.		Currently,	over	7000	acetylated	proteins	have	been	identified	in	mammalian	 cell	 lines,	 with	 more	 continuing	 to	 be	 discovered	 through	 proteomics	 and	computational	 analyses	 (5,	6).	 	 In	 light	 of	 these	many	non-histone	HDAC	 targets,	 a	more	suitable	 name	 for	 these	 enzymes	 is	 acetyllysine	 deacetylases,	 or	 acKDACs.	 	 Aberrant	regulation	of	protein	acetylation	has	been	observed	 in	various	 types	of	cancers	 including	prostate	 (7),	breast	 (8),	 and	colon	 (9),	 among	others,	 in	addition	 to	a	variety	of	diseases,	such	 as	 Cornelia	 de	 Lange	 Syndrome	 (CdLS)	 (10),	 Huntington’s	 disease	 (11),	 and	inflammation	(12).	The	 increasingly	 evident	 role	 of	 HDACs	 in	 multiple	 cancers	 has	 made	 them	 an	interesting	anticancer	target.		Current	research	shows	that	there	are	multiple	mechanisms	by	 which	 HDACs	 affect	 cancer	 development,	 including	 inducing	 growth	 arrest,	differentiation,	senescence,	and	death	of	cancerous	cells	(12,	13).		Several	HDAC	inhibitors	(HDACi)	have	been	developed	to	combat	these	mechanisms,	however,	the	current	clinically	used	 compounds	 do	 not	 possess	 isozyme	 selectivity.	 	 Three	 pan-HDAC	 inhibitors	 –	suberoylanilide	 hydroxamic	 acid	 (SAHA)	 (14),	 Romidepsin	 (cyclic	 peptide)	 (14),	 and	belinostat	(hydroxamic	acid)	(15)		–	have	been	approved	by	the	FDA	for	the	treatment	of	T-cell	lymphomas	and	a	fourth	inhibitor,	Panobinostat	(hydroxamic	acid),	has	recently	been	approved	for	multiple	myeloma	treatment	(16).	Studies	have	recently	demonstrated	that	pan-HDACi	can	also	be	used	to	increase	the	effectiveness	of	anti-cancer	immunotherapy	treatments.		In	one	mechanism,	T-cell	survival	is	enhanced	by	HDAC	inhibitor	treatment	through	the	prevention	of	activation-induced	cell	death	by	lymphocytes	(13,	17).		However,	these	effects	vary	significantly	and	can	produce	a	
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variety	 of	 non-desirable	 side	 effects	 as	 a	 consequence.	 	 Additionally,	 HDACis	 have	 been	used	to	enhance	vaccine	strategies;	namely,	mice	vaccinated	with	melanoma	cells	that	have	been	pre-treated	with	trichostatin	A	(TSA)	show	an	increase	in	immune	response	towards	additional	 tumors,	 effectively	 enhancing	 their	 tumor	 specific	 immunity	mechanisms	 (12,	
18).	 HDACs	 are	 divided	 into	 four	 classes	 based	 on	 their	 phylogeny	 and	 sequence	homology	to	yeast	orthologs	(19).		Class	I	HDACs,	which	share	homology	with	Rpd3,	consist	of	HDACs	1,	2,	3	and	8.		Class	II,	with	homology	to	Hda1,	can	be	divided	into	two	subclasses	–	 IIa	 (HDACs	4,	7	and	9)	and	 IIb	 (HDACs	6	and	10).	 	Class	 III,	with	homology	 to	 the	Sir2	family,	 is	 known	 as	 the	 sirtuins	 and	 utilizes	 NAD+	 as	 a	 cofactor.	 	 Class	 IV,	 which	 shares	homology	with	both	class	I	and	class	II,	consists	of	HDAC11.		Classes	I,	II	and	IV	are	metal-dependent	 HDACs	 that	 use	 a	 metal-water	 as	 a	 catalytic	 nucleophile	 in	 a	 general	 acid	general	 base	mechanism	 (Figure	 2)	 (20).	 	 In	 addition,	 the	 catalytic	 activity	 of	 HDACs	 is	sensitive	to	concentrations	of	monovalent	metal	cations,	 including	potassium	and	sodium	(21).			 	
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Figure	1.2:	General	acid	general	base	mechanism	of	catalysis	utilized	by	metal-
dependent	deacetylases(20).	The	 conserved	 Asp-His-Asp	 triad	 coordinates	 a	 divalent	 metal	 ion	 that	 coordinates	 the	 metal-water	nucleophile.	 	His143	acts	as	both	a	general	acid	and	a	general	base,	while	Tyr306	and	His142	stabilize	 the	oxyanion	intermediate.		Metal-dependent	 HDACs	 share	 common	 sequence	 motifs	 (Figure	 3),	 including	 a	deacetylase	domain	that	is	comprised	of	an	arginase-deacetylase	fold	consisting	of	a	multi-strand	β-sheet	surrounded	by	α-helices	and	a	divalent	metal	ion	cofactor	coordinated	by	an	Asp-His-Asp	 triad	(22).	 	Class	 I	HDACs	possess	a	deacetylase	domain	with	 little	sequence	variation	and	are	localized	mainly	to	the	nucleus	(19),	with	the	exception	of	HDAC8	which	has	 been	 observed	 in	 the	 cytoplasm	 of	 smooth	 muscle	 cells	 (23).	 	 Class	 II	 HDACs	 are	shuttled	between	the	nucleus	and	the	cytoplasm	and	possess	additional	domains,	such	as	MEF2	 binding	 domains.	 	 HDAC6	 has	 the	 largest	 array	 of	 domains	 with	 two	 deacetylase	domains	 and	 a	 zinc	 finger	 protein-binding	 domain	 (19).	 	 Class	 II	 HDACs	 are	 expressed	
FDA for the treatment of T-cell lymphomas, and a fourth
inhibitor, Panobinostat (hydroxamic acid), has recently been
approved for multiple myeloma treatment.13
Studies have recently demonstrated that pan-HDACi can
also be used to increase the effectiveness of anticancer
immunotherapy treatments. In one mechanism, T-cell survival
is enhanced due to prevention of activation-induced cell death
by lymphocytes.14,15 However, these effects vary significantly
and can produce a variety of nondesirable side effects as a
consequence. Additionally, HDACi’s have been used to
enhance vaccine strategies; namely, mice vaccinated with
melanoma cells that have been pretreated with trichostatin A
(TSA) show an increase in immune response toward additional
tumor , effectively enhancing their tumor specific immunity
mechanisms.16,17
HDACs are divided into four different classes based on their
sequence homology to yeast orthologs.18 Class I, which shares
homology with Rpd3, consists of HDACs 1, 2, 3, and 8. Class
II, with homology to Hda1, can be divided into two
subclassesIIa (HDACs 4, 7 and 9) and IIb (HDACs 6 and
10). Class III, with homology to the Sir2 family, is known as the
sirtuins and utilizes NAD+ as a cofactor. Class IV, which shares
homology with both class I and class II, consists of HDAC11.
Classes I, II, and IV are metal-dependent HDACs that use a
metal−water as the nucleophile during catalysis, which is
activated via a general acid−base mechanism (Figure 2).19 In
Figure 1. Acetylation, critical for regulation and proper cellular function. Lysine acetyltransferases (KATs) and histone deacetylases (HDACs)
maintain acetylation at an optimal level. HATs and HDACs regulate essential processes such as DNA repair, chromatin and actin remodeling, and
proteins that serve as checkpoints during the cell cycle.
Figure 2. General acid/base mechanism of catalysis utilized by metal-dependent deacetylases.19 The conserved Asp−Asp−His triad coordinates a
divalent metal ion that coordinates the metal−water nucleophile. His143 acts as both a general acid and a general base, while Tyr306 and His142
stabilize the oxyanion intermediate.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b01067
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ubiquitously	 through	 the	 cell	 and	 generally	 have	 lower	 catalytic	 activity	 in	 vitro	when	compared	 to	 class	 I	 enzymes.	 	 Finally,	 HDAC11,	 the	 only	 class	 IV	 metal-dependent	deacetylase,	possesses	characteristics	from	both	class	I	and	II	enzymes,	and	is	expressed	in	higher	abundance	in	specific	tissues	such	as	brain,	heart	and	kidney	(24).	Crystal	 structures	 have	 been	 solved	 for	 HDAC1	 (PDB:	 4BKX)	 (25),	 HDAC2	 (PDB:	3MAX)	 (26),	 HDAC3	 (PDB:	 4A69)	 (27),	 HDAC4	 (PDB:	 2VQM)	 (28),	 HDAC6	 (PDB:	 3PHD,	5EDU)	(29,	30),	HDAC7	(PDB:	3C0Y;	catalytic	domain	only)	(31),	HDAC8	(PDB:	2V5W)	(32),	and	 HDAC9	 (PDB:	 1TQE)	 (33).	 	 The	 isozymes	 lacking	 crystal	 structures	 are	 HDAC5,	HDAC10	and	HDAC11.	 		
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Figure	1.3:	Schematic	comparison	of	the	metal-dependent	deacetylases.	Class	I	isozymes	are	highly	conserved	and	small.	 	Class	IIa	isozymes	have	specific	MEF2-binding	domains	in	addition	to	their	conserved	deacetylase	domains.		Class	IIb	isozymes	contain	unique	domains	unlike	the	other	classes.		Only	the	deacetylase	domain	has	been	identified	in	class	IV.		 	One	of	the	most	prevalent	questions	in	the	HDAC	field	is	the	substrate	selectivity	of	each	 isozyme.	 	There	are	 thousands	of	validated	mammalian	acetylation	 sites	 (5)	and	18	deacetylase	 isozymes.	 	Thus,	defining	 the	substrate	pool	 for	each	 isozyme	 is	essential	 for	understanding	the	biological	functions	of	acetylation.		Additionally,	the	substrate	specificity	of	 HDACs	might	 be	 regulated	 by	 oxidative	 stress,	 protein-protein	 interactions	 and	 other	
addition, the activity of HDACs can be regulated by
monovalent metal cations.20 Metal-dependent HDACs are the
focus of this review.
Metal-dependent HDACs share common sequence motifs
(Figure 3), including a deacetylase domain that is comprised of
an arginase-deacetylase fold consisting of a multistrand β-sheet
surrounded by α-helices a d a divalent metal ion cofactor
coordinated by an Asp−Asp−His triad.23 Class I HDACs
possess a deacetylas domain with littl sequ nce variation and
are localized mainly in the nucleus,18 with the exception of
HDAC8, which has been observed in the cytoplasm of smooth
muscle cells.21 Class II HDACs are shuttled between the
nucleus and the cytoplasm and possess additional domains,
such as MEF2 binding domains. HDAC6 has the largest array
of domains with two deacetylase domains and a zinc finger
protein binding domain.18 Class II HDACs are expressed
ubiquitously through the cell and generally have lower catalytic
activity in vitro when compared to class I enzymes. Finally,
HDAC11, the only class IV metal-dependent deacetylase,
possesses characteristics from both class I and II enzymes and is
expressed in higher abundance in specific tissues such as brain,
heart, and kidney.22
Crystal structures have been solved for HDAC1 (PDB:
4BKX), HDAC2 (PDB: 3MAX), HDAC3 (PDB: 4A69),
HDAC4 (PDB: 2VQM), HDAC6 (PDB: 3PHD), HDAC7
(PDB: 3C0Y; catalytic domain only), HDAC8 (PDB: 2V5W),
and HDAC9 (PDB: 1TQE). The isozymes lacking crystal
structures are HDAC5, HDAC10, and HDAC11.
One of the most prevalent questions in the HDAC field is
the substrate selectivity of each isozyme. There are over 3600
validated mammalian acetylation sites5 and 18 deacetylase
isozymes. Thus, defining the substrate pool for each isozyme is
essential for understanding the biological functions of
acetylation. Additionally, the substrate specificity of HDACs
might be regulated by oxidative stress, protein−protein
interactions, and other PTMs. Elucidating HDAC substrate
specificity and regulation will provide insight into the function
and control of acetylation sites in proteins. Much research in
the field has focused on class I HDACs; thus, only the most
recent work on that class is cited in this review. Classes IIa, IIb,
and IV have fewer published studies, and the literature is
therefore covered more extensively.
In this review, we highlight functions of metal-dependent
deacetylases with regard to epigenetic regulation and homeo-
stasis and how these modifications play a role in cell
proliferation and growth in various cancers, in addition to
other, as of now, unknown roles.
■ CLASS I HDACS
The class I HDAC subfamily is disregulated in cancers and is
the best studied subfamily of the metal-dependent deacetylases.
Overexpression of this subclass has been observed in a variety
of cancers such as gastric,24 breast,9 prostate,8 and colon,10 as
well as T-cell25 and Hodgkin’s lymphoma.26 Class I protein−
protein interactions are currently the most well understood
(Table 1).
In the majority of cases, upregulation of HDAC1 is
associated with poor cancer prognosis.91 Silencing of HDAC1
using siRNA knockouts results in cell cycle arrest, growth
inhibition, and induction of apoptosis in breast cancer cells27
and induction of a plasminogen activator in neuroblastoma
cells, increasing their invasive capacity.28 Mass proteomic
analyses have revealed additional HDAC1 protein−protein
interactions, ranging from short-lived interaction proteins, such
as IKF2, HMG box transcription factor BBX, and activity-
dependent neuroprotector homeobox protein ADNP to
proteins with methylation-related functions such as ARID5B
to previously uncharacterized zinc-binding proteins and
domains, such as C16orf87.29 Additionally, HDAC1 has been
Figure 3. Schematic comparison of the metal-dependent deacetylases. All isozymes possess a common deacetylase domain. Class I isozymes are
highly conserved and small. Class IIa isozymes have specific MEF2-binding domains in addition to their conserved deacetylase domains. Class IIb
isozymes contain unique domains unlike the other classes. Only the deacetylase domain has been identified in class IV.
ACS Chemical Biology Reviews
DOI: 10.1021/acschembio.5b01067
ACS Chem. Biol. 2016, 11, 706−716
708
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PTMs.	 	Elucidating	HDAC	substrate	specificity	and	regulation	will	provide	insight	 into	the	function	and	control	of	acetylation	sites	in	proteins.			Here,	 we	 highlight	 functions	 of	 metal-dependent	 deacetylases	 with	 regard	 to	epigenetic	 regulation	 and	 homeostasis,	 and	 how	 these	 modifications	 play	 a	 role	 in	 cell	proliferation	and	growth	in	various	cancers,	in	addition	to	other,	as	of	now,	unknown	roles.	
	
Class	I	HDACs	The	 class	 I	 HDAC	 subfamily	 is	 disregulated	 in	 cancers	 and	 is	 the	 best-studied	subfamily	of	the	metal-dependent	deacetylases.	 	Overexpression	of	this	subclass	has	been	observed	in	a	variety	of	cancers	such	as	gastric	(34),	breast	(8),	prostate	(7),	and	colon	(9),	as	well	as	T-cell	(35)	and	Hodgkin’s	lymphoma	(36).	In	 the	 majority	 of	 cases,	 upregulation	 of	 HDAC1	 is	 associated	 with	 poor	 cancer	prognosis	 (37).	 	 Silencing	 of	 HDAC1	 using	 siRNA	 knockouts	 results	 in	 cell	 cycle	 arrest,	growth	inhibition	and	induction	of	apoptosis	in	breast	cancer	cells	(38)	and	induction	of	a	plasminogen	activator	in	neuroblastoma	cells,	increasing	their	invasive	capacity	(39).		Mass	proteomic	analyses	have	revealed	additional	HDAC1	protein-protein	interactions,	ranging	from	short-lived	interaction	proteins,	such	as	IKF2,	HMG	box	transcription	factor	BBX,	and	activity-dependent	neuroprotector	homeobox	protein	ADNP,	to	proteins	with	methylation-related	functions	such	as	ARID5B,	to	previously	uncharacterized	zinc-binding	proteins	and	domains,	such	as	C16orf87	(40).	 	Additionally,	HDAC1	has	been	demonstrated	to	 interact	with	the	oncogene	fusion	protein	PML-RAR,	a	protein	involved	in	the	pathogenesis	of	acute	promyelocytic	lymphoma	(APL);	 in	particular,	HDAC1	diminishes	the	tumorigenic	activity	of	 PML-RAR	 by	 blocking	 differentiation,	 impairing	 genetic	 stability	 and	 increasing	 the	
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renewal	 of	 progenitor	 cells.	 	 However,	 HDAC1	 expression	 enhances	 cell	 survival	 after	differentiation,	suggesting	a	dual	role	in	cancerous	tissue	(41).	Immunodeficient	 mice	 have	 been	 used	 to	 evaluate	 the	 role	 of	 HDAC1	 in	 tumor	formation	 using	 teratomas.	 	 In	 these	 models,	 HDAC1	 deficiency	 leads	 to	 partially	undifferentiated	carcinomas,	upregulation	of	HDAC2,	elevated	levels	of	SNAIL1	expression	and	 delocalization	 of	 E-cadherin	 (42).	 	 Knockouts	 of	 HDAC1	 and	 2	 show	 dramatic	acceleration	of	leukemogenesis	in	preleukemic	mice.		HDAC1	knockouts	also	led	to	deletion	of	 p53	 and	 c-myc	 overexpression	 (41).	 	 Additionally,	 Dovey	 et	 al.	 	 demonstrated	 that	knockouts	of	key	components	of	 the	HDAC1/2	deacetylase	complex	(Sin3A	and	Mi2)	that	decrease	HDAC	activity	 in	T-cells	perturb	the	differentiation	of	thymocytes	 into	mature	T	lymphocytes	 (43).	 	 Similarly,	 mice	 knockouts	 of	 HDAC1/2	 demonstrate	 that	 the	 loss	 of	HDAC	activity	leads	to	the	accumulation	of	thymocytes	in	addition	to	blocking	early	thymic	development	(44).	The	previously	described	protein-protein	interactions	have	led	to	the	proposal	that	some	HDACs	 function	 in	 large	deacetylase	complexes.	 	HDAC1	and	HDAC2,	 together	with	histone	 binding	 proteins	 RBBP4	 and	 RBBP7,	 DNA/chromatin	 recognition	 motifs	 and	transcription	factors	form	the	core	deacetylase	complexes	that	help	localize	HDACs	1	and	2	to	 chromatin	 (45).	 	 Expression	 of	 HDAC1	 and	 HDAC3	 correlate	 with	 both	 estrogen	 and	progesterone	receptor	expression	and	have	been	proposed	as	prognostic	markers	in	breast	cancer	tumors	(45).	HDAC2	is	overexpressed	in	lung	cancer	tissue	and	mesenchymal	tumors,	suggesting	that	it	is	an	effector	for	the	disease.	 	Silencing	of	HDAC2	via	siRNA	leads	to	an	increase	in	p53	DNA	binding	activity,	Bax	activation	and	Bcl2	suppression	(46).		These	changes	in	Bax	
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activation	 and	 Bcl2	 suppression	 are	 consistent	with	 suppressed	 expression	 of	 cyclin	 E2,	cyclin	D1	and	CDK2,	blocking	cell	proliferation	and	inducing	apoptosis	(47).		Truncations	of	HDAC2	have	been	detected	in	a	large	number	of	cancers	(48)	and	knockouts	of	both	HDAC1	and	 HDAC2	 prompt	 TRAIL-induced	 apoptosis	 in	 chronic	 lymphocytic	 leukemia	 (CLL),	indicating	 a	 possible	 level	 of	 cooperativity	 between	 these	 two	 isozymes	 (49).	 	 Recent	studies	 have	 also	 shown	 that	 both	 HDAC2	 silencing	 and	 inhibition	 induce	 regression	 of	fibrotic	formation	in	Peyronie’s	disease	models	(50,	51).		Using	mutant	fibroblasts	that	are	HDAC2-deficient,	Zimmerman	et	al.	demonstrated	a	lack	of	response	to	insulin-like	growth	factors	(IGFs)	when	compared	to	wild	type	cells,	showing	a	potential	link	between	HDACs	and	IGFs	(52).		Mice	models	lacking	HDAC1	and	with	a	single	HDAC2	allele	develop	a	lethal	pathology	 within	 3	months,	 likely	 due	 to	 neoplastic	 transformation	 of	 immature	 T	 cells	(43).	 	 Additionally,	 mutant	 mice	 with	 an	 inactive	 HDAC2	 mutant	 exhibit	 a	 25	 percent	decrease	in	body	size	and	reduced	cell	number	and	thickness	of	intestinal	mucosa	(52).	HDAC3,	 along	with	HDAC1	 and	HDAC2,	 is	 often	 expressed	 in	 high	 levels	 in	 renal,	colorectal	and	gastric	cancer	(36,	53).		High	expression	of	HDAC3	has	also	been	observed	in	eight	 different	 pancreatic	 cancer	 cell	 lines	 and	 potentially	 generates	 a	 post-induction	repression	 of	 p53,	 p27	 and	 Bax	 genes	 through	 deacetylation	 of	 K9	 of	 histone	 H3	 (54).		Knockouts	of	HDAC3	in	promyelocytic	leukemia	cells	restores	retinoic	acid	dependent	gene	expression,	 primarily	 due	 to	 loss	 of	 the	 interactions	 between	 HDAC3,	 the	 nuclear	 co-repressor	NCoR	and	PML-RARalpha	 fusion	protein.	 	HDAC3	 interactions	with	 the	nuclear	co-repressor	NCoR	to	block	transcription	are	enhanced	by	PML-RARalpha	binding	to	DNA	(55).	 	The	best	understood	example	of	HDAC3	 function	 is	 repression	of	 retinoic	acid	and	thyroid	hormone	receptors,	which	can	modulate	p53	expression	(54).		Additionally,	HDAC3	
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depletion	in	mouse	liver	upregulates	lipogenic	genes	and	causes	histone	hyperacetylation,	leading	to	hepatostaetosis	(56).		However,	expression	of	inactive	HDAC3	mutant	proteins	in	these	 knockout	 mice	 almost	 completely	 rescues	 the	 metabolic	 and	 gene	 transcription	alterations,	 suggesting	 that	 HDAC3	 plays	 important	 non-catalytic	 roles,	 such	 as	 protein-protein	 interactions.	 	 Consistent	 with	 this,	 mice	 knockouts	 of	 the	 nuclear	 co-repressor	NcoR,	 an	 essential	 part	 of	 the	 HDAC3	 deacetylase	 complex,	 exhibit	 metabolic	 and	transcriptional	 effects	 resembling	 those	 of	 mice	 without	 hepatic	 HDAC3,	 demonstrating	that	interaction	with	NcoR	is	essential	for	the	deacetylase-independent	function	of	HDAC3	(56).	 HDAC8	 is	 the	 best	 biochemically	characterized	HDAC	 isozyme	 to	 date	 (20,	21,	57,	
58).	 	 HDAC8	 is	 the	 only	 class	 I	 isozyme	 that	 is	 localized	 to	 both	 the	 cytoplasm	 and	 the	nucleus,	 and	 is	 not	 observed	 in	 large,	 multi-protein	 complexes	 in	 vivo	 (59).	 	 HDAC8	 is	overexpressed	in	childhood	neuroblastoma	(60)	and	T-cell	 lymphoma	(35).	 	Knockouts	of	HDAC8	produce	skull	morphology	and	growth	complications	in	mice	models	(19)	and	stop	cell	proliferation	 in	 lung,	 colon	and	cervical	 cancer	cells	 (60).	 	Point	mutations	 in	HDAC8	have	been	observed	in	patients	with	symptoms	similar	to	the	Cornelia	de	Lange	Syndrome	(CdLS).	 	 Lack	 of	 deacetylation	 of	 SMC3	 in	 the	 cohesin	 complex	 has	 been	 implicated	 as	 a	contributor	to	this	disease,	inhibiting	the	cell	cycle,	disrupting	proper	chromatid	separation	and	causing	debilitating	mental	and	physical	abnormalities	(discussed	further	below)	(10).		Currently,	work	on	HDAC8	has	focused	on	mass	spectrometry	and	co-immunoprecipitation	studies	 using	 the	HDAC8	 specific	 inhibitor	 -	 PCI-34051	 –	 and	have	provided	 insight	 into	potential	protein	substrates	and	interaction	partners	(40,	61).		Knockouts	and	inhibition	of	HDAC8	have	been	shown	to	 induce	apoptosis	 in	T-cell	 lymphoma	and	 leukemia	cell	 lines	
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(35).	 	 Using	 mice	 xenograft	 models	 of	 oncogene-amplified	 neuroblastoma,	 Rettig	 et	 al.	demonstrated	that	selective	inhibition	of	HDAC8	shows	antineuroblastoma	activity	without	significant	toxicity	and	induces	cell	cycle	arrest	and	differentiation	both	in	vivo	and	in	vitro	(62).	 	 Additionally,	 the	 combined	 treatment	with	 HDACi	 and	 retinoic	 acid	 enhanced	 cell	differentiation,	 demonstrating	 that	 inhibition	 of	 HDAC	 isozymes	 can	 be	 combined	 with	differentiation-inducing	agents	to	target	tumors	(62).	 	 Investigations	of	HDAC8	specificity	are	poised	 to	provide	 insight	 into	 the	 role	of	protein-protein	 interactions	 in	determining	substrate	specificity	of	metal-dependent	deacetylases.			
	
Class	II	HDACs	Class	 II	 HDACs	 were	 discovered	 in	 the	 early	 2000s	 (63–65).	 	 These	 proteins	 are	significantly	larger	than	both	class	I	and	class	IV	HDACs	due	to	N-terminal	and	C-terminal	tails	 and/or	 domains	 attached	 to	 the	 canonical	 deacetylase	 domain.	 	 This	 class	 is	subdivided	into	two	subfamilies:	Class	IIa	and	IIb.		Class	IIa	consists	of	HDAC	4,	5,	7	and	9	and	class	IIb	is	comprised	of	HDAC	6,	and	10.		These	isozymes	differ	from	class	I	HDACs	in	that	the	additional	N-terminal	domains	interact	with	transcription	factors	and	target	genes,	such	 as	 the	 MEF2	 proteins,	 a	 family	 of	 transcription	 factors	 that	 are	 key	 regulators	 of	cellular	 differentiation	 (64).	 	 Recruitment	 of	 class	 II	HDACs	by	MEF2	proteins	 to	protein	complexes	can	heavily	alter	the	protein	acetylation	landscape	due	to	blocking	interactions	with	acetylation	complexes	such	as	p300/CBP	in	non-Hodgkin	lymphoma	(33,	66).		Class	II	HDACs	 are	 localized	 to	 both	 the	 cytoplasm	 and	 the	 nucleus.	 	 Additionally,	 both	 up-regulation	 and	 down-regulation	 of	 these	 enzymes	 have	 severe	 repercussions	 in	 various	types	of	cancers.	
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Class	IV	HDACs	HDAC11,	the	most	recently	discovered	isozyme,	 is	the	sole	member	of	the	Class	IV	HDAC	subfamily	(24).	 	At	39	KDa,	HDAC11	is	the	smallest	 isozyme.	 	Sequence	alignments	suggest	that	HDAC11	is	more	closely	aligned	with	Class	I	HDACs	(28%	sequence	identity	to	HDAC8)	than	Class	II,	with	retention	of	highly	conserved	residues	in	the	active	site	and	in	the	mono-	 and	 divalent	metal	 binding	 sites	 seen	 in	 other	metal-dependent	 deacetylases.		HDAC11	sequence	alignments	identify	one	significant	sequence	change,	an	aspartate	(D101	in	HDAC8)	to	asparagine,	a	residue	located	on	the	flexible	L2	loop,	near	the	entrance	to	the	active	site	tunnel	(32).	HDAC11	expression	is	tissue	specific,	with	the	greatest	expression	occurring	in	the	brain,	heart,	kidneys,	skeletal	muscle,	and	testis	(24).		Studies	of	murine	brain	development	suggest	 a	 role	 for	 HDAC11	 in	 the	 formation	 of	 mature	 oligodendrocytes	 (67).		Overexpression	of	HDAC11	in	RAW264.7	cells	is	associated	with	a	decrease	in	mRNA	levels	of	the	anti-inflammatory	cytokine	interleukin-10,	indicating	a	possible	role	for	HDAC11	in	inflammatory	 and	 autoimmune	diseases	 (68).	 	 Furthermore,	mRNA	analysis	 uncovered	 a	link	 between	 HDAC11	 and	 cancer;	 mRNA	 levels	 for	 HDAC11	 are	 in	 the	 top	 1%	 of	differentially	overexpressed	genes	 in	ductal	breast	 carcinoma	when	compared	 to	healthy	breast	 tissue	 (69).	 	 In	 addition,	 the	 DNA	 replication	 factor	 Cdt1	 is	 a	 potential	 HDAC11	substrate.		Cdt1	is	integral	in	recruiting	mini-chromosome	maintenance	(MCM)	helicase	to	DNA,	which	is	required	for	DNA	replication	during	the	cell	cycle.		To	maintain	a	single	copy	of	DNA	per	cell,	Cdt1	must	be	inhibited	after	loading	MCM	in	the	G1	phase	(70).		Cdt1	is	an	
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acetylated	 protein	 that	 co-immunoprecipitates	 with	 HDAC11	 (71).	 	 Finally,	 HDAC11	knockout	mice	are	viable,	but	 they	exhibit	 increased	cell	proliferation	and	secrete	higher	levels	of	IL-2,	TNF,	and	IFN-y	than	WT	mice	(72).	
	
	
HDACs:	mechanism	and	inhibition	While	class	I,	II,	and	IV	HDACs	(HDACs	1-11)	vary	in	sequence	and	size,	they	are	all	metal-dependent	enzymes	 that	share	a	common	deacetylase	domain	(Fig.	1.3)	 (73).	 	This	domain	 features	 a	 highly	 conserved	 pair	 of	 histidine	 residues	 as	 well	 as	 a	 tyrosine,	 all	located	within	the	active	site	tunnel	(74).		Because	HDAC8	has	more	extensive	biochemical	characterization	in	vitro,	all	residue	numbers	will	correspond	to	their	placement	in	HDAC8	unless	otherwise	specified.		While	each	of	the	active	site	mutants	have	not	been	studied	for	all	HDAC	 isozymes,	 the	high	degree	of	conservation	of	 these	residues	suggests	 that	 these	enzymes	share	a	common	mechanism.	A	divalent	metal	is	situated	at	the	bottom	of	the	HDAC	active	site	tunnel.		This	metal	ion,	 in	 a	 pentacoordinate,	 square-pyramidal	 geometry,	 interacts	with	 an	Asp178-His180-Asp267	triad	and	two	displaceable	water	molecules	(58,	74).		The	identity	of	this	metal	ion	is	frequently	reported	to	be	zinc,	though	the	enzyme	is	activated	by	a	number	of	divalent	metals	and	the	potential	for	Fe-bound	HDAC	in	vivo	has	been	raised	(57).	The	 mechanism	 of	 HDAC-catalyzed	 deacetylation,	 a	 general	 acid	 general	 base	process,	 has	 been	 thoroughly	 investigated	 (Fig.	 1.2)	 (20).	 	 Briefly,	 an	 acetylated	 lysine	residue	 enters	 the	 active	 site	 tunnel.	 	 The	 carbonyl	 oxygen	 of	 the	 acetate	 moiety	 is	coordinated	by	the	divalent	metal	 ion	and	 forms	a	hydrogen	bond	with	Tyr306,	properly	
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orienting	 the	 substrate.	 	 The	metal-bound	water	 is	 deprotonated	 by	 His143,	 acting	 as	 a	general	base	in	concert	with	nucleophilic	attack	at	the	carbonyl	carbon	atom	of	the	acetyl	moiety	 of	 the	 substrate.	 	 This	 forms	 a	 tetrahedral	 intermediate	 where	 the	 oxyanion	 is	stabilized	 by	 interactions	 with	 Tyr306,	 the	 divalent	 metal	 ion,	 and	 the	 nearby	 His142.		His143,	acting	as	a	general	acid,	donates	a	proton	to	the	terminal	amine	of	the	lysine	side	chain	 to	 facilitate	 the	 collapse	 of	 this	 tetrahedral	 intermediate	 to	 form	 the	 acetate	 and	lysine	products	(20).	The	divalent	metal	ion	is	critical	to	proper	substrate	orientation	and	catalysis.		It	is	also	the	target	of	most	HDAC	inhibitors.		Of	the	four	FDA-approved	HDAC	inhibitors,	three	are	hydroxamic	acid	based	(Vorinostat,	Panobinostat,	and	Belinostat)	(Fig.	1.4)	and	one	is	a	cyclic	 peptide	with	 a	 reducible	 disulfide	 (14–16).	 	 All	 four	 of	 these	 pan-HDAC	 inhibitors	function	by	chelating	the	active	site	metal	ion.		Additional	isozyme-specific	inhibitors	have	been,	and	continue	to	be,	developed.		Of	particular	interest	here	are	two	specific	inhibitors:	PCI-34051	and	MGCD0103.	PCI-34051	is	an	HDAC8-specific	inhibitor	(Fig.	1.5A).		It	has	a	Ki	of	10	nM	for	HDAC8,	making	 it	 200-fold	 more	 potent	 toward	 HDAC8	 than	 any	 of	 the	 other	 HDACS	 tested	(HDAC1,	2,	3,	6,	and	10)	(35).		This	inhibitor	has	been	used	extensively	in	studying	HDAC8	and	has	played	an	important	role	in	identifying	HDAC8	substrates	(61).		MGCD0103	is	also	an	 isoform-selective	 inhibitor,	 though	 not	 as	 specific	 as	 PCI-34051	 (Fig.	 1.5B).	 	 This	inhibitor	 has	 nanomolar	 IC50	 values	with	 HDACs	 1,	 2,	 and	 11,	 and	 <	 2	 µM	with	 HDAC3.		However,	 it	 is	 not	 a	 potent	 inhibitor	 toward	 HDAC8	 or	 class	 II	 HDACs	 (75).	 	 These	inhibitors	were	both	used	in	the	work	presented	in	this	thesis.		
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Figure	1.4:	Structure	of	FDA-approved	hydroxamic	acid	HDAC	inhibitors	Each	 inhibitor	has	a	 capping	group,	a	 linker,	and	a	metal	 chelator.	 	These	FDA-approved	 inhibitors	 share	a	common	chelating	group,	a	hydroxamic	acid	(blue).		They	differ	in	the	length	and	composition	of	their	linker	regions,	 and	 all	 contain	 a	 hydrophobic	 capping	 group	 composed	 of,	 at	 a	minimum,	 a	 benzene	 ring.	 	 These	inhibitors	are	Vorinostat	(A),	Panobinostat	(B),	and	Belinostat	(C).				
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Figure	1.5:	Isozyme-selective	HDAC	inhibitors	(A)	An	HDAC8-specific	inhibitor,	PCI-34051,	with	a	hydroxamic	acid	moiety	(blue).		This	HDACi	is	>	200	fold	more	potent	toward	HDAC8	than	other	class	I	HDACs.		(B)	MGCD0103	is	an	isozyme-selective	inhibitor	with	sub-micromolar	potency	toward	HDACs	1,	2,	and	11.		This	inhibitor	also	chelates	metal,	but	the	warhead	is	a	benzamide	(red)	instead	of	a	hydroxamic	acid.	
	
Current	methods	to	assay	HDAC-catalyzed	deacetylation		 Methods	 to	 accurately	 determine	 HDAC	 catalytic	 activity	 are	 central	 to	 studying	these	 enzymes	 in	 vitro	 and	 understanding	 their	 cellular	 roles	 in	 vivo.	 	 HDAC-catalyzed	deacetylation	has	been	measured	in	vitro	almost	exclusively	with	peptide	substrates.	 	The	most	common	assay	for	determining	catalytic	activity	is	the	Fluor-de-Lys	assay	(Enzo	Life	Sciences)	(Fig.	1.6).		This	assay	makes	use	of	short	peptides	(~	4	–	6	amino	acids),	with	a	C-terminal	 methyl-coumarin	 fluorophore.	 	 The	 target	 acetyllysine	 residue	 is	 positioned	adjacent	 to	 the	 fluorophore.	 	 Upon	HDAC-catalyzed	 deacetylation	 of	 the	 acetyllysine,	 the	
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peptide	is	exposed	to	a	developing	reagent,	which	includes	trypsin.		Trypsin	recognizes	and	cleaves	at	lysine	but	not	acetyllysine.		Therefore,	only	HDAC	product	peptides	are	cleaved.		This	generates	free	methyl-coumarin,	which	can	be	observed	as	an	increase	in	fluorescence	(ex.	 	 =	 340	 nm,	 em.	 	 =	 450	 nm)	 (Fig.	 1.6).	 	 This	 assay	 is	 broadly	 applicable	 to	 all	 HDAC	isozymes,	and	peptide	substrates	can	differ	in	their	sequence	upstream	of	the	acetyllysine.		However,	 physiological	 relevance	 is	 somewhat	 limited,	 as	 the	 peptides	 cannot	 differ	 in	sequence	downstream	of	the	acetyllysine,	where	the	methyl-coumarin	is	situated.				
	
Figure	1.6:	The	Fluor-de-Lys	assay	Methyl-coumarin-labled	peptide	substrate	 is	deacetylated	by	HDAC.	 	The	 free	 lysine	 is	 then	recognized	and	the	peptide	cleaved	by	 trypsin,	 releasing	 free	methyl-coumarin.	 	This	 results	 in	an	 increase	 in	 fluorescence	intensity	(ex.		=	340	nm	and	em.		=	450	nm).		Reproduced	with	permission	from	Wolfson	et	al.,	2013.		 researchers to hunt for other possible HDAC substrates. Thesearch for new HDAC8 substrates was further spurred by the
finding that this enzyme is present in the cytoplasm of
smooth muscle cells,36,37 causing evaluation of non-nuclear
substrates. In fact, HDAC8 catalyzes deacetylation of a
peptide corresponding to the C-terminal end of the p53
transcription factor (Figure 2a) faster than the K(ac)16 H4
histone peptide (Biomol, unpublished). HDAC8 catalyzes
deacetylation of coumarin derivatives of the acetylated p53
and H4 peptides with kcat/KM values of 7500 M
21s21 and
2800 M21s21, respectively.26,39 As the kcat/KM parameter
reflects the relative reactivity of an enzyme with different
substrates,40 these values suggest that HDAC8 has a modest
preference for catalyzing deacetylation of p53 over the H4
histone. It is important to note that these kcat/KM values for
HDAC8 were measured using the commercially available
Fluor-de-lys assay (Biomol). This assay uses peptide sub-
strates containing a methylcoumarin fluorophore conjugated
to the C-terminal side of the acetyllysine residue. After
deacetylation, digestion by trypsin cleaves the coumarin
fluorophore, causing an increase in fluorescence at 460 nm;
deacetylation is measured from an increase in the fluores-
cence signal38 (Figure 2b). While this assay has been a valua-
ble tool for studying histone deacetylases, the methylcou-
marin fluorophore increases the reactivity with HDAC8.41
Therefore, deacetylation of the nonlabeled acetylated p53
and H4 histone peptides catalyzed by HDAC8 may be slower
than reported using this assay. Furthermore, the coumarin
substrates may not reliably reflect HDAC substrate specificity
in the context of full-length proteins.
The steady-state kinetic parameters for catalysis of the
deacetylation of peptides can provide insight into both the
kinetic mechanism and the in vivo reactivity of these sub-
strates. HDAC8-catalyzed deacetylation of the p53 and H4
coumarin peptides has a low value of kcat/KM (10
3–
104M21s21) in comparison to enzymes that function near
diffusion-controlled limits (106–108M21s21) and a high
value for KM (320 lM, H4 peptide)
39 compared to other
HDAC isozymes (! 30 lM).42 These data suggest a simple
Michaelis–Menten kinetic model whereby substrate binding
and dissociation is rapid, and is followed by rate-limiting
deacetylation. This conclusion is bolstered by the observed
enhancement of the kcat value for deacetylation of peptides
labeled with a more reactive trifluoroacetyl group.43,44 There-
fore, substrate specificity is determined by both the affinity
of HDAC8 for a peptide substrate and the reactivity of the
enzyme–substrate complex. Assuming that the kinetic con-
stants for deacetylation of these peptides mimic the full-
length proteins, the low kcat/KM and high KM values for the
H4 and p53 peptides compared to reactivity with other iso-
zymes26,39,42 suggest that HDAC8 may not catalyze deacetyla-
tion of these sites in vivo. However, natural, full-length sub-
strates may be better optimized for efficient deacetylation to
allow for regulation of these post-translational modifications.
Cellular data implicating HDAC8-catalyzed deacetylation of
H4 and p53 in vivo is also sparse. In addition to these pro-
posed substrates, in vitro kinetic studies combined with cellu-
lar assays have yielded several promising candidates for in
vivo HDAC8 substrates (discussed further below).
There are a number of factors that must be taken into
account when parsing whether substrates are acted on by a
given enzyme in vivo. HDAC selectivity is minimally
described by the relative values of kcat/KM for deacetylation,
the relative concentrations of the HDAC isozymes, and the
concentrations of competing substrates. The relative kcat/KM
values indicate the substrate preference of an enzyme when
FIGURE 2 The Fluor-de-lys assay [Biomol].38 A. The sequence of
two HDAC8 substrates used for the Fluor-de-lys assay. B. Schematic
of the Fluor-de-lys assay, including the wavelengths used to measure
the methylcoumarin fluorophores.
114 Wolfson, Pitcairn, and Fierke
Biopolymers
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	 A	recent	advance	in	measuring	HDAC	catalysis	 in	vitro	 is	an	enzyme-coupled	assay	developed	in	our	lab	(76).		This	assay	utilizes	free	acetate	to	yield	an	observable	change	in	equilibrium	between	NAD+	and	NADH	(Fig.	1.7).		This	assay	does	not	rely	on	fluorophore-labeled	 peptides	 to	 generate	 a	 signal,	 and	 therefore,	 HDAC-catalyzed	 deacetylation	 of	unlabeled	peptides	of	any	sequence	can	be	assayed.		The	applications	and	modifications	of	this	assay	are	discussed	further	in	Chapter	2.	 	
	
Figure	1.7:	Scheme	for	the	enzyme-coupled	assay	Briefly,	acetate	(generated	by	HDAC	activity)	is	converted	into	acetyl-CoA	by	acetyl-CoA	synthetase.	 	Citrate	synthase	 then	 converts	 oxaloacetate	 and	 acetyl-CoA	 into	 citrate	 and	 regenerates	 CoA	 in	 the	 process.		Oxaloacetate	 is	 present	 as	 the	 product	 of	 malate	 dehydrogenase.	 	 As	 citrate	 is	 formed,	 oxaloacetate	 is	depleted.		Thus	driving	the	equilibrium	of	malate	and	NAD+	(via	malate	dehydrogenase)	toward	oxaloacetate	and	NADH.	
		 Detecting	 HDAC-catalyzed	 deacetylation	 in	 vivo	 presents	 a	 different	 set	 of	challenges.		Ed	Holson’s	laboratory	at	the	Broad	Institute	has	used	stable	isotope	labeling	of	amino	acids	in	cell	culture	(SILAC)	to	successfully	measure	changes	in	protein	acetylation	upon	perturbation	of	HDAC	 isozymes.	 	More	specifically,	 they’ve	shown	that	 inhibition	of	
Stopped assay
We first optimized the acetate assay in a stopped format to
measure HDAC8 activity. After reacting HDAC8 with the substrate
of interest, the reaction was quenched by the addition of HCl and
flash frozen in liquid nitrogen. On thawing, the pH was neutralized
by the addition of NaHCO3. Using the Fluor de Lys assay to measure
activity, the HCl solution quenches HDAC8 activity immediately
(<10 s), and HDAC8 activity is not restored on neutralization (data
not shown). The acetate concentration in this sample is then mea-
sured using the coupled assay. Under these optimized conditions,
formation of NADH from the addition of acetate occurs within min-
utes. On mixing the coupling enzymes with the assay substrates,
NAD+ and L-malic acid equilibrate to form NADH and OAA. This
equilibration is complete in 20 min (Fig. 4), forming approximately
4 lM NADH, consistent with the equilibrium constant for the reac-
tion catalyzed by malate dehydrogenase [30]. The reaction of up to
20 lM acetate is complete within 30 min, and the signal remains
stable for more than 1 h. The limiting step in this assay is the
formation of citrate and CoA catalyzed by CS. Therefore, the rate
of acetate production can be increased by the addition of higher
concentrations of CS if needed.
To demonstrate the effectiveness of the acetate assay in mea-
suring deacetylation, we compared the rate of HDAC8-catalyzed
deacetylation determined using the coupled assay with that using
the fluorescamine assay. Fluorescamine is a reagent that increases
in fluorescence intensity on reaction with primary amines [31];
therefore, a fluorescent signal is coupled to the formation of lysine
generated by HDAC-catalyzed deacetylation. We measured the
reactivity of Co(II)–HDAC8 with an unlabeled peptide (Ac-KGGA-
Kac-COO!) representing the sequence of the H4 histone K16
acetylation site (H4 K16ac). HDAC8-catalyzed deacetylation of this
peptide (200 lM peptide, 0.5 lM HDAC8) measured by the cou-
pled acetate assay and the fluorescamine assay yielded comparable
rates within experimental error of 0.0021 ± 0.0003 lM s!1 and
0.0027 ± 0.0008 lM s!1, respectively. Therefore, both assays
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Fig.1. Assay scheme. Acetate is a product of deacetylation catalyzed by HDAC8. Acetate, ATP, and CoA are converted into acetyl-CoA, adenosine monophosphate (AMP), and
inorganic pyrophosphate by acetyl-CoA synthetase. Acetyl-CoA and OAA are converted into citrate and CoA catalyzed by CS. Simultaneously, MDH catalyzes equilibration of
NAD+ and malate with NADH and OAA. When a molecule of OAA is removed from solution by the CS reaction, a molecule of NADH is formed. NADH concentrations are
quantified using absorbance or fluorescence.
Fig.2. Comparison of R-Biopharm kit and optimized assay for detection of acetate.
The fluorescence change as a function of acetate concentration is measured using
the R-Biopharm kit (h) and the optimized acetate assay (4). The fluorescent signal
is normalized to 0 lM acetate using the optimized assay. The signal from the
optimized assay is much larger in the micromolar (lM) range, which is required to
measure steady-state turnover catalyzed by HDAC8. This signal is accurate to
approximately 1 lM, with a coefficient of variance equal to 2.2. The R-Biopharm kit
standard curve is linear at higher concentrations of acetate (250–1250 lM) (see
Fig. S1 in the supplementary material).
Fig.3. Standard curve for the acetate assay compared with NADH fluorescence. The
fluorescence change observed upon addition of acetate to the coupled assay (j) is
compared with the NADH fluorescence under comparable conditions (50 mM
Hepes, 100 mM NaCl, 3 mM KCl, and 50 mM MgCl, pH 8.0) (N). The two slopes are
equal, indicating that in the coupled assay one mole of NADH is formed per mole of
acetate. The higher background observed in the acetate standard curve is a result of
NADH formed before the addition of acetate due to the equilibrium of the MDH-
catalyzed reaction.
64 Coupled assay for profiling HDAC8 specificity /N.A. Wolfson et al. / Anal. Biochem. 456 (2014) 61–69
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HDAC8	in	vivo	leads	to	an	increase	in	acetylation	of	several	proteins,	as	visualized	by	mass	spectrometry	(61).	
	
	
Putative	HDAC8	in	vivo	substrates	and	their	biological	relevance	Several	proteins	have	been	 identified	as	putative	HDAC8	substrates,	using	various	techniques,	 including	 stable	 isotope	 labeling	 of	 amino	 acids	 in	 cell	 culture	 (SILAC),	RNAi	knockdowns,	 and	 co-immunoprecipitation	 (40,	 61).	 	 Perhaps	 one	 of	 the	 best-validated	substrates	 is	SMC3,	a	protein	for	which	misregulation	of	acetylation	is	directly	associated	with	disease.	HDAC8	has	 recently	been	 identified	 as	 a	 causative	 agent	 in	 the	Cornelia	de	Lange	syndrome	 (CdLS).	 	 CdLS	 is	 a	 rare	 genetic	 disorder,	 occurring	 in	 about	 1	 in	 10,000	individuals.	 	 It	 is	marked	 by	 visible,	 physical	 deformities,	 including	 limb	malformations,	small	hands	and	feet,	and	facial	deformities.		The	disorder	is	also	associated	with	cognitive	impairment	 and	 low	 IQ.	 	 CdLS	 results	 from	alterations	 in	 the	 cohesin	 complex,	 a	protein	complex	that	mediates	cohesion	of	sister	chromatids	during	cell	division	(77,	78).	 	A	core	component	 of	 the	 cohesin	 complex	 is	 SMC3,	 a	member	 of	 the	 structural	maintenance	 of	chromosome	family	of	ATPases.	SMC3	 is	 an	 acetylated	 protein	whose	 acetylation	 profile	 changes	 as	 the	 cell	 cycle	progresses.		As	cells	leave	anaphase,	SMC3	acetylation	levels	decrease,	regenerating	a	pool	of	non-acetylated	SMC3	to	start	the	next	cell	cycle	(79).		This	deacetylation	is	attributed	to	HDAC8	activity	 in	vivo	based	on	an	RNAi	screen	and	a	SILAC	experiment	in	which	HDAC8	was	specifically	inhibited	(10,	61).		Additionally,	in	2012,	four	unique	mutations	in	HDAC8	
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were	 discovered	 in	 several	 CdLS	 patients	 who	 tested	 negative	 for	 traditional	 genetic	markers	 associated	 with	 the	 disease.	 	 When	 expressed	 recombinantly	 in	 E.	 coli,	 these	mutations	(H180R,	T311M,	G320R,	and	H334R)	result	in	a	significant	decrease	in	HDAC8-catalyzed	 deacetylation	 of	 a	 Fluor-de-Lys	 substrate	 (10).	 	 Further,	 we	 have	 verified	 that	WT-HDAC8	catalyzes	the	deacetylation	of	an	SMC3	peptide	in	vitro	(61).	Additional	 proposed	 substrates	 of	HDAC8	 include	 estrogen-related	 receptor	 alpha	(ERRa)	 (80),	 cAMP	 response	 element-binding	 protein	 (CREB)	 (81,	 82),	 and	 AT-rich	interactive	domain-containing	protein	1A	(ARID1a)	(61),	among	others.		Of	these,	perhaps	ERRa	 is	 the	best	characterized.	 	This	protein,	along	with	other	members	of	 the	estrogen-related	 receptor	 family	 and	 additional	 co-activators,	 functions	 to	 regulate	 energy	metabolism	during	periods	of	stress	(83).		Acetylated	ERRa	has	significantly	reduced	ability	to	activate	a	target	promoter	in	Cos1	cells	(80).		HDAC8	and	Sirt1	led	to	the	greatest	rescue	of	ERRa	activity	upon	co-transfecting	ERRa	with	a	panel	of	deacetylases,	suggesting	these	two	enzymes	function	as	the	in	vivo	ERRa	deacetylases	(80).	
	
HDAC11	biological	significance	and	potential	in	vivo	substrates		 Since	 its	 discovery	 in	 2002,	 a	 physiological	 role	 for	 HDAC11	 has	 not	 been	 well	studied.	 	Unlike	the	Class	I	HDACs,	mRNA	levels	of	HDAC11	are	less	ubiquitous	and	more	concentrated	in	specific	areas:	the	heart,	brain,	kidneys,	skeletal	muscle,	and	testis	(24).		In	accordance	with	 this	 tissue	 specific	 data	 from	 human	 northern	 blot	 analysis,	 a	 research	group	 at	 UNC	 Chapel	 Hill	 found	 that	 expression	 of	 HDAC11	 is	 elevated	 in	 the	 brains	 of	newborn	to	4	week	old	mice,	and	expression	is	abundant	in	mature	oligodendrocytes	(67).		Additionally,	these	researchers	note	that	postnatal	central	nervous	system	development	is	
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correlated	with	a	decrease	in	core	histone	acetylation	(84).		Based	on	this	evidence,	it	has	been	 proposed	 that	 HDAC11	 is	 involved	 in	 the	 formation	 of	 mature	 oligodendrocytes	through	deacetylation	of	histones	3	and/or	4	(67).	 	Evidence	 for	deacetylation	of	specific	side	 chains	 in	 histones	 is	 currently	 limited	 to	 the	 correlation	 between	 the	 observed	decreases	 in	 histone	 acetylation	 in	 the	 brain	 at	 the	 same	 stage	 in	 development	 that	HDAC11	expression	increases	(84).		Mammalian	HDAC11	is	highly	conserved	between	mice	and	humans	(92%	identity),	suggesting	that	these	finding	may	hold	value	for	human	brain	development	as	well.		 HDAC11	has	also	been	investigated	as	a	negative	regulator	of	interleukin	10	(IL-10)	expression	 (68).	 	 IL-10	 is	 an	 anti-inflammatory	 cytokine	 responsible	 for	 regulating	 the	magnitude	 of	 the	 immune	 response	 and	 minimizing	 self-tissue	 damage.	 	 Villagra	 et	 al	demonstrated	that	overexpression	of	HDAC11	decreases	IL-10	mRNA	levels	in	RAW264.7	mouse	cells.		They	also	showed,	using	a	luciferase-based	assay,	that	HDAC11	interacts	with	the	IL-10	promoter	region	(68).	 	These	findings	suggest	that	HDAC11,	by	suppressing	the	expression	of	IL-10,	plays	a	pro-inflammatory	role.		These	data	highlight	a	potential	use	for	HDAC11	 inhibitors	 as	 a	 therapeutic	 in	 autoimmune	 diseases.	 	 Subsequent	 studies	 have	suggested	that	HDAC11-mediated	regulation	of	IL-10	may	be	 less	straightforward.	 	HDAC	inhibitor	studies	and	HDAC	knockdowns	(RNAi)	have	demonstrated	a	link	between	the	loss	of	 HDAC11	 and	 an	 increase	 in	 OX40L,	 the	 ligand	 responsible	 for	 activation	 of	 the	 OX40	receptor.	 	The	OX40	receptor,	once	paired	with	the	OX40L,	generates	a	pro-inflammatory	immune	 response.	 	 This	 pathway	 ultimately	 leads	 to	 a	 reduction	 of	 IL-10	 (85).	 	 These	findings	demonstrate	the	complexity	of	the	role	HDAC11	plays	in	regulating	the	severity	of	an	immune	response	(Fig.	1.8).	
	 23	
	 Additionally,	a	strong	link	exists	between	HDAC11	and	cancer	suppression.		Analysis	of	 mRNA	 expression	 for	 HDAC11	 revealed	 that	 it	 is	 in	 the	 top	 1%	 of	 differentially	overexpressed	genes	in	ductal	breast	carcinoma	when	compared	to	normal	breast	tissue.		It	is	 also	 in	 the	 top	 5%	 of	 differentially	 overexpressed	 genes	 for	 several	 other	 cancers,	including	 renal	 and	 hepatic	 (69).	 	 Deubzer	 et	 al	 performed	 knockdowns	 of	 HDAC11	 in	several	 cancerous	 and	 non-cancerous	 cell	 lines	 using	 siRNA.	 	 They	 found	 that	 lowered	levels	of	HDAC11	led	to	decreases	in	the	metabolic	activity	and	viability	of	cancerous	cells	but	had	no	effect	on	the	viability	of	non-cancerous	cell	lines.		Additionally,	expression	of	a	catalytically	 impaired	HDAC11	variant	 in	 cancerous	 cells	produced	 the	 same	detrimental	effects	 seen	 with	 the	 knockdowns,	 suggesting	 that	 loss	 of	 HDAC11	 activity	 is	 likely	responsible	for	these	observations	(69).		 Finally,	there	is	evidence	that	the	DNA	replication	factor	Cdt1,	which	recruits	mini-chromosome	maintenance	(MCM)	helicase	to	DNA,	is	a	strong	candidate	to	be	an	HDAC11	substrate.		Regulation	of	Cdt1	is	critical,	as	MCM	is	required	for	DNA	replication	during	the	cell	cycle.		After	MCM	loading	onto	DNA	in	the	G1	phase,	Cdt1	must	be	inhibited	to	maintain	a	 single	 copy	of	DNA	per	 cell	 (70).	 	 Reactivity	 of	 Cdt1	with	 an	 anti-acetyllysine	 antibody	demonstrated	 acetylation	 of	 this	 protein,	 and	 co-immunoprecipitation	 experiments	 have	demonstrated	an	interaction	between	Cdt1	and	HDAC11.		Furthermore,	this	study	showed	that	acetylation	of	Cdt1	protects	it	from	degradation	(71).		
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Figure	1.8:	Role	of	HDAC11	in	immunity	HDAC11	plays	 a	 complex	 role	 in	 cellular	 immunity,	 and	may	 be	 cell-type	 specific.	 	 (A)	HDAC11	 (in	mouse	macrophage	cells	and	human	antigen	presenting	cells,	APC)	suppresses	expression	of	interleukin	10,	which	in	turn	generates	an	increase	in	immunity	and	inflammation.		(B)	Upon	inhibition	of	HDAC11	in	these	cells	IL-10	expression	 increases,	 resulting	 in	 tolerance	 and	 an	 anti-inflammatory	 response.	 	 (C)	 However,	 in	 three	Hodgkin	 lymphoma-derived	 cell	 lines	 (HL	 cells),	 inhibition	of	HDAC11	 resulted	 in	 an	 increase	 in	 the	OX40	ligand	(OX40L).	 	This	 ligand,	when	paired	with	the	receptor	OX40R,	suppressed	IL-10	and	generates	a	pro-inflammatory,	anti-tumor	immune	response.	
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Conclusions	Lysine	 acetylation/deacetylation	 is	 a	 dynamic,	 reversible	 post-translational	modification	with	a	defined	role	in	histone	modification	and	a	growing	pool	of	non-histone	substrates	that	are	critical	 for	epigenetic	regulation,	DNA	repair,	cell	cycle	regulation	and	cancer	growth	and	proliferation.	 	The	HDAC	family	of	enzymes	catalyzes	deacetylation	of	both	histones	and	non-histone	proteins	to	maintain	acetylation	homeostasis	that	is	critical	for	cell	regulation	and	survival.		Changes	in	acetylation	patterns	have	become	a	key	feature	of	 various	 types	 of	 cancer	 and	 many	 of	 these	 changes	 in	 acetylation	 levels	 are	 due	 to	increased	expression	and/or	misregulation	of	HDACs.		Due	to	the	link	between	HDACs	and	cancer	 prognosis	 and	 survival,	 these	 enzymes	 have	 become	 an	 attractive	 target	 for	 drug	development,	as	shown	by	the	development	and	FDA	approval	of	pan-HDAC	inhibitors	and	the	current	development	of	novel	immuno-	and	oncolytic	virus-	(OV)	therapies.		To	further	our	understanding	of	the	cellular	function	of	HDACs,	huge	strides	are	currently	being	made	in	discovering	HDAC	specific	binding	partners	and	substrates	using	a	variety	of	methods,	from	knockouts	and	mass	spectrometric	techniques	to	 in	vivo	mammalian	cell	work.	 	The	current	body	of	literature	on	HDACs	has	shed	light	on	the	multiple	roles	of	these	enzymes	in	 both	 transcriptional	 regulation	 and	 in	 protein-protein	 interactions,	 particularly	 with	respect	to	their	roles	in	disease,	including	multiple	cancers,	Alzheimer’s	disease,	and	many	others.	We	 predict	 that	 future	 work	 will	 incorporate	 varied	 approaches	 such	 as	 mass	spectrometry,	co-immunoprecipitation,	in	vivo	perturbation,	in	vitro	functional	studies,	etc.,	to	 advance	 our	 understanding	 of	 the	 cellular	 role	 of	 each	 isozyme.	 	 Understanding	 the	
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specificity	 of	 each	 HDAC	 will	 provide	 further	 insight	 into	 their	 individual	 roles	 in	 the	regulation	of	cellular	pathways	and	various	diseases	states.		
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Chapter	2	
Using	peptide	substrates	to	measure	HDAC-catalyzed	deacetylation3,4	
Introduction	
	 Histone	deacetylases	(HDACs),	or	acetyllysine	deacetylases,	catalyze	the	hydrolysis	of	 acetate	 from	 the	 side	 chain	 of	 acetylated	 lysine	 residues	 in	 proteins.	 	 This	 process,	occurring	at	thousands	of	sites	throughout	the	proteome	(86),	has	many	different	cellular	roles.	 	 Acetylation	 of	 histone	 proteins	 can	 result	 in	 changes	 in	 chromatin	 structure	 and	gene	 transcription.	 	 Acetylation	 of	 other	 proteins	 yields	myriad	phenotypes,	 as	 the	 post-translational	 modification	 has	 been	 shown	 to	 impact	 protein	 function,	 protein-protein	interactions,	and	protein	signaling	(4).	As	 the	 acetylome	 continues	 to	 grow	 (6),	 so	 too	 does	 the	 importance	 of	understanding	the	biochemical	relationship	between	HDACs	and	their	substrates.		Current	
in	vivo	 and	 in	vitro	 techniques	are	uncovering	 links	between	specific	HDAC	 isozymes	and	their	 substrates.	 	 These	 methods	 include	 gene	 knockdowns,	 protein	 co-immunoprecipitation,	 and	 mass-spectrometry-based	 proteomics.	 	 These	 methods	 are	
																																																								3	The	optimization	of	the	continuous	format	of	the	coupled-enzyme	assay	and	the	HDAC3/NCOR1	stopped	assay	data	are	published	in	Wolfson	et	al.,	2014.		The	optimization	of	the	continuous	assay	was	performed	by	Eric	Sullivan	and	Noah	Wolfson.		The	assaying	of	HDAC3	was	performed	by	Eric	Sullivan.		The	manuscript	was	written	by	Noah	Wolfson,	Carol	Ann	Pitcairn,	Eric	Sullivan,	Caleb	Joseph,	and	Carol	Fierke.		Text,	where	reproduced,	is	footnoted.	4	The	validation	of	peptides	from	the	SILAC	experiment	is	published	in	Olson	et	al.,	2014.		The	in	vivo	HDAC8	inhibition	and	mass	spec	workup	were	performed	by	the	Holson	group.		Peptides	representing	the	protein	targets	were	assayed	by	Eric	Sullivan	and	Carol	Ann	Pitcairn,	and	analyzed	by	Sullivan,	Pitcairn,	and	Wolfson.		Text	from	this	manuscript,	reproduced	in	the	methods	section,	is	footnoted.	
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powerful	tools	to	identify	potential	protein	targets	for	individual	HDACs,	however,	many	of	these	candidate	protein	targets	lack	additional	biochemical	validation	in	vitro.	Recombinant	 expression	 of	 full-length	 target	 proteins	 is	 a	 cumbersome	 task,	 and	requires	 proper	 lysine	 acetylation.	 	 Deacetylation	 of	 fluorophore-labeled	 peptide	substrates	has	been	in	wide-use	for	over	a	decade	(87),	and	allows	for	the	rapid	analysis	of	the	catalytic	activity	of	HDAC	enzymes.		However,	this	method	requires	a	non-physiological	substrate,	and	is	of	limited	use	in	determining	the	selectivity	differences	between	isozymes.		A	 reproducible	 method	 to	 assay	 unlabeled	 peptides,	 which	 can	 be	 used	 to	 measure	reactivity	 with	 myriad	 sequences,	 has	 remained	 a	 more	 difficult	 challenge.	 	 Via	 several	interdisciplinary	 collaborations,	we	have	made	 strides	 in	 advancing	 the	use	 of	 unlabeled	peptide	substrates	as	a	tool	to	investigate	HDAC	activity.			Here,	we	report	on	current	advances	in	using	peptide-based	assays	in	vitro	to	study	HDAC	specificity	and	catalysis.	 	We	provide	recent	innovations	to	a	current	method	using	an	enzyme-coupled	assay	and	provide	a	case	study	 in	which	the	ability	 to	assay	peptides	based	on	physiological	protein	sequences	provided	evidence	 for	 the	validation	of	HDAC8	substrates	and	the	extent	to	which	those	proteins	might	be	selective	toward	HDAC8	over	other	 HDAC	 isozymes.	 	 We	 also	 discuss	 the	 strengths	 and	 weaknesses	 of	 two	 mass	spectrometry-based	peptide	assay	approaches.		
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Methods	
HDAC8	expression	and	purification	HDAC8	was	expressed	and	purified	as	described	previously	(57),	with	the	exception	that	 a	 20	 mL	 DEAE	 Sepharose	 column	 was	 used	 after	 the	 second	 Chelating	 Sepharose	column.		This	column	used	a	gradient	from	low-	to	high-salt	buffer	(50	mM	HEPES	pH	7.8,	10	µM	ZnSO4,	1	mM	TCEP,	50	mM	NaCl,	and	5	mM	KCl;	and	50	mM	HEPES	pH	7.8,	10	µM	ZnSO4,	1	mM	TCEP,	1	M	NaCl,	and	5	mM	KCl,	respectively).		
HDAC8	and	HDAC3	activity	using	the	stopped	enzyme-coupled	assay5	To	remove	contaminating	metals	from	peptide	substrates,	approximately	6%	(v/v)	hydrated	Chelex	100	was	added	to	the	Ac-KGGAKac-NH2	and	Ac-KGGAKacW-NH2	peptides	and	incubated	at	room	temperature	for	3	h.		The	Ac-KGGAKacW-NH2	peptide	concentration	was	 determined	 from	 the	 absorbance	 measurement	 at	 280	 nm	 using	 an	 ND-1000	spectrophotometer	 (NanoDrop)	with	 a	 calculated	 extinction	 coefficient	 of	 5500	M-1	 cm-1	(88).	 	 In	 addition,	 the	 concentration	 of	 peptides	 containing	 a	 free	 amine	 (lysine)	 was	measured	 using	 the	 fluorescamine	 assay	 described	 below.	 	 Peptide	 substrates	without	 a	fluorophore	 (0–1600	 µM)	 were	 pre-incubated	 in	 HDAC8	 stopped	 assay	 buffer	 (25	 mM	HEPES	pH	8.0,	137	mM	NaCl,	3	mM	KCl)	at	30	°C	for	10	min.		The	reactions	were	initiated	by	adding	Co(II)-HDAC8	or	HDAC3/NCOR1	to	a	final	concentration	of	0.5	µM	and	incubated	for	 0,	 30,	 60,	 and	 90	 min.,	 and	 quenched	 by	 the	 addition	 of	 0.37%	 (v/v)	 HCl	 (final	concentration).		The	reactions	were	flash	frozen	within	20	min	of	quenching	and	stored	at	-
																																																								5	Methods	for	the	coupled-enzyme	assay	and	optimization	of	a	continuous	format	for	this	assay	are	revised	from	Wolfson	et	al.,	2014.	
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80°C.	 	On	thawing,	the	reactions	were	neutralized	by	the	addition	of	0.6%	(w/v)	NaHCO3	(final	concentration).		The	coupler	mixture	(50	mM	HEPES,	400	µM	adenosine	triphosphate	(ATP),	 10	µM	nicotinamide	 adenine	dinucleotide	 (NAD+),	 30	µM	coenzyme	A	 (CoA),	 0.07	U/µl	 citrate	 synthase	 (CS),	 0.04	 U/µl	 malate	 dehydrogenase	 (MDH),	 50	 µM	 acetyl	 CoA	synthetase	(ACS),	100	mM	NaCl,	3	mM	KCl,	50	mM	MgCl,	and	2.5	mM	L-malic	acid,	pH	8.0)	was	incubated	for	20	min	at	room	temperature	and	added	to	each	quenched	reaction	(at	a	ratio	 of	 10	 µl	 coupler	mix/65	 µl	 reaction)	 in	 a	 96-well	 black	 plate.	 	 The	 reactions	were	incubated	at	room	temperature	for	40	min,	and	the	NADH	fluorescence	(Ex	=	340	nm,	Em	=	460	 nm)	 was	 measured.	 	 The	 steady-state	 kinetic	 parameters	 for	 the	 Ac-KGGAKac-COO	peptide	 were	 determined	 from	 fitting	 the	 Michaelis–Menten	 equation	 (v0/[HDAC]	 =	(kcat[S])	/	(KM	+	[S]))	to	the	concentration	dependence	of	HDAC-catalyzed	deacetylation.				
Optimizing	a	continuous	version	of	a	stopped	enzyme-coupled	assay	to	monitor	HDAC8	
activity		The	continuous	assay	was	run	according	to	the	same	basic	method	as	the	stopped	enzyme-coupled	 assay,	 as	 described	 above	 and	 in	 Wolfson	 et	 al.,	 with	 the	 following	differences.		The	96-well	plates	were	soaked	(>3	hrs)	in	100	mM	divalent	metal	free	EDTA	to	strip	the	plates	of	contaminating	metal.	 	Plates	were	then	rinsed	5	times	with	divalent	metal	free	ultrapure	water.	 	The	continuous	assay	buffer	(50	mM	HEPES,	400	µM	ATP,	10	µM	NAD+,	30	µM	CoA,	0.07	U/µl	CS,	0.04	U/µl	MDH,	50	µM	ACS,	127	mM	NaCl,	2.7	mM	KCl,	and	 2.5	 mM	 L-malic	 acid,	 pH	 8.0)	 was	 incubated	 with	 Chelex	 resin	 for	 1	 h	 at	 room	temperature.		The	mixture	was	clarified	by	centrifugation	at	16,800	x	g	for	2	min,	and	the	supernatant	was	collected.	 	Then,	6	mM	magnesium	(MgCl2)	was	added	to	the	buffer,	and	
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the	 mixture	 was	 incubated	 for	 20	 min	 to	 allow	 NAD+/malate	 and	 NADH/OAA	(oxaloacetate)	to	equilibrate.	 	The	peptide	(100	µM	final	concentration	Ac-KGGAKac-NH2)	in	 HDAC8	 assay	 buffer	 was	 added	 to	 this	 mixture	 at	 a	 ratio	 of	 2:1.	 	 The	 reaction	 was	initiated	 with	 the	 addition	 of	 Co(II)–HDAC8	 (0.5	 –	 1	 µM	 final	 concentration),	 and	deacetylation	was	measured	from	the	time-dependent	increase	in	NADH	fluorescence	(Ex	=	340	nm,	Em	=	460	nm).				
SILAC	target	verification	by	in	vitro	peptide	assays6	Peptides	were	purchased	from	Peptide	2.0	with	a	purity	of	>	75%	with	an	acetylated	N-terminus	 and	 an	 amidated	 C-terminus	 and	 were	 resuspended	 in	 water.	 	 The	concentrations	 of	 peptides	 containing	 an	 unmodified	 lysine	 were	 measured	 using	 the	fluorescamine	assay	as	previously	described	(76).		All	peptide	concentrations	were	within	two-fold	of	the	calculated	concentration	based	on	weight.	 	The	CSRP2BP	peptide	contains	no	amine	or	aromatic	amino	acids;	and	therefore,	the	concentration	was	calculated	based	on	the	mass	provided	by	Peptide	2.0.	 	Recombinant	human	HDAC8	was	either	purchased	(BPS	Bioscience)	or	purified	from	E.	coli	as	previously	described	(57),	and	all	other	HDAC	homologues	were	purchased	from	BPS	Biosciences.		HDAC	assays	were	performed	using	an	enzyme-coupled	system	to	measure	acetate	production	as	described	above.		The	reactions	were	measured	under	standard	HDAC	reaction	conditions	(137	mM	NaCl,	2.7	mM	KCl,	25	mM	HEPES,	pH	7.8,	30˚C).	 	Reactions	measuring	deacetylation	of	acetylated	peptides	(0	–	1600	 μM)	were	 initiated	 by	 addition	 of	 recombinant	 Zn(II)-HDAC8	 (0.5	 –	 2.0	 μM).	 	 The	reactions	were	quenched	by	the	addition	of	HCl,	and	the	acetate	product,	as	reflected	by	an																																																									6	Methods	for	HDAC-assays	on	SILAC	peptides	are	revised	from	Olson	et	al.,	2014.	
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increase	 in	 the	 NADH	 fluorescence,	 was	 measured	 at	 4	 time	 points	 (up	 to	 50	 min).		Recombinant	HDAC	isozymes	1-9	(0.4	μM),	prepared	by	BPS	Biosciences	from	baculovirus	expression,	were	mixed	with	 acetylated	 peptides	 (100	 μM)	 and	 the	 formation	 of	 acetate	product	was	measured	as	a	function	of	time.		The	initial	velocities	(v0)	were	calculated	from	a	linear	fit	of	the	time-dependent	increase	in	NADH	fluorescence.	 	The	kinetic	parameters	were	determined	from	fitting	either	a	line	or	the	Michaelis-Menten	equation	(v0/[HDAC8]	=	(kcat[S])	/	(KM	+	[S]))	to	the	dependence	of	the	initial	velocity	on	the	peptide	concentration.			
	
Peptide	detection	by	HPLC-MS		
	 Peptides	 for	HPLC-MS	 analysis	were	 purchased	 from	 Peptide2.0	 at	 ≥	 70%	purity.		Peptides	 were	 ordered	 with	 an	 acetylated	 N-terminus	 and	 an	 amidated	 C-terminus.		Identical	 peptides	 were	 ordered	 with	 and	 without	 an	 acetyllysine	 residue.	 	 Solutions	 of	acetylated	and	non-acetylated	peptide	were	prepared	at	various	ratios.		Formic	acid	(0.1%)	was	added	to	peptide	solutions.		The	samples	were	injected	into	an	Agilent	Q-TOF	HPLC-MS	instrument	 at	 15	 –	 20	 µL.	 	 Samples	 were	 run	with	 a	 flow	 rate	 of	 0.4	mL/min.	 	 Peptide	samples	were	loaded	onto	an	in-line	C8	column	at	95%	buffer	A	(water	with	0.1%	formic	acid)	and	5%	buffer	B	(95%	acetonitrile	with	0.1%	formic	acid).		Peptides	were	eluted	over	a	 20-minute	 gradient	 of	 increasing	 buffer	 B,	 up	 to	 100%.	 	 Eluant	 was	 fed	 into	 an	electrospray	 ionization	 source	 and	 analyzed	 by	 time	 of	 flight.	 	 The	 instrument	 was	operated	 in	positive	 ion	mode,	 and	 analysis	was	performed	using	 the	Agilent	Qualitative	Analysis	 software.	 	 Total	 ion	 count	 traces	 were	 integrated	 to	 determine	 area	 under	 the	curve	(AUC)	for	generating	standard	curves.	
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	 Peptide	 reactions	 for	 HPLC-MS	 analysis	 were	 carried	 out	 after	 a	 1-hour	reconstitution	of	2:1	cobalt	to	apo-HDAC8.		Reactions	were	run	in	1x	HDAC	assay	buffer	(25	mM	 HEPES	 pH	 8.0,	 137	 mM	 NaCl,	 3	 mM	 KCl)	 at	 34˚C	 with	 100	 µM	 substrate	 (Ac-KLIS[KAc]FDKL-NH2).		Reactions	were	initiated	by	addition	of	HDAC8	(1	µM	final).		
Peptide	deacetylation	detected	by	MALDI-MS	
	 Peptides	for	this	experiment	were	purchased	from	Synthetic	Biomolecules	and	were	ordered	as	‘crude’	purity.		They	ranged	from	6-10	amino	acids	in	length,	with	acetylated	N-termini	and	amidated	C-termini.		Peptide	reactions	were	carried	out	in	8	and	6	µL	volumes,	with	100	and	75	µM	peptide	concentrations.	 	HDAC8	was	reconstituted	1:1	with	zinc	 for	one	hour	 on	 ice.	 	 Reaction	 components	were	 all	 diluted	 into	HDAC	assay	buffer,	 and	 the	final	reactions	were	incubated	at	25˚C	in	1x	HDAC	assay	buffer.		Reactions	were	initiated	by	addition	of	HDAC8	(1	µM	final).	 	At	 time	points	between	0	and	30	minutes,	2	µL	aliquots	were	 removed	 from	 the	 reactions	 and	 quenched	 into	 1	 µL	 10%	 hydrochloric	 acid.		Quenched	time	points	were	then	mixed	1:1	(v/v)	with	an	α-Cyano-4-hydroxycinnamic	acid	(HCCA)	matrix	solution	prepared	fresh	daily.		Single	use	1	mg	vials	of	HCCA	from	Thermo	Fisher	 were	 dissolved	 to	 10	 mg/mL	 in	 70/30	 acetonitrile/water	 with	 0.1%	 TFA.	 	 The	reaction	 time	 points	were	mixed	with	matrix,	 immediately	 spotted	 on	 a	 96-spot	 ground	steel	MALDI	target	(Bruker),	and	allowed	to	dry	completely.		Five	peptides	of	higher	purity	(>75%)	were	 also	mixed	with	matrix	 solution	 and	 spotted	 on	 the	MALDI	 target.	 	 These	peptides	were	used	to	calibrate	the	mass	spectrometer.	
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Results	and	Discussion	
HDAC8	activity	can	be	monitored	continuously	by	an	enzyme-coupled	assay	 	
7A	previous	lab	member,	Dr.	Noah	Wolfson,	optimized	a	stopped	coupled-enzyme	assay	for	determining	HDAC8-catalyzed	 deacetylation	 of	 unlabeled	 protein	 and	 peptide	 substrates	(76).		After	optimizing	this	stopped	assay,	we	next	evaluated	whether	this	same	assay	could	be	 carried	 out	 as	 a	 continuous	 real-time	 assay	 to	 measure	 HDAC8	 activity.	 	 HDAC8	 is	sensitive	 to	 inhibition	 by	 metals	 (57)	 and	 monovalent	 cations	 (21),	 thus	 the	 acetate	coupling	solutions	for	the	continuous	assay	were	reformulated	with	concentrations	of	NaCl	and	KCl	typically	used	to	assay	HDAC8	activity	(BIOMOL,	unpublished;	see	also	(21))	and	were	treated	with	Chelex	resin	prior	to	the	addition	of	magnesium.	 	The	concentration	of	magnesium	 was	 decreased	 to	 2	 mM	 to	 minimize	 inhibition	 of	 HDAC8	 activity	 (~2-fold	inhibition	 under	 these	 conditions).	 	 To	 counteract	 the	 loss	 in	 activity	 of	 the	 coupling	enzymes	due	to	the	lower	concentration	of	magnesium,	the	concentration	of	these	enzymes	was	 increased	by	2.3-fold	 to	 yield	 a	 final	 rate	 for	 the	 coupling	 reactions	of	0.046	µM•s-1.		These	assay	 conditions	were	used	 to	measure	HDAC8-catalyzed	deacetylation	of	 the	100	µM	 Ac-KGGAKac-NH2	 peptide.	 	 We	 repeated	 this	 assay	 with	 multiple	 concentrations	 of	HDAC8,	yielding	rates	from	0.006	to	0.024	µM•s-1	(Fig.	2.1A).		The	linear	dependence	on	the	HDAC8	 concentration	 demonstrates	 that	 the	 assay	 rate	 is	 not	 limited	 by	 the	 coupling	reactions	(Fig.	2.1B).		Furthermore,	the	HDAC8	activity	measured	using	the	stopped	assay	(0.5	µM	HDAC8	and	100	µM	Ac-KGGAKac-NH2)	is	0.033	±	0.0034	µM•s-1,	which	is	within	2-fold	of	 the	rate	measured	using	the	continuous	assay	and	 is	consistent	with	the	expected	inhibition	of	Co-HDAC8	by	magnesium.																																																											7	This	paragraph	revised	from	Wolfson	et	al.,	2014.	
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By	monitoring	 HDAC8	 activity	 continuously,	 we	were	 able	 to	 significantly	 reduce	both	the	time	needed	to	complete	an	assay	and	the	amount	of	material	required.		The	time	course	 for	 the	HDAC-catalyzed	 reaction	did	 not	 change	during	 continuous	 assay,	 but	 the	lengthy	work	up	after	 the	reaction	was	quenched	was	eliminated.	 	This	also	meant	assay	time	points	did	not	need	to	be	thawed,	neutralized,	or	aliquoted	 into	plates	with	coupled	solution;	all	steps	that	had	the	potential	to	introduce	error	into	the	discontinuous	method.		Additionally,	instead	of	a	stopped	assay	that	required	60	µL	per	each	time	point,	with	the	continuous	method	only	 the	 equivalent	of	 one	 time	point	was	 required.	 	By	doing	 so	we	saved	 HDAC,	 substrate	 peptides,	 and	 the	 enzyme	mixture	 used	 in	 the	 coupled	 reaction.		Additionally,	 the	 increased	 number	 of	 data	 points	 collected	 during	 the	 continuous	 assay	increases	 its	 precision.	 	 Table	 2.1	 summarizes	 the	 differences	 between	 the	 stopped	 and	continuous	versions	of	this	assay.			
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Table	2.1	Two	methods	for	running	our	enzyme-coupled	assay	
Stopped	Assay Continuous	Assay
Prepare	coupled	enzyme	
solution	(1	hour),
Prepare	copuled	enzyme	
solution	(1	hour),
HDAC-reaction	time	(0	-	2	
hours),
HDAC-reaction	time	(0	-	2	
hours),
Freeze/thaw/neutralize	(1	hour	-	
overnight),
N/A,
Plate	time	points/coupled-
enzyme	reaction	(1-2	hours),
N/A,
Total	Time	=	1	-	1.5	days Total	Time	=	half	day
HDAC	(0.5	µM)		-		>	300	µL HDAC	(0.5	µM)		-		60	µL
Coupled	solution		-		>	50	µL Coupled	solution		-		10	µL
HCl	(10%)		-		12.5	µL N/A
NaHCO3	(6%)		-		37.5	µL N/A
Plate	wells	required		-		5 Plate	wells	required		-		1
HDAC	
Activity
Full	activity	(100%) Reduced	activity	(40-60%)
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Figure	2.1	Continuous	measurement	of	HDAC8	activity	 	(A)	Continuous	measurement	of	HDAC8	activity.	 	Activity	was	assayed	at	0	µM	(blue),	0.25	µM	(brown),	0.5	µM	(green),	0.75	µM	(red),	and	1	µM	(black).	 	 (B)	Dependence	of	 the	continuously	measured	HDAC8	 initial	rates	on	enzyme	concentration.		The	linear	correlation	here	indicates	that	HDAC8-catalyzed	deacetylation	is	rate-limiting,	not	the	coupled-enzyme	reactions.		
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Measuring	deacetylation	catalyzed	by	other	HDAC-isozymes	using	the	coupled-enzyme	assay		 We	 optimized	 this	 enzyme-coupled	 assay	 using	 HDAC8.	 	 We	 next	 sought	 to	demonstrate	 that	 this	 assay	 that	 detects	 low	 micromolar	 concentrations	 of	 acetate	 was	broadly	capable	of	measuring	activity	for	any	HDAC	isozyme.		Using	the	same	peptide	that	we	 used	 to	 characterize	HDAC8	with	 this	 assay,	we	measured	 the	 activity	 of	 HDAC3	 (in	complex	with	NCOR1)	using	the	stopped	assay	format	as	proof	of	principle	(Fig.	2.2).		The	ratio	 of	 HDAC3-catalyzed	 deacetylation	 of	 this	 peptide	was	 about	 half	 of	 that	 seen	with	HDAC8	at	comparable	substrate	concentrations.				
	
Figure	2.2	HDAC3-catalyzed	deacetylation	HDAC3/NCOR1	 was	 assayed	 with	 the	 stopped	 version	 of	 the	 coupled-enzyme	 assay	 to	 validate	 that	 this	method	 is	 useful	 for	 assaying	multiple	 HDAC-isozymes.	 	 HDAC3	 (0.5	 µM)	was	 incubated	with	 100	 µM	Ac-KGGAKac-NH2	in	1x	HDAC	assay	buffer	at	30˚C.		Time	points	were	quenched	into	HCl	and	the	reaction	progress	was	measured	by	NADH	fluorescence,	as	described.		
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	 We	 next	 used	 this	 assay	 to	 validate	 putative	 HDAC8	 substrates	 identified	 by	 our	collaborator	Ed	Holson	at	 the	Broad	 Institute	(61).	 	Briefly,	 the	Holson	group	grew	 three	cell	cultures,	each	with	a	unique	stable	 isotope	label.	 	They	treated	cultures	with	a	DMSO	vehicle	control,	a	pan-HDAC	inhibitor,	or	an	HDAC8	specific	inhibitor.		After	treatment,	cells	were	 lysed,	 enriched	 for	 acetyllysine,	 and	 analyzed	 by	mass	 spectrometry.	 	 Importantly,	they	identified	a	small	set	of	proteins	whose	acetylation	profile	increased	upon	addition	of	the	HDAC8-specific	 inhibitor	but	not	upon	addition	of	DMSO	only.	 	We	used	our	enzyme-coupled	 assay	 to	 examine	 reactivity	 of	 acetylated	 peptides	 from	 these	 proteins	 with	HDAC8,	identify	which	acetyllysine	sites	were	most	likely	to	be	deacetylated	by	HDAC8,	and	probe	 the	 degree	 to	 which	 these	 substrates	might	 be	 specific	 to	 HDAC8	 vs	 other	 HDAC	isozymes	(61).		 To	answer	the	first	two	questions,	we	used	the	stopped	version	of	the	coupled	assay	to	measure	kinetic	rate	constants	for	peptides	corresponding	to	acetyllysine	residues	in	the	identified	 proteins.	 	We	 found	 that	 our	 in	 vitro	 assay	 showed	 good	 agreement	 with	 the	hypothesis	 that	 these	 proteins	 could	 be	 deacetylated	 in	 vivo	 by	 HDAC8.	 	 All	 acetylated	peptides	tested	were	deacetylated	by	HDAC8	in	vitro.		The	measured	rate	constant,	kcat/KM,	which	is	also	known	as	the	specificity	constant,	varied	over	three	orders	of	magnitude	from	less	than	5	M-1s-1	for	the	slowest	substrate	to	over	700	M-1s-1	for	the	fastest	(Table	2.2).				 To	determine	which	peptides	are	specifically	deacetylated	by	HDAC8	compared	to	other	HDAC	isozymes,	we	used	commercially	available	recombinant	HDACs	1-9	to	generate	apparent	kcat/KM	values	for	each	isozyme	with	each	substrate.	 	We	found	that	none	of	the	tested	peptides	were	deacetylated	only	by	HDAC8.	 	 Interestingly,	 the	fastest	peptide	with	
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HDAC8	was	also	rapidly	deacetylated	by	HDAC3,	 the	closest	homologue	to	HDAC8	(Table	2.3).				 The	ability	to	quickly	assay	unlabeled	peptide	substrate	in	vitro,	with	either	a	single	HDAC	 isozyme	or	a	panel	of	HDACs,	 is	a	powerful	new	technique	 in	 the	acetylation	 field.		This	 approach	has	 furthered	our	 ability	 to	 use	biochemical	 approaches	 to	 further	 test	 in	
vivo	data	suggesting	HDAC	substrates	 from	perturbation	of	cellular	deacetylation.	 	The	 in	
vitro	assay	provides	evidence	to	support	or	refute	direct	interactions	between	HDACs	and	substrates,	and	can	be	used	to	evaluate	if	phenotypic	changes	in	acetylation	are	primary	or	downstream	effects.		
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Table	2.2	Specificity	constants	for	HDAC8-catalyzed	deacetylation	of	SILAC-based	
peptides	Peptides	were	all	N-terminally	acetylated	and	C-terminally	amidated.		Deacetylation	was	measured	with	Zn-HDAC8	expressed	and	purified	in-house	using	the	stopped	form	of	the	enzyme-coupled	assay.	Protein	 Peptide	Sequence	 kcat/KM	(M-1s-1)	RAI1	 KLGGKacQRAA	 			11	±	1	ZRANB2	 TEIGKacTLAEK	 		4.1	±	0.3	THRAP3	 LGDGKacMKS	 		4.6	±	0.1	NCOA3	 KRILHKacLLQN	 			50	±	5	SRSF5	 KLSGKacEING	 		9.8	±	2	ARID1A	 KLISKacFDKL	 		740	±	40	CSRP2BP	 STPVKacFISR	 		160	±	30	MLL2	 SKIQKacQLDQ	 			32	±	6	SMC3	 RVIGAKKacDQY	 			63	±	11		
	 42	
Table	2.3	Results	from	screening	HDAC-isozymes	against	peptide	substrates8	HDACs	 in	 these	 experiments	were	 commercially	purchased	 recombinant	 enzymes	expressed	 in	 insect	 cells	(BPS	Bioscience).	 	 If	 an	 isozyme-substrate	pair	was	not	 tested,	 it	 is	marked	with	 a	dashed	 line	 (-).	 	HDAC-catalyzed	deacetylation	was	measured	using	the	stopped	form	of	 the	coupled-enzyme	assay.	 	All	substrates	were	deacetylated	by	at	least	two	isozymes.		Values	shown	are	kcat/KM,	app	in	M-1s-1.			Protein	 HDAC1	 HDAC2	 HDAC3	 HDAC4	 HDAC6	 HDAC7	 HDAC8	 HDAC9	RAI1	 50	 <	20	 1700	 -	 -	 -	 <	20	 <	20	ZRANB2	 <	20	 <	20	 50	 <	20	 270	 <	20	 <	20	 <	20	THRAP3	 <	20	 30	 1600	 -	 -	 -	 <	20	 <	20	NCOA3	 70	 <	20	 2200	 <	20	 70	 140	 -	 <	20	SRSF5	 <	20	 <	20	 60	 70	 820	 -	 <	20	 <	20	ARID1A	 50	 <	20	 2500	 <	20	 1200	 <	20	 2400	 <	20	CSRP2BP	 50	 <	20	 1500	 <	20	 210	 -	 740	 <	20	MLL2	 <	20	 30	 220	 -	 -	 -	 -	 <	20			
HDAC8-catalyzed	deacetylation	of	peptides	can	be	quantified	by	LC-MS		 In	 addition	 to	 an	 enzyme-coupled	 assay,	 we	 are	 also	 interested	 in	 identifying	methods	 to	 directly	 measure	 HDAC	 activity.	 	 To	 this	 effect	 we	 have	 shown	 that	 HDAC	catalysis	of	peptides	in	solution	can	be	visualized	as	a	stopped	assay	by	mass	spectrometry.		We	 first	 demonstrated	 that	 an	 acetylated	 peptide	 could	 be	 discriminated	 from	 a	deacetylated	 peptide	 by	 coupling	 an	 HPLC	 with	 a	 reversed	 phase	 C8	 column	 to	 an	 ESI	source	 time-of-flight	 mass	 spectrometer.	 	 As	 expected,	 the	 acetylated	 substrate	 peptide	elutes	 more	 slowly	 from	 a	 C8	 column	 than	 the	 deacetylated,	 more	 hydrophilic	 product	
																																																								8	Data	in	table	reproduced	from	Olson	et	al.,	2014.	
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peptide	 (Fig.	 2.3).	 	 By	 injecting	 various	 ratios	 of	 ‘substrate’	 and	 ‘product’	 peptide,	 we	generated	a	standard	curve	based	on	 integrating	 the	area	under	 the	curve	(AUC)	created	from	 the	 total	 ion	 counts	 from	 each	 peptide	 (Fig.	 2.4).	 	 A	 linear	 relationship	 between	fraction	 product	 and	 AUC	 is	 observed	 up	 to	 ~50%	 product.	 	 This	 range	 is	 sufficient	 for	monitoring	 the	 first	 10-20%	 of	 a	 reaction	 to	 determine	 an	 initial	 rate.	 	 Finally,	 we	demonstrated	that	this	approach	could	be	used	to	measure	HDAC8-catalyzed	deacetylation,	with	minimal	 sample	 preparation.	 	We	 incubated	HDAC	with	 an	 acetylated	 peptide	 (Ac-KLISKacFDKL-NH2)	 and	 quenched	 HDAC8	 activity	 at	 various	 time	 points	 by	 diluting	samples	 of	 the	 reaction	 into	 10%	 hydrochloric	 acid.	 	 Fractionation	 using	 an	 on-line	 C8	column	provides	sufficient	separation	of	substrate,	product,	and	HDAC8	(Fig.	2.5).				 This	 technique	 is	 advantageous	 in	 its	 straightforward	 measurement	 of	 peptide	deacetylation.	 	 This	 method	 does	 not	 require	 preparation	 of	 coupling	 reagents	 and	enzymes,	and	because	an	exact	mass	is	determined	for	substrate	and	product	peaks,	there	is	no	ambiguity	in	whether	or	not	deacetylation	of	the	peptide	has	occurred.		This	method	is	best	suited	to	studying	HDAC	activity	on	a	single	substrate.		A	calibration	curve	must	be	prepared	 for	 each	 substrate	 because	 acquisition	 times	 and	 the	 separation	 between	substrate	and	product	peaks	are	variable	and	depend	on	the	peptide	being	analyzed.				
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Figure	2.3	Separation	of	acetylated	and	non-acetylated	peptide	mixtures	To	determine	the	effectiveness	of	HPLC-MS	in	the	separation	and	quantification	of	acetylated	(substrate)	and	non-acetylated	(product)	peptides,	a	series	of	samples	were	run	with	varying	concentrations	of	substrate	and	product.	 	 The	 graphs	 shown	 are	 total	 ion	 count	 (TIC)	 vs.	 	 peptide	 acquisition	 time	 from	 the	 mass	spectrometer.	 	 These	 peptides	 (based	 on	 ARID1A,	 Table	 2.2)	 were	 purchased,	 at	 >75%	 purity,	 with	(substrate)	and	without	(product)	an	acetyllysine	reside.	 	The	substrate:product	peptide	ratios	included	are	Mixture	1	=	80:20,	Mixture	2	=	50:50,	Mixture	3	=	30:70,	and	Mixture	4	=	10:90.		Each	major	peak	is	rapidly	followed	 by	 a	 less	 intense	 peak,	 which	 corresponds	 to	 a	 different	 protonation	 state.	 	 Both	 the	major	 and	minor	peaks	for	each	peptide	were	included	in	the	analysis.		
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Figure	2.4	HPLC-MS	peptide	standard	curve	Acetylated	 and	 non-acetylated	 peptides	 (sequence	 based	 on	 ARID1A	 in	 table	 2.2)	 were	 injected	 into	 an	Agilent	Q-TOF	HPLC-MS	in	various	substrate	and	product	ratios.		The	resulting	ion	count	vs	acquisition	time	data,	shown	in	Fig.	2.3,	was	quantified	according	to	AUC.		These	data	were	used	to	generate	a	standard	curve.		This	curve	is	linear	through	50%	product.		
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Figure	2.5	HPLC-MS	measurement	of	HDAC8-catalyzed	deacetylation		Good	 separation	 between	 substrate	 and	 product	 peaks	 was	 observed	 following	 HDAC8-catalyze	deacetylation.	 	 Reactions	were	 run	with	 1	 µM	 Co-HDAC8	 and	 100	 µM	 substrate	 in	 1x	 HDAC	 assay	 buffer.		Reaction	time	points	(35	µL),	 from	top	to	bottom	(1	min.,	5	min.,	10	min.),	were	quenched	in	10	µL	of	10%	hydrochloric	acid	and	15	µL	were	injected	into	the	mass	spectrometer.		The	peptide	substrate	was	based	on	ARID1A	(table	2.2).		
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Peptide	substrate	libraries	can	be	screened	by	MALDI-TOF	mass	spectroscopy	
	 With	 the	 HPLC-MS	 peptide	 method	 optimized	 for	 quantitative	 analysis	 of	 single	substrates,	 we	 next	 looked	 to	 find	 a	 qualitative	 mass	 spectrometry	 method	 suitable	 for	assaying	 multiple	 substrates.	 	 Using	 a	 96-well	 MALDI	 target,	 we	 were	 able	 to	 detect	deacetylation	of	peptide	substrates	in	a	method	that	is	both	rapid	and	consumes	a	minimal	amount	of	material.		Using	a	small	volume	of	75	µM	peptide,	we	measured	time	dependence	of	deacetylation	catalyzed	by	HDAC8	(Fig.	2.6).		We	initially	developed	this	assay	using	four	peptide	substrates	that	had	not	previously	been	tested	with	HDAC8	but	scored	well	 in	an	algorithm	designed	to	predict	HDAC8	substrates	(89).	 	Ultimately,	we	used	this	technique	to	evaluate	a	larger	peptide	library,	finding	a	mix	of	substrate	and	non-substrate	peptides.		We	 then	 used	 the	 enzyme-coupled	 assay	 to	 corroborate	 these	 results.	 	 We	 found	 good	agreement	between	the	predicted	substrates,	the	MALDI	results,	and	the	activity	measured	using	 our	 coupled	 assay.	 	 The	 biological	 significance	 and	 rational	 behind	 the	 peptides	chosen	for	this	experiment,	as	well	as	a	more	detailed	explanation	of	results,	 is	discussed	further	in	Chapter	4	(Proteome	chips).		 Unlike	our	HPLC-MS	method,	this	technique	using	a	MALDI	source	does	not	provide	quantitative	 kinetic	 data.	 	 This	 is	 an	 inherent	 limitation	 of	 MALDI,	 where	 replication	 of	ionization	by	laser	is	frequently	variable.	 	We	are	instead	able	to	determine,	qualitatively,	whether	or	not	a	peptide	is	deacetylated	to	some	extent	over	a	given	time	course.		With	this	technique,	we	have	eliminated	the	need	for	a	new	calibration	curve	for	each	peptide,	and	can	instead	use	a	small	set	of	known	molecular	weight	peptides	to	calibrate	the	instrument	in	a	general	manner	for	all	peptides	to	be	tested.		This	method	requires	only	small	volumes	for	each	point	to	be	measured,	allowing	reactions	to	be	run	at	volumes	under	10	µL.		This	
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assay	therefore	represents	a	rapid	method	to	qualitatively	scan	a	peptide	library	using	30-50	fold	 less	material	 than	would	be	required	for	the	enzyme-coupled	assay.	 	Positive	hits	from	a	MALDI	screen	can	then	be	selected	and	kinetic	parameters	can	be	measured	using	a	more	resource-intensive	method.			We	 have	 described	 various	 techniques,	 which	 differ	 in	 their	 set-up	 times,	 material	requirements,	and	detection	methods.		The	advantages	and	disadvantages	of	each	of	these	techniques	 are	 summarized	 in	 Table	 2.4.	 	 The	 MALDI	 assay	 can	 be	 combined	 with	 the	coupled-enzyme	assay	to	first	screen	and	then	quantify	HDAC-catalyzed	deacetylation	of	a	peptide	 library.	 	The	Q-TOF	HPLC-MS	method	 is	best	suited	 for	experiments	 that	 require	only	one	substrate.		This	could	be	investigating	the	effects	of	site-directed	mutagenesis	on	enzyme	 activity,	 environmental	 variations	 like	 divalent	 metals,	 salts,	 and	 pH,	 effect	 of	inhibitors,	 etc.	 	 This	 method	 is	 also	 a	 useful	 tool	 for	 the	 validation	 of	 indirect	 assay	measurements.	 	 The	 development	 and	 optimization	 of	 these	methods	 has	 expanded	 the	available	techniques	by	which	HDAC	activity	and	selectivity	can	be	assayed.					
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Table	2.4	Summary	of	peptide-based	HDAC	assay	methods	
Advantages Disadvantages
Sensitive	detection	of	
acetate	(low	µM),
Resource	intensive,
HDAC-reaction	not	
dependent	on	speed	of	
coupled	enzymes,
Time	consuming
HDAC-buffer	can	be	altered	
without	affecting	coupled	
enzyme	activity
Rapid,	no	post	reaction	work-
up	required,
HDAC	is	partially	inhibited,
Smaller	HDAC	and	coupled	
enzyme	volumes,
Sensitive	to	activity	of	coupled	
enzymes,
No	quench	solution HDAC	deacetylation	rate	must	be	
slower	than	coupled	reactions
Direct	measurement	of	
substrate	and	product,
Variation	between	substrates	
requires	multiple	standard	curves,
No	coupled-reaction	
enzymes	required
HPLC-MS	instrument	cost	to	
own/operate
Lowest	HDAC	and	substrate	
usage,
Requires	that	peptide	ionizes	well,
Rapid	screen	of	multiple	
substrates,
Not	quantitative,
No	coupled-reaction	
enzymes	required
MALDI-MS	instrument	cost	to	
own/operate,
Requires	matrix	solution
MALDI-MS
Coupled-enzyme	
assay	(stopped)
Coupled-enzyme	
assay	(continuous)
HPLC-MS
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Figure	2.6	MALDI-MS	detection	HDAC8-catalyzed	deacetylation	(A)	Deacetylation	of	peptide	substrates	results	 in	a	42-dalton	shift	down	 in	molecular	weight.	 	 (B)	 	HDAC8	was	used	at	0.5	µM	to	catalyze	deacetylation	of	a	peptide	substrate	(75	µM)	based	on	the	protein	isocitrate	dehydrogenase	1.		The	reaction	was	quenched	at	3	time	points	(0.5	min.,	15	min.,	30	min.),	shown	from	top	to	bottom.		The	substrate	peptide	has	a	molecular	weight	of	909	Da,	and	the	deacetylated	product	peptide	has	a	molecular	weight	of	867	Da,	a	loss	of	42	Da.		By	30	min.,	the	substrate	peak	is	no	longer	visible.		
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Chapter	3	
Expression	and	Characterization	of	HDAC119	
Introduction	Nε-lysine	 acetylation	 is	 a	 dynamic	 post-translational	 modification	 occurring	ubiquitously	in	eukaryotic	cells	(90,	91).		Recent	studies	estimate	that	acetylation	occurs	on	thousands	 of	 different	 proteins	 (86),	 at	 over	 20,000	 lysine	 residues	 (6).	 	 Regulation	 of	lysine	acetylation	is	controlled	by	the	activity	of	two	families	of	enzymes,	the	lysine	acetyl	transferases	(KATs)	and	the	histone	deacetylases	(HDACs).		The	HDACs	are	the	divided	into	four	classes.		Class	I	(HDACs	1,	2,	3,	8),	class	II	(HDACs	4,	5,	6,	7,	9,	10),	class	III	(sirtuins),	and	class	IV	(HDAC11).		The	class	I,	II,	and	IV	HDACs	are	metal-dependent	deacetylases	that	are	phylogenetically	similar	to	one	another	but	distinct	from	the	class	III	sirtuins	(73).			HDAC11,	the	only	class	IV	HDAC,	is	the	most	recently	identified	HDAC	isozyme	(24).		It	 is	also	among	the	 least	studied	and	most	poorly	understood	HDACs.	 	A	pubmed	search	(title/abstract)	 for	 the	 last	10	years	shows	that	HDAC11	was	the	second	 least	mentioned	isozyme,	ahead	of	only	HDAC10.		HDAC11	was	referenced	70	times,	while	HDAC1,	the	most	highly	published	isozyme,	had	1,666	hits	over	the	same	10-year	span.	The	bulk	of	HDAC11	studies	are	cell	based	and	have	uncovered	a	few	potential	roles	for	 this	 enzyme	 in	 major	 pathways	 and	 disease	 states.	 	 Changes	 in	 HDAC11	 expression																																																									9	Lubomir	Dostal	carried	out	the	expression	and	purification	of	HDAC11	from	HEK293	cells.		HDAC11	was	expressed	in	insect	cells	by	Clay	Brown	(LSI)	and	purified	by	Eric	Sullivan.		E.	coli	expression	and	purification	of	HDAC11	was	carried	out	by	Eric	Sullivan.	
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levels	 have	 been	 linked	 to	 ductal	 breast	 carcinomas,	where	HDAC11	 is	 in	 the	 top	 1%	of	genes	 that	 are	 differentially	 overexpressed	 in	 the	 disease	 state	 (69).	 	 This	 same	 study	showed	that	knockouts	of	HDAC11	resulted	in	a	selective	decrease	in	cancer	cell	viability	when	compared	to	non-cancerous	cells.	 	Additionally,	HDAC11	has	been	implicated	in	the	adaptive	immune	response,	where	it	influences	the	expression	of	interleukin-10	(68).	The	discovery	of	disease-related	physiological	 functions	 for	HDAC11	 increases	 the	importance	 of	 understanding	 the	 mechanism	 by	 which	 this	 enzyme	 is	 able	 to	 influence	these	phenotypic	results.		Here,	we	sought	to	develop	biochemical	methods	to	characterize	the	 catalytic	 activity	 of	 HDAC11.	 	 We	 successfully	 expressed	 HDAC11	 in	 bacterial	 and	eukaryotic	cells.	 	HDAC11	expressed	in	E.	coli	is	inactive;	HDAC11	from	eukaryotic	cells	is	active	and	mass	spectra	of	the	protein	expressed	in	insect	sf9	cells	has	a	mass	that	is	42	Da	higher	than	expected,	suggesting	a	post-translational	modification.	 	We	used	the	HDAC11	purified	 from	 insect	 cells	 to	probe	 the	 substrate	 selectivity	of	HDAC11	by	measuring	 the	rate	 constants	 for	 deacetylation	 of	 several	 unique	 peptide	 substrates.	 	We	 show,	 for	 the	first	time,	that	purified	HDAC11	is	catalytically	active,	catalyzing	deacetylation	of	unlabeled	and	non-fluorinated	peptide	substrates.		
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Methods	
Reagents	Reagents	 used	 to	 prepare	 buffers	 were	 from	 Fisher	 or	 Sigma,	 unless	 otherwise	specified.	 	 DH10bac	 cells	were	 a	 generous	 gift	 from	Clay	Brown	 at	 the	UM	Life	 Sciences	Institute	Protein	Core.		
HDAC11	E.	coli	constructs		 The	 human	 HDAC11	 gene	 was	 used	 in	 several	 different	 constructs.	 	 Our	 starting	gene,	based	on	the	human	cDNA,	was	synthesized	by	GeneScript.		We	worked	with	both	the	cDNA-transcribed	 human	 codons,	 as	 well	 as	 a	 gene	 with	 codon	 usage	 optimized	 for	bacterial	expression.	 	Our	optimization	was	done	 through	GeneScript.	 	We	used	standard	PCR	techniques	to	clone	HDAC11	into	pET	21a+	and	pET	M11	vectors,	and	add	or	remove	various	 tags	 and	 fusion	 proteins.	 	 A	 his6-SUMO-HDAC11	 construct	 in	 a	 pET	 21a+	 vector	yielded	the	best	results	and	was	the	expression	construct	used	for	the	majority	of	the	work	with	 the	bacterially	expressed	enzyme	 in	 this	 study.	 	We	also	created	WT	HDAC11,	his6-TEV-HDAC11,	his10-TEV-HDAC11,	HDAC11-TEV-his6,	and	his10-TEV-HDAC11-eGFP-TEV-his6.		The	his10-tagged	constructs	are	codon	optimized	for	bacterial	expression.		
Bacterial	expression	of	HDAC11	in	various	cell	lines	
	 Fresh	transformations	were	used	for	each	HDAC11	culture.	 	Transformations	were	generally	done	with	75-150	µL	of	plasmid	DNA.		Plasmids	were	transformed	into	either	BL-21,	arabinose	induced	(AI),	or	Rosetta	II	competent	cells.		AI	cells	have	a	tighter	regulation	on	 protein	 expression	 than	 standard	 T7	 systems.	 	 They	 feature	 an	 arabinose-inducible	
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araBAD	 promoter	 upstream	 of	 the	 T7	 RNA	 polymerase	 gene.	 	 Cells	 were	 plated	 on	 LB-Amp/Kan/combo	 plates,	 as	 appropriate	 and	 grown	 overnight	 at	 37˚C.	 	 Antibiotic	concentrations	were	100	µg/mL	ampicillin	and	50	µg/mL	kanamycin.		Single	colonies	were	selected	and	 inoculated	 into	10	mL	starter	 cultures	of	2xYT,	plus	antibiotics	 (present	 for	the	rest	of	the	expression).		These	were	grown,	with	shaking,	at	37˚C	until	cloudy	(~4	hrs).		These	 starter	 cultures	were	 then	 used	 to	 inoculate	 1-liter	 cultures	 of	 terrific	 broth	 (TB)	media,	buffered	with	potassium	phosphate.	 	Cells	were	grown,	 in	the	same	manner,	to	an	OD600	of	0.6,	at	which	point	the	temperature	was	decreased	to	18˚C.		After	cooling	(~1	hr),	the	 cells	 were	 induced	 as	 follows;	 BL-21,	 Rosetta	 II,	 and	 AI	 cultures	were	 induced	with	isopropyl	B-D-1-thiogalactopyranoside	(IPTG)	at	a	final	concentration	of	0.4	mM.	 	AI	cells	were	also	 treated	with	0.2%	 (final)	 arabinose.	 	 Cultures	were	grown	 for	16	hours.	 	 Cells	were	then	pelleted	by	centrifugation	at	for	15	minutes	at	4,000	x	g	in	a	Beckman	JLA	8.1000	rotor.		Cell	pellets	were	resuspended	in	HDAC11	E.	coli	lysis	buffer	1	(30	mM	HEPES	pH	8.0,	80	mM	NaCl,	1	mM	TCEP,	5%	glycerol)	with	a	Roche	EDTA-free	protease	inhibitor	cocktail	tablet	 and	 lysed	 using	 a	 microfluidizer	 (DivTech	 Equipment).	 	 Protein	 expression,	 both	soluble	 and	 insoluble	 (separated	 by	 centrifugation	 of	 the	 lysate	 at	 27,000	 x	 g),	 was	determined	by	a	western	blot	probing	for	HDAC11.		
Bacterial	expression	of	HDAC11	in	various	growth	mediums		 His6-SUMO-HDAC11	was	transformed	into	BL-21	(DE3)	cells,	plated,	and	grown	in	10	mL	starter	cultures	as	described	above.		Starter	cultures	were	then	used	to	inoculate	1-liter	cultures	of	LB,	2xYT,	or	TB	media	with	ampicillin	present.		Cells	were	grown	according	to	 the	 conditions	 described	 above	 for	 BL-21	 cells	 (starter	 cultures	 at	 37˚C	 and	 larger	
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cultures	 at	 34˚C,	 followed	 by	 a	 decrease	 to	 18˚C	 at	 OD600	 =	 0.6),	 and	 all	 cell	 lines	 were	induced	with	0.5	mM	IPTG	and	grown	overnight.		Additionally,	a	second	2xYT	culture	was	induced	 with	 only	 0.2	 mM	 IPTG.	 	 Overnight	 cultures	 were	 pelleted,	 and	 lysed	 via	 a	microfluidizer.		Soluble	expression	of	HDAC11	was	determined	by	a	western	blot	using	an	antibody	that	recognizes	poly-histidine.				
Adjusting	buffers	and	addition	of	alcohol	to	HDAC11	E.	coli	expressions		 SUMO-HDAC11	was	transformed	into	BL-21	cells,	plated,	and	inoculated	into	starter	cultures	 as	described	above.	 	 Starter	 cultures	were	 then	used	 to	 inoculate	 several	1-liter	cultures.		The	following	expressions	were	performed	in	parallel	to	test	the	effect	of	added	zinc	to	the	media.		One	set	of	expressions	(3,	1	L	cultures)	was	performed	in	TB	media	with	ampicillin	 and	 a	 potassium	 phosphate	 buffer.	 	 The	 parallel	 expressions	 (3,	 1	 L	 cultures)	were	performed	in	TB	media	with	ampicillin	and	a	tris	buffer.		These	tris	cultures	were	also	supplemented	with	100	µM	zinc	sulfate	at	induction.		All	cultures	were	grown	according	to	the	procedure	 above.	 	At	 induction,	 one	 liter	 of	 culture	 from	each	buffer	 set	was	 treated	with:	1.5%	(final)	ethanol,	10	mM	(final)	benzyl	alcohol,	or	no	additive.	 	Each	culture	was	then	induced	with	0.5	mM	IPTG.		Cells	were	grown,	pelleted,	and	lysed	as	described	above.		Soluble	 and	 insoluble	 expression	 was	 determined	 by	 western	 blot	 using	 an	 antibody	toward	HDAC11.		
Preparation	of	competent	cells	transformed	with	plasmids	encoding	molecular	chaperones		 Z-competent	“mix	and	go”	cells	(Zymo	Research)	were	prepared	according	to	the	kit.		Briefly,	 BL-21	 (DE3)	 cells	 (10	mL)	were	 transformed	with	 various	molecular	 chaperone	
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plasmids	 (Takara)	 (Table	 3.1)	 and	 grown	 overnight	 in	 LB	medium	with	 the	 appropriate	antibiotics.		0.5	mL	of	these	starter	cultures	was	used	to	inoculate	50	mL	cultures	of	Super	Optimal	 Broth	 (S.O.B.)	 medium.	 	 These	 were	 grown,	 with	 shaking,	 at	 34˚C	 until	 OD600	reached	0.4.		The	kit	buffers	were	diluted	to	1x	concentration	ahead	of	time	and	chilled	on	ice.	 	Once	the	bacterial	cultures	had	reached	the	desired	OD,	they	were	transferred	to	 ice	for	10	minutes.		The	cells	were	then	pelleted	by	centrifugation	at	2,000	x	g	for	10	minutes.		The	 supernatants	were	 removed	and	 the	 cell	pellets	were	 resuspended	 in	5	mL	1x	wash	buffer.	 	 Cells	 were	 pelleted	 again.	 	 The	 supernatants	 were	 removed	 and	 cells	 were	 not	resuspended	in	5	mL	1x	competent	buffer.		Cells	were	immediately	aliquoted	(200	µL)	into	microcentrifuge	 tubes	 on	 ice	 before	 being	 flash	 frozen	 in	 liquid	 nitrogen	 and	 stored	 at	 -80˚C.		
Table	3.1:	Chaperone	proteins	co-expressed	with	HDAC11.	
Plasmid Chaperone Promoter Inducer Resistance
pG-KJE8 dnaK-dnaJ-grpE	
groES-groEL
araB				
Pzt1
L-Arabinose	
Tetracyclin
chloramphenicol
pKJE7 dnaK-dnaJ-grpE araB L-Arabinose chloramphenicol
pG-Tf2 groES-groEL-tig Pzt1 Tetracyclin chloramphenicol
pTf16 tig araB L-Arabinose chloramphenicol 		
Co-expression	of	molecular	chaperones	with	HDAC11	in	E.	coli		 SUMO-HDAC11	was	transformed	into	four	different	BL-21	competent	cell	lines,	each	with	a	different	expression	vector	for	molecular	chaperones	(described	above).		Cells	were	plated	on	LB-Amp/Chloramphenicol	 (100	µg/mL	and	34	µg/mL,	 respectively)	plates	and	grown	overnight	at	37˚C.		Starter	cultures,	grown	as	described	above,	were	inoculated	into	
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1-liter	cultures.		Cultures	1,	3,	and	5	were	treated	with	1	mg/ml	arabinose,	and	cultures	1	and	4	were	treated	with	1	ng/ml	tetracycline	to	induce	expression	of	the	chaperones.		After	cells	reached	OD600	=	0.6,	the	temperature	was	decreased	to	20˚C	and	HDAC11	was	induced	by	addition	of	0.5	mM	IPTG	in	all	culures.		Cells	were	grown	and	lysed	as	described	above,	with	the	following	exception.		The	cell	pellet	was	resuspended	and	lysed	in	E.	coli	HDAC11	lysis	buffer	2	 (50	mM	HEPES	pH	8.0,	300	mM	NaCl,	10%	glycerol).	 	HDAC11	expression,	both	soluble	and	 insoluble,	was	again	determined	by	a	western	blot	using	an	antibody	to	probe	for	poly-histidine.		
Purification	of	E.	coli	expressed	SUMO-HDAC11		 His6-SUMO-HDAC11	was	expressed	in	the	presence	of	trigger	factor	in	TB	medium,	as	 described	 above.	 	 Culture	 sizes	 were	 scaled	 from	 1-liter	 expressions	 to	 up	 to	 4-liter	expressions.	 	Cell	pellets	were	resuspended	with	25	mL	of	lysis	buffer	per	liter	of	culture.		After	 lysing	 the	 cells	 using	 a	 microfluidizer,	 lysate	 was	 incubated	 on	 ice	 with	 2	 µL	 of	benzonase	per	25	mL	for	15	minutes.		Lysate	was	then	cleared	via	centrifugation	at	27,000	x	g	(Sorvall	SS-34	rotor)	for	1	hour.		Cleared	lysate	was	decanted	and	added	to	5	mL	of	pre-charged	 nickel	 resin	 in	 buffer	 A	 (HDAC11	E.	coli	 lysis	 buffer	 2	with	 only	 2.5%	 glycerol).		This	slurry	was	incubated,	with	mild	shaking,	at	4˚C	for	four	hours.		Lysate	and	resin	were	then	 poured	 into	 a	 gravity-flow	 bench-top	 column,	 and	 the	 flow-through	 was	 collected.		The	 resin	was	 then	washed	with	a	 stepwise	elution	of	 increasing	buffer	B	 (buffer	A	plus	500	 mM	 imidazole)	 (steps	 at	 10	 mM,	 25	 mM,	 50	 mM,	 100	 mM,	 200	 mM	 and	 500	 mM	imidazole)	 and	 fractions	 were	 collected.	 	 HDAC11	 elution	 was	 determined	 by	 both	coomassie	staining	of	an	acrylamide	gel	and	by	western	blot	probing	for	HDAC11.		Samples	
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with	HDAC11	were	pooled,	ubiquitin	ligase	specific	protease	1	(Ulp1)	was	added,	and	the	mixture	was	dialyzed	overnight	at	4˚C	against	buffer	A.		Protein	was	then	run	over	a	second	nickel	column	to	remove	His6-Ulp1	and	any	proteins	that	bind	non-specifically	to	the	nickel	resin,	and	again	a	stepwise	elution	was	run	with	buffer	B	(steps	at	10	mM,	50	mM,	and	500	mM	 imidazole).	 	 HDAC11-containing	 fractions	 from	 the	 flow	 through	 and	 low	 imidazole	washes	were	pooled	and	concentrated	using	Amicon	Ultra	 centrifugal	 filters.	 	Purity	was	assessed	by	sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	(SDS-PAGE).		If	the	protein	was	pure	(>	50%	purity),	it	was	aliquoted	and	flash	frozen	in	liquid	nitrogen	before	storage	 at	 -80˚C.	 	 If	 HDAC11	 needed	 additional	 purification,	 the	 enzyme	 was	 further	fractionated	on	either	a	size	exclusion	column	(SEC)	(GE	sephacryl	S-200	26/60)	or	a	5	mL	mono-Q	column.	 	Both	columns	were	run	on	an	FPLC	at	4˚C.	 	The	SEC	column	was	run	in	nickel	column	buffer	A,	with	a	constant	flow	rate	of	1	mL/min.		The	Q	column	was	run	at	5	ml/min.		Additionally,	the	Q-column	was	pre-washed	with	5	column	volumes	(CV)	of	Q-Low	Salt	buffer	(50	mM	HEPES	pH	8.0,	50	mM	NaCl,	2.5%	glycerol)	and	the	sample	was	diluted	in	Q-Low	Salt	buffer	to	bring	[NaCl]	<	80	mM	before	the	sample	was	loaded.	 	The	sample	was	 eluted	 using	 a	 linear	 gradient	 over	 20	 CV	 to	 100%	 Q-High	 Salt	 buffer	 (Q-Low	 Salt	buffer	with	1	M	NaCl).		HDAC11	was	concentrated	after	these	additional	purification	steps	and	flash	frozen	for	storage.		
HDAC11	cloning	for	insect	cell	expression		 The	 human	 HDAC11	 gene	was	 PCR	 amplified	 from	His6-SUMO-HDAC11	 in	 a	 pET	21a+	vector.	 	The	forward	and	reverse	primers	(Fig.	3.1)	add	restriction	sites	(BamHI	and	EcoRI)	to	the	N-	and	C-terminal	ends,	respectively.	 	A	pFASTBAC	dual	vector	(courtesy	of	
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Clay	 Brown,	 UM)	 and	 the	HDAC11	 insert	were	 digested	with	 the	 appropriate	 restriction	enzymes.		The	digestion	was	stopped	and	fragments	separated	on	a	1%	agarose	gel.		Insert	and	vector	were	excised	from	the	gel	and	purified	using	a	Promega	DNA	gel	purification	kit.		The	 HDAC11	 gene	was	 ligated	 to	 the	 pFASTBAC	 vector	 on	 ice	 using	 Quick	 Ligase	 (New	England	Biolabs)	for	5	minutes.		The	plasmid	was	then	immediately	transformed	into	XL1-Blue	competent	cells	to	assess	ligation	efficiency.		Cells	transformed	with	the	plasmid	were	grown	on	LB-Amp	plates	at	37˚C.	 	Single	colonies	were	selected	and	used	to	 inoculate	10	mL	cultures	of	2xYT	with	ampicillin.		These	cultures	were	grown	overnight	with	shaking	at	37˚C.	 	 Cells	 were	 then	 pelleted	 by	 centrifugation	 in	 falcon	 tubes.	 	 Plasmid	 DNA	 was	extracted	 using	 a	 Promega	Mini-Prep	 kit.	 	 Proper	 gene	 insertion	was	 verified	 by	 Sanger	sequencing	at	the	UM	DNA	sequencing	core.			
Forward Primer 
5’- GCA CTG GGA TCC GGT ACC ATG CTA CAC ACA ACC 3’ 
 
Reverse Primer 
5’- CCA GCT GAA TTC TCA GTG GTG GTG GTG GTG GTG CTC 3’ 
	
Figure	3.1:	Primers	for	cloning	HDAC11	into	pFASTBAC	The	forward	and	reverse	primers	used	to	clone	HDAC11	into	pFASTBAC.		The	restrictions	site	are	colored	red	(forward:	BamHI,	reverse:	EcoRI).		Regions	that	overlap	with	the	HDAC11	gene	are	highlighted	in	yellow.		
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	 At	this	point	we	gave	the	pFASTBAC	HDAC11	plasmid	to	the	LSI	protein	core.		They	transformed	 the	 plasmid	 into	 DH10bac	 cells,	 which	 produces	 bacmid	 DNA.	 	 They	 then	isolated	 the	 bacmid	 DNA	 and	 transfected	 it	 into	 insect	 cells	 (sf9	 and	 HighFive).	 	 This	method	generates	recombinant	baculovirus,	which	was	amplified	and	stored	as	a	high	titer	stock	to	infect	insect	cells	for	large-scale	expression	of	HDAC11.	
	
HDAC11	validation	techniques	(western	blotting	and	mass	spectrometry)		 For	 western	 blotting,	 HDAC11,	 following	 fractionation	 by	 SDS-PAGE,	 was	transferred	to	a	nitrocellulose	membrane	in	a	semi-dry	transfer	cell.	 	Western	blots	were	then	run	according	to	one	of	the	two	following	methods.		The	first	method	involves	1	hour	of	blocking	with	5%	non-fat	milk,	followed	by	1-2	hours	of	incubation	at	room	temperature	with	a	primary	anti-HDAC11	or	anti-polyhistidine	antibody	in	2%	milk.		Blots	were	washed	3x	for	5	minutes	each	with	tris-buffered	saline	(20	mM	tris	pH	7.6,	150	mM	NaCl)	and	0.1%	tween	20	 (TBST).	 	Blots	were	 then	 incubated	with	a	 secondary	antibody	 for	1	hour,	 and	again	washed	3x	with	TBST.		In	the	second	method,	blots	were	developed	using	in	a	Snap	I.D.	 	2.0	 instrument.	 	The	nitrocellulose	membrane	was	blocked	with	0.5%	bovine	serum	albumin	(BSA)	in	TBST.		The	blocking	solution	was	then	pulled	through	the	membrane	by	vacuum.	 	 Primary	 antibody,	 in	 blocking	 solution,	 was	 incubated	 with	 the	 blots	 for	 10	minutes,	 and	 then	 pulled	 through	 with	 vacuum.	 	 With	 the	 vacuum	 running,	 blots	 were	quickly	 washed	 3x	 with	 TBST.	 	 Secondary	 antibody,	 in	 blocking	 solution,	 was	 also	incubated	for	10	minutes,	and	blots	were	again	washed	under	vacuum	3x	with	TBST.		The	following	 primary	 antibodies	 were	 used:	 Sigma	 anti-HDAC11	 polyclonal	 antibody	 from	rabbit	or	Sigma	monoclonal	anti-polyhistidine	alkaline	phosphatase	antibody	from	mouse.		
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The	 following	 secondary	 antibodies	 were	 used:	 Life	 Technologies	 Alexa	 Fluor	 633	 goat	anti-rabbit	or	Cell	Signaling	anti-rabbit	IgG	HRP-linked.	 	Antibodies	were	visualized	on	an	Azure	 Biosystems	 C-series	 imager	 using	 either	 chemiluminescence	 (HRP)	 or	 fluorescent	excitation	at	628	nm	(Alexa	Fluor).		 Prior	to	mass	spectrometry,	HDAC11	samples	were	desalted	using	7	kDa	molecular	weight	 cutoff	 Zeba	 desalting	 spin	 columns.	 	 Intact	 protein	 was	 separated	 on	 an	 HPLC	through	 a	 C18	 column	 before	 being	 injected	 into	 an	 electrospray	 mass	 spectrometer	(Agilent	Q-TOF).		Protein	peaks	were	deconvoluted	and	identified	based	on	mass.				
Expression	and	purification	of	HDAC11	from	HEK293		 We	cloned	a	wild-type	HDAC11	gene	(from	our	bacterial	expression	vectors)	into	a	pcDNA4	mammalian	 expression	 vector	with	 an	N-terminal	 ZZ-tag	 and	 a	TEV	 recognition	site.		The	plasmid	encodes	resistance	to	puromycin,	which	was	used	(at	1	µg/mL)	to	select	for	stable	incorporation	of	the	HDAC11	expression	plasmid	after	transfection	into	HEK293	cells.	 	These	cells	were	cultured	 in	75	cm2	 flasks	at	37˚C.	 	Before	purifying	HDAC11,	cells	were	harvested	by	 treatment	with	 trypsin	and	pelleted	by	 centrifugation	 in	 falcon	 tubes,	followed	 by	 lysis	 via	 freeze-thaw	 cycles.	 	 Lysate	 was	 incubated	 with	 protein	 IgG	 beads	(ThermoFisher)	 to	 immobilize	ZZ-tagged	HDAC11.	 	Lysate	was	decanted	and	beads	were	washed	three	times	with	pull-down	buffer.		Cells	were	then	incubated	overnight	at	4˚C	with	TEV	 protease	 to	 cleave	 HDAC11	 from	 the	 beads.	 	 Beads	 were	 pelleted	 and	 HDAC11	 in	solution	was	decanted	and	flash	frozen	in	liquid	nitrogen.		
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Fluor-de-Lys	HDAC11	assays		 We	 measured	 HDAC11	 activity	 against	 several	 substrates	 using	 the	 Fluor-de-Lys	assay	(Enzo	Life	Sciences	and	(87)).	 	HDAC11	was	reconstituted	with	cobalt	or	zinc	 for	1	hour	on	 ice	at	a	2:1	cobalt	 to	enzyme	or	1:1	zinc	 to	enzyme	ratio.	 	All	assay	components	were	diluted	in	1x	HDAC8	assay	buffer	(25	mM	HEPES	pH	8.0,	137	mM	NaCl,	3	mM	KCl).		Substrates	were	used	at	 final	 concentrations	 ranging	 from	20	–	200	µM.	 	 Initial	 rates	 for	HDAC11	catalysis	were	assayed	at	 final	enzyme	concentrations	 from	500	nM	–	1	µM.	 	All	assays	were	conducted	at	34˚C.	 	Time	points	were	quenched	 in	a	 commercial	 solution	of	trypsin	developer	and	 trichostatin	A	 (TSA)	 (Enzo	Life	Sciences).	 	The	 fluorescence	of	 the	product	 (ex.	 	 340	 nm,	 em.	 	 450	 nm)	 and	 substrate	 (ex.	 	 340	 nm,	 em.	 	 380	 nm)	 were	measured	using	a	PolarStar	Fluorescent	plate	reader	and	Corning	96-well	half	area	black	plates.	 	 Standard	 curves	were	prepared	by	mixing	 known	 concentrations	 of	 product	 and	substrate.				
HDAC11	activity	using	a	coupled	enzyme	assay		 HDAC11	activity	on	unlabeled	peptides	was	determined	using	an	enzyme-coupled	assay	as	described	in	Wolfson	et	al.	((76)	and	Chapter	2).		Briefly,	hydrolysis	of	acetyllysine	results	 in	 the	 release	 of	 free	 acetate.	 	 This	 is	 ultimately	 converted	 to	 citrate	 through	 the	enzymatic	activity	of	acetyl-CoA	synthetase,	citrate	synthetase,	and	malate	dehydrogenase.		A	 byproduct	 of	 the	malate	 dehydrogenase	 reaction	 is	 the	 conversion	 of	 NAD+	 to	 NADH,	which	 detected	 by	 fluorescent	 excitation	 at	 340	 nm	 and	 emission	 at	 460	 nm.	 	We	 used	concentrations	of	 substrate	 ranging	 from	50	–	200	µM,	 and	enzyme	 concentrations	 from	0.2-1.5	µM.	 	Assays	were	conducted	at	34˚C.	 	HDAC11	was	reconstituted	with	cobalt	 (2:1	
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metal	to	enzyme)	or	zinc	(1:1	metal	to	enzyme)	for	1	hour	on	ice	prior	to	usage.		All	assays	were	run	in	HDAC8	assay	buffer.		Aliquots	at	various	time	points	(60	µL)	were	quenched	by	addition	of	2.5	µL	of	10%	hydrochloric	acid	and	flash	frozen	in	liquid	nitrogen.		Quenched	points	were	stored	for	up	to	2	days	at	-20˚C	or	longer	at	-80˚C.		Immediately	before	being	mixed	with	 the	 coupled	 enzymes,	 reaction	 aliquots	were	 thawed	 and	 neutralized	 by	 the	addition	 of	 7.5	 µL	 of	 6%	 sodium	 bicarbonate.	 	 In	 a	 black	 Corning	 3868	 plate,	 10	 µL	 of	coupling	solution	(as	described	in	(76))	was	added	to	60	µL	of	reaction.		NADH	formation	was	monitored	in	a	PolarStar	fluorescent	plate	reader	every	1	–	2	minutes	until	reactions	reached	 completion	 (less	 than	 2	 hours).	 	 Results	 were	 compared	 to	 a	 standard	 curve	generated	 by	 addition	 of	 known	 concentrations	 of	 acetate	 to	 the	 coupled	 solution	 and	monitoring	NADH	formation.		
HDAC11	inhibition	by	SAHA	and	MGCD0103	
	 Inhibition	 of	 HDAC11	 was	 measured	 using	 the	 Fluor-de-Lys	 assay,	 as	 described	above,	with	 the	 BOC-Lys	 substrate	 (shown	 in	 Fig.	 3.11).	 	 Briefly,	 10	mM	 SAHA	 in	 100%	DMSO	was	serially	diluted	into	HDAC8	assay	buffer.		HDAC11	was	reconstituted	on	ice	for	1	hour	at	a	2:1	cobalt:enzyme	ratio.		Substrate	was	diluted	into	HDAC	assay	buffer	and	used	at	 final	concentrations	of	50	and	100	µM	and	SAHA	concentrations	varied	(up	to	10	µM).		SAHA	and	BOC-Lys	were	pre-incubated	in	buffer	at	34˚C	before	initiation	of	the	reaction	by	addition	of	HDAC11.		HDAC	concentration	was	0.15	–	0.55	µM.		Reaction	time	points	were	quenched	into	a	mixture	of	trypsin	developer	and	TSA.		After	a	15-minute	incubation	with	the	developer	solution,	time	points	were	read	in	a	PolarStar	fluorescence	plate	reader,	as	described	above.	
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	 MGCD0103	inhibition	was	performed	as	described	for	SAHA,	with	0.2	µM	HDAC11	and	up	to	10	µM	MGCD	(structure	shown	in	Fig.	3.11).			
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Results	
Optimization	of	expression	of	recombinant	human	HDAC11	in	E.	coli.	We	 originally	 expressed	 a	 His6-tagged	 HDAC11	 in	 a	 pET	 vector.	 	 After	 induction	with	 IPTG	 of	 BL-21	 (DE3)	 cells	 containing	 this	 HDAC11	 plasmid,	 a	 prominent	 band	appeared	 at	 the	 correct	 molecular	 weight	 after	 coomassie	 staining	 an	 SDS-PAGE	 gel.		However,	mass	spectrometry	of	this	protein	showed	that	it	was	about	3	kDa	heavier	than	expected	 from	 the	 HDAC11	 sequence.	 	 The	 molecular	 weight	 was	 consistent	 with	 the	bacterial	 elongation	 factor	Ef-Tu,	 suggested	by	our	 collaborator,	David	Christianson.	 	We	determined	the	protein	was	likely	the	bacterial	elongation	factor	Ef-Tu.		We	confirmed	that	this	 protein	 was	 Ef-Tu	 by	 probing	 a	 western	 blot	 with	 a	 primary	 anti-Ef-Tu	 antibody.		Therefore,	we	tried	alternative	methods	to	express	and	purify	HDAC11.	
	 To	 better	 separate	 HDAC11	 from	 Ef-Tu	 by	 SDS-PAGE,	 we	 fused	 the	 sequence	 for	SUMO	 protein	 to	 the	 5’	 end	 of	 the	 HDAC11	 gene	 behind	 a	 T7	 promoter.	 	 This	 fusion	increased	 the	molecular	weight	 by	 12	 kDa.	 	We	next	 optimized	 expression	 conditions	 to	increase	the	yield	of	soluble	HDAC11.		We	examined	three	different	cell	lines,	BL-21	(DE3),	Rosetta	 II,	 and	 arabinose	 induced	 (AI)	 cells,	 and	 found	 that	 after	 induction	with	 IPTG	 at	18˚C	 in	TB	media,	 the	soluble	yield	of	HDAC11	was	highest	 in	 the	BL-21	(DE3)	cells	 (Fig.	3.2).	 	However,	only	a	small	percent	of	 the	 total	HDAC11	was	 in	 the	soluble	 fraction.	 	To	evaluate	 whether	 the	 expression	 of	 HDAC11	 was	 dependent	 on	 the	 media,	 we	 tested	expression	levels	in	2xYT,	LB,	and	TB	medias.	 	We	also	tested	two	concentrations	of	IPTG	(0.2	mM	and	0.5	mM)	in	2xYT.		We	found	that	the	total	yield	of	HDAC11	was	significantly	higher	 in	TB	media	 (Fig.	3.3).	 	LB	and	2xYT	(with	0.5	mM	IPTG)	yielded	similar	 levels	of	HDAC11,	and	the	2xYT	sample	with	0.2	mM	IPTG	yielded	the	least	amount	of	protein.	
	 67	
	
	
Figure	3.2:	HDAC11	expression	trials	in	various	cell	lines	His6-SUMO-HDAC11	expression	after	induction	with	IPTG	of	1	liter	cultures	in	arabinose	inducible	(AI)	cells,	standard	 BL21	 (DE3)	 cells,	 or	 Novagen	 Rosetta	 II	 (Rose)	 cells	 grown	 overnight	 at	 18˚C.	 	 Lysates	 were	centrifuged	 to	 separate	 soluble	 and	 insoluble	 cellular	 components.	 	HDAC11	 expression	 levels	 (at	 52	 kDa)	were	 determined	 by	 a	 western	 blot	 probed	 with	 an	 anti-HDAC11	 primary	 antibody.	 	 Soluble	 yield	 was	greatest	using	the	BL21	cell	line,	and	lowest	using	the	Rosetta	II	cells.	
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Figure	3.3:	HDAC11	expression	trials	in	various	medias	Western	blot	of	lysate	from	BL-21	(DE3)	cells	containing	the	His-SUMO-HDAC11	plasmid.		Cells	were	induced	with	IPTG	and	grown	overnight	in	2xYT	(A	and	B),	LB	(C),	or	TB	(D)	media.	 	Total	HDAC11	expression	was	determined	here	by	a	western	blot	probed	against	poly-histidine.		The	cells	in	lane	A	were	induced	with	0.2	mM	IPTG,	while	cells	in	lanes	B-D	were	induced	with	0.5	mM	IPTG.		The	greatest	expression	of	HDAC11	was	observed	in	TB-grown	cells,	and	0.5	mM	IPTG	yielded	more	protein	than	0.2	mM	IPTG.	
	 We	 had	 successfully	 increased	 expression,	 using	 TB	 media	 with	 0.5	 mM	 IPTG	induction,	 of	 total	 expression	 of	 HDAC11	 in	 BL-21	 (DE3)	 cells	 using	 the	 His6-SUMO-HDAC11	plasmid.		Further	more,	the	SUMO	fusion	separated	HDAC11	from	Ef-Tu	by	mass	for	 easier	 identification	 and	 purification.	 	 However,	 the	majority	 of	 His6-SUMO-HDAC11	was	 insoluble.	 	We	decided	 to	 try	 increasing	 soluble	 expression	 through	additives	 to	 the	media,	 including	alcohols	and	metals,	as	well	as	coexpressing	molecular	chaperones.	 	We	found	that	including	1.5%	ethanol	at	induction	had	little	effect	on	protein	solubility,	while	10	mM	benzyl	alcohol	modestly	increased	soluble	expression	(Fig.	3.4).		Interestingly,	this	effect	was	only	observed	in	media	buffered	with	phosphate.		In	a	tris-buffered	culture	with	added	zinc,	we	observed	that	neither	alcohol	improved	solubility.		Finally,	we	assessed	the	
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impact	on	soluble	expression	of	HDAC11	of	co-transformation	with	four	different	plasmids	expressing	molecular	chaperones.		These	plasmids	encoded:	1)	dnaK-dnaJ-grpE	and	groES-groEL;	2)	dnaK-dnaJ-grpE;	3)	groES-groEL-trigger	factor;	and	4)	trigger	factor.	 	We	found	that	 co-expression	 with	 trigger	 factor	 (Tig)	 alone	 had	 a	 significant	 impact	 on	 SUMO-HDAC11	solubility.				 Based	on	these,	we	used	the	following	method	for	optimal	HDAC11	expression:		The	HDAC11	construct	contained	both	a	His6-tag	and	a	SUMO	tag	on	the	N-terminus	(Fig.	3.5).		We	created	a	stock	of	BL-21	(DE3)	competent	cells	that	contained	the	expression	vector	for	Tig,	and	transformed	these	cells	with	the	HDAC11	plasmid	prior	to	each	expression.		Using	this	combination,	a	1	L	culture	of	HDAC11	grown	at	18˚C	 in	TB	media	with	0.5	mM	IPTG	added	at	induction	yielded	>	5	mg	of	soluble	enzyme.			
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Figure	3.4:	HDAC11	solubility	with	added	alcohols	visualized	on	a	western	blot	The	effects	of	 adding	alcohol	 to	expression	media	were	 tested.	 	 Labels	S	 (soluble)	and	 I	 (insoluble)	denote	which	portion	of	the	lysate	was	run	in	each	lane.		Lanes	1-6	represent	bacteria	grown	in	media	buffered	with	potassium	phosphate.	 	Lanes	7-12	represent	bacteria	grown	in	tris-buffered	media,	supplemented	with	zinc	(200	µM).		Additionally,	lanes	1,	2,	7,	and	8	are	from	expressions	with	no	added	alcohols.		Lanes	3,	4,	9,	and	10	are	from	expressions	with	1.5%	ethanol	(Et).		Lanes	5,	6,	11,	and	12	are	from	expressions	with	10	mM	benzyl	alcohol	 (BA).	 	 HDAC11	 (52	 kDa)	 expression	 is	 determined	 here	 by	 a	 western	 blot	 probed	 with	 an	 anti-HDAC11	 primary	 antibody.	 	 Soluble	 yield	 of	 HDAC11	 is	 greater	 using	 a	 potassium	 phosphate	 buffer,	 and	greatest	in	the	presence	of	benzyl	alcohol.	
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Figure	3.5:	HDAC11	E.	coli	construct	The	His6-SUMO-HDAC11	construct	used	for	our	E.	coli	growths.		The	construct	is	sufficiently	heavier	than	the	bacterial	 elongation	 factor	 Ef-Tu,	 and	 has	 a	 higher	 expression	 of	 soluble	 protein	 than	 non-SUMO	 tagged	HDAC11.	
	
Expression	and	purification	of	active	HDAC11	from	insect	sf9	cells	
	 Concurrent	 with	 our	 work	 on	 expressing	 HDAC11	 in	 E.	 coli,	 we	 also	 prepared	HDAC11	 for	expression	 in	 sf9	 cells.	 	We	cloned	a	His-tagged	human	HDAC11	gene	 into	a	pET	 21a+	 vector	 using	 PCR	 and	 transformed	 this	 plasmid	 into	 DH10	 alpha	 cells	 for	transfection.	 	 We	 looked	 at	 His6-HDAC11	 expression	 in	 two	 insect	 cell	 lines:	 sf9	 and	HighFive.		We	found	expression	to	be	similar,	though	slightly	higher	in	HighFive	cells	(Fig.	3.6).		However,	the	lysate	from	the	HighFive	cells	was	more	difficult	to	clear	and	contained	a	greater	percentage	of	insoluble	His6-HDAC11.		For	this	reason,	we	chose	to	move	forward	expressing	HDAC11	in	sf9	cells.		 Purification	 of	 HDAC11	 from	 these	 cells	 proved	 to	 be	 challenging.	 	 Our	 initial	attempts	to	purify	the	protein	using	a	Ni-column	demonstrated	that	the	his-tagged	protein	did	not	bind	to	the	Ni-resin.		We	varied	the	incubation	time	for	batch	loading	the	Ni-resin,	from	30-minutes	to	16	hours.	 	We	found	that	a	4	–	5	hour	incubation	at	4˚C	was	optimal.		Longer	 incubation	 times	 led	 to	 a	modest	 increase	 in	 HDAC11	 recovery,	 but	 non-specific	binding	of	host	proteins	also	increased	significantly.		We	purified	His6-HDAC11	from	insect	cells	 using	 His6-TEV	 protease	 to	 cleave	 the	 His-tag	 from	 HDAC11	 after	 the	 first	 nickel	
His6	 SUMO	 HDAC11	
1	 12	 39	KDa:	
N	-	 -	C	
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column.	 	 His6-TEV	 protease	 was	 then	 removed	 on	 a	 second	 nickel	 column.	 	 This	purification	 scheme	 yields	 protein	 that	 is	 >	 60%	 pure.	 	 Approaches	 to	 further	 purify	HDAC11	are	addressed	in	the	discussion.		
	
Figure	3.6:	HDAC11	expression	in	insect	cells	An	 SDS-PAGE	 gel	 comparing	 expression	 of	 HDAC11	 in	 two	 insect	 cell	 lines,	 sf9	 and	HighFive.	 	 Small	 scale	expressions	were	stopped	after	48	or	72	hours,	lysed,	and	passed	over	a	nickel	column.		HDAC11	(lane	11)	is	highlighted	with	a	red	arrow.		Expression	is	similar	in	both	cell	lines.			
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Validation	of	HDAC11	from	sf9	expression		 To	validate	the	identity	of	the	purified	HDAC11,	we	first	fractionated	the	protein	by	SDS-PAGE	 stained	with	 coomassie,	 followed	by	a	western	blot	probed	with	 anti-HDAC11	antibodies	(Fig.	3.7).		The	gels	confirmed	that	the	purified	protein	is	HDAC11.		We	also	used	liquid-chromatography	mass	spectrometry	of	the	intact	protein	to	determine	the	molecular	weight	 of	 the	 purified	 protein	 (Fig.	 3.8).	 	 The	 intact-protein	MS	 data	 gave	 an	 interesting	result,	the	mass	of	HDAC11	purified	from	insect	cells	is	42	daltons	heavier	than	predicted	from	the	amino	acid	sequence	for	the	wild-type	enzyme.		This	is	based	on	the	assumption	that	 the	 purified	 protein	 has	 no	 remaining	 tags	 and	 the	N-terminal	methionine	 remains.		We	hypothesize	that	 this	 increase	 in	mass	 is	due	to	a	post-translational	modification;	 the	42	 dalton	 increase	 in	 the	 molecular	 weight	 is	 consistent	 with	 the	 addition	 of	 an	 acetyl	group	or	tri-methylation,	among	others.		Possible	PTMs	are	discussed	in	more	detail	in	the	discussion	section.	
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Figure	3.7:	SDS-PAGE	gel	and	western	blot	of	HDAC11	from	sf9	Validation	of	HDAC11	expressed	and	purified	from	sf9	cells.		In	both	gels	lane	1	is	molecular	weight	ladder.		A.		SDS-PAGE	stained	with	coomassie	blue.	 	HDAC11	(~	40	kDa)	was	run	along	with	a	horseradish	peroxidase	control	(~	40	kDa).		B.		Western	blot	probed	with	an	anti-HDAC11	primary	antibody	(Sigma).		HDAC11	(exact	concentration	unknown)	was	loaded	at	1x	and	0.5x	concentration.	
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Figure	3.8:	Mass	Spectra	of	HDAC11	from	sf9	Intact	HDAC11	from	an	sf9	expression	was	desalted	on	a	zeba	spin	column.		The	protein	solution	(~15	µM)	was	injected	into	an	HPLC-MS	and	run	across	a	C8	reverse	phase	column	before	being	shot	 into	the	Q-TOF.		(A)	Raw	trace	of	ion	count	vs.		acquisition	time.		(B)	The	deconvoluted	mass	of	the	highlighted	region	from	the	ion	counts	in	A.		(C)	HDAC11	gene	sequence	used	in	insect	cell	expression.		The	mass	of	the	wild-type	protein,	with	an	intact	N-terminal	methionine,	is	expected	to	be	42,076	Da.		This	is	42	daltons	lower	than	we	observed,	consistent	with	a	post-translational	modification.	
42118	
a	
b	
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Na7ve	sequence:	 			42,076	Da	
Observed	sequence:	42,118	Da	
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HDAC11	exhibits	different	activity	depending	on	the	host	expression	system	HDAC11	 was	 expressed	 in	 HEK293	 cells	 transfected	 with	 a	 plasmid	 encoding	HDAC11	 with	 an	 N-terminal	 ZZ	 tag.	 	 This	 allowed	 for	 purification	 of	 the	 protein	 using	protein	A	beads.	 	We	were	only	able	 to	 recover	a	 small	portion	of	 the	enzyme	by	simply	cleaving	the	tag,	perhaps	suggesting	that	HDAC11	itself	was	bound	to	either	protein	A	or	the	sepharose	beads.		In	an	effort	to	disrupt	the	S-S	bonds	between	ZZ-tagged	HDAC11	and	IgG	sepharose	beads,	we	added	molar	concentrations	of	DTT.			We	 assayed	 HDAC11	 expressed	 and	 purified	 from	 E.	 coli,	 sf9,	 and	 HEK293	 cells.		Activity	was	determined	using	a	peptide	with	a	 tri-fluorinated	acetyllysine,	 followed	by	a	methyl-coumarin	moiety.		Deacetylation	is	observed	from	a	change	in	fluorescence	caused	by	 cleavage	 of	 the	methyl-coumarin	moiety	 from	 the	 deacetylated	 product,	 catalyzed	 by	trypsin(87).	 	 This	 substrate,	 BPS	 Bioscience’s	 HDAC	 Substrate	 2a	 (Fig.	 3.11),	 is	 a	 highly	reactive	 peptide.	 	We	 observed	 little	 change	 in	 the	 fluorescence	 signal	 over	 background	when	HDAC11	expressed	and	purified	from	E.	coli	was	incubated	with	HDAC	substrate	2a,	with	 enzyme	 concentrations	 from	 500	 nM	 to	 2	 µM	 tested.	 	 HDAC11	 expressed	 in	 and	purified	 from	 eukaryotic	 sf9	 cells,	 however,	 does	 catalyze	 deacetylation	 of	 the	 trifluoro-substrate	2a	 (Fig.	 3.9).	 	Additionally,	HDAC11	expressed	and	purified	 from	HEK293	 cells	also	catalyzes	deacetylation	of	substrate	2a.	 	However,	HDAC11	recovered	from	protein	A	beads	after	addition	of	high	concentrations	of	DTT	was	no	 longer	active	 (Fig.	3.10).	 	The	significance	and	potential	cause	of	these	differences	is	discussed	below.	
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Figure	3.9:	HDAC11	from	bacterial	and	insect	expression	systems10	Progress	curves	 for	HDAC11-catalyzed	deacetylation	of	HDAC	substrate	2a	 (BPS	Bioscience).	 	HDAC11	(0.5	µM,	purchased	from	BPS	Biosciences)	 from	an	sf9	expression	( )	showed	significantly	higher	activity	 than	HDAC11	(1	µM)	from	a	bacterial	expression	( ).		The	rate/[HDAC11]	from	sf9-expressed	HDAC11	is	0.0022	fluorescence	units	•	s-1	•	µM-1	enzyme	and	for	the	bacterial	HDAC11	it	 is	<	0.0001	fluorescence	units	•	s-1	•	µM-1	enzyme,	a	decrease	of	more	than	20-fold.	
	
																																																								10	This	graph	depicts	HDAC11	activity	based	on	a	recombinant	enzyme	purchased	from	BPS	Biosciences,	expressed	in	sf9	cells.		All	other	HDAC11	activity	in	this	chapter	is	from	HDAC11	expressed	in	house.	
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Figure	3.10:	HDAC11	from	HEK	cells	is	active	and	sensitive	to	DTT	HDAC11	was	overexpressed	 in	HEK	cells	 transfected	with	a	plasmid	encoding	ZZ-tagged	HDAC11.	 	Protein	was	purified	by	affinity	to	sepharose	beads	labeled	with	protein	A	and	cleaved	with	TEV	protease.		HDAC11	catalyzed	deacetylation	of	HDAC	substrate	2a	was	determined	by	fluorescence	of	the	product	(ex.		=	340	nm	and	em.		=	450	nm)	of	a	trypsin	digest	of	the	deacetylated	peptide.		HDAC11	was	overexpressed	and	purified	twice	and	both	preparations	had	similar	activity	(WT1	and	WT2).		However,	a	sample	that	was	subjected	to	1	–	2	M	DTT,	to	free	residual	HDAC11	from	protein	A	beads,	showed	no	measurable	activity.	
	
HDAC11	catalyzes	deacetylation	of	several	FdL-style	peptides	Using	 human	 HDAC11	 expressed	 and	 purified	 from	 sf9	 cells,	 we	 measured	deacetylase	activity	using	a	variety	of	coumarin-labeled	peptide	substrates.		These	included	Substrate	2a	(BPS	Bioscience),	BOC-Lys	substrate	(Bachem),	HDAC8	FdL	substrate	(Enzo),	and	Sirt1	FdL	substrate	(Enzo)	(Fig.	3.11).		The	BOC-Lys	substrate	was	used	previously	by	Fournel	 et	al.,	 (75)	 to	 screen	 their	 isozyme	 selective	 inhibitor	MGCD0103.	 	 Interestingly,	HDAC11	 does	 not	 show	 catalytic	 activity	 toward	 Enzo’s	 HDAC8	 substrate	 (at	 the	concentration	 and	 time	 range	 tested)	 but	 does	 catalyze	 deacetylation	 of	 the	 other	 three	substrates.		Between	the	two	non-fluorinated	substrates,	both	assayed	at	100	µM,	HDAC11	catalyzes	 deacetylation	 of	 the	 Sirt1	 substrate	 more	 rapidly	 than	 the	 BOC-Lys	 substrate	
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(Table	3.2).		We	measured	the	dependence	of	activity	on	the	concentration	of	the	BOC-Lys	substrate	to	calculate	kcat/KM	=	250	±	100	M-1s-1	(Fig.	3.12).			
	
	
Figure	3.11:	Tested	HDAC11	FdL-style	substrates	Structures	for	the	commercially	available	coumarin	labeled	substrates	used	to	test	HDAC11	activity.		HDAC11	showed	measurable	deacetylase	activity	toward	substrate	2a,	BOC-Lys,	and	the	Sirt1	substrate.		HDAC11	did	not	show	activity	toward	Enzo’s	HDAC8	substrate,	which	differs	from	the	Sirt1	substrate	in	just	one	place:	an	additional	acetyl	moiety	on	the	lysine	residue	just	upstream	of	the	target	acetyllysine.		The	Nε	position	of	the	lysine	 that	 is	 deacetylated	 is	 highlighted	 in	 blue	 in	 each	 structure.	 	 All	 structures	 were	 prepared	 using	ChemDraw.	
	
Table	3.2:	HDAC11	specific	activity	on	coumarin-labeled	peptides	
Substrate
Activity	at	100	µM	substrate	
(initial	rate	/	µM	HDAC11)
BOC-Lys 0.00011
Enzo	HDAC8 																	<	0.00001
Enzo	Sirt1 0.00069
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Figure	3.12:	HDAC11	activity	toward	BOC-Lys	substrate	(A)		Progress	curves	for	HDAC11	(0.2	µM)	catalyzed	deacetylation	of	varying	concentrations	of	the	BOC-Lys	substrate	(Bachem).	 	Deacetylation	was	measured	from	a	change	 in	 fluorescence	(ex.	 	=	340	nm	and	em.	 	=	450	nm.)	after	quenching	the	reaction	mixture	with	trypsin	and	TSA.		Product	concentrations	were	calculated	from	standard	curves.		(B)		Plot	of	HDAC11-catalyzed	initial	rates	vs.		BOC-Lys	concentration.		The	Michaelis–Menten	equation	is	fit	to	the	data	to	yield	kcat/KM	=	250	±	100	M-1s-1,	kcat	=	0.09	±	0.02	s-1,	and	KM	=	0.00037		±	0.0001	M.	
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HDAC11	catalyzes	deacetylation	of	unlabeled	peptides	We	next	examined	whether	HDAC11	catalyzed	deacetylation	of	peptides	that	do	not	contain	a	coumarin	moiety.	 	We	initially	measured	HDAC11	activity	using	non-fluorinated	peptides	 that	 had	 been	 chosen	 as	 likely	 HDAC8	 substrates.	 	While	 the	majority	 of	 these	peptides	 showed	 little	 to	 no	 activity	 with	 HDAC11	 (kcat/KM,	app	 <	 0.5	M-1s-1),	 a	 couple	 of	peptides	 showed	 measurable	 deacetylation.	 	 The	 best	 HDAC8-based	 peptide	 was	deacetylated	 by	 HDAC11	 with	 a	 kcat/KM,	 app	 =	 7	 M-1s-1	 (Fig.	 3.13A).	 	 We	 also	 measured	activity	against	one	peptide	from	Cdt1,	a	protein	associated	with	HDAC11	in	literature	(71),	and	a	histone	H4	K16	peptide.	 	These	two	peptides	were	the	best	substrates	 for	HDAC11	identified	yet,	with	kcat/KM,	app	values	of	30	and	50	M-1s-1,	respectively	(Fig.	3.13B).		 The	Cdt1	and	H4	K16	peptides	have	similarities	in	both	sequence	and	charge	(Table	3.3).		Both	peptides	have	an	arginine	residue	immediately	downstream	of	the	acetyllysine.		Additionally,	 both	 peptides	 have	 an	 abundance	 of	 positively	 charged	 residues.	 	 This	 is	 a	potentially	important	pattern,	and	one	that	may	be	useful	for	predicting	additional	HDAC11	substrates.	
	
Table	3.3:	Sequences	of	unlabeled	peptides	with	the	highest	kcat/KM	values	The	final	protein,	nMBP,	is	representative	of	the	average	non-membrane	bound	protein.		The	average	nMBP	is	comprised	 of	 24%	 charged	 residues.	 	 The	 %	 charged	 residues	 column	 has	 two	 values;	 the	 value	 in	parentheses	assumes	histidine	residues	are	charged.	
Protein Peptide	Sequence %	charged	residues kcat/KM	(M-1s-1)
H4	K16 Ac-KGGA(Kac)RHR-NH2 38	(50) 50
Cdt1	K49 Ac-GSR(Kac)RAR-NH2 43	(43) 30
IDH1 Ac-KLKQMW(Kac)SPN-NH2 20	(20) 7
nMBP - 24	(26) - 	
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Figure	3.13:	HDAC11	activity	toward	unlabeled	peptides	Progress	curves	for	HDAC11	deacetylase	activity	toward	unlabeled	peptide	substrates.		Deacetylation	of	these	peptides	was	measured	using	an	enzyme-coupled	assay,	described	in	chapter	2	and	(76).		(A)	Deacetylation	of	an	HDAC8-substrate	peptide	(from	isocitrate	dehydrogenase	1,	see	Table	3.3)	by	HDAC11.		The	reaction	was	run	at	two	concentrations	of	HDAC11,	0.24	µM	and	0.48	µM.		Both	experiments	were	consistent	with	a	kcat/KM,	app	 =	 7	 M-1s-1,	 with	 the	 assumption	 that	 the	 [S]	 <	 KM.	 	 (B)	 	 HDAC11	 (0.15	 µM)	 catalyzed	 deacetylation	 of	peptides	 (100	µM)	 from	Cdt1	 (red)	and	Histone	H4	K16	 (black),	 along	with	a	no-enzyme	control	 (orange).		These	assays	were	performed	without	replicates.	
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HDAC11	is	inhibited	by	SAHA	and	MGCD	
	 We	 measured	 HDAC11	 inhibition	 by	 both	 the	 pan-HDAC	 inhibitor	 SAHA	 and	 an	isozyme-selective	 inhibitor	MGCD0103	 (Fig.	 3.14).	 	 The	 isozyme	 selective	 inhibitor	has	 a	reported	IC50	of	600	nM	against	HDAC11	(75).		It	is	also	reported	to	have	sub-micromolar	IC50	 values	 against	 HDACs	 1	 and	 2.	 	 We	 pre-incubated	 the	 coumarin-labeled	 BOC-Lys	substrate	with	 SAHA	or	MGCD0103	 at	 various	 concentrations,	 and	 initiated	 reactions	 by	addition	 of	 HDAC11.	 	 The	 SAHA-treated	 HDAC11	 (0.55	 µM)	 reaction	 showed	 complete	inhibition	 at	 stoichiometric	 concentrations	 of	 inhibitor	 (Fig.	 3.15AB).	 	 We	 repeated	 this	SAHA	 titration	with	150	nM	HDAC11.	 	This	 titration	 also	 showed	 complete	 inhibition	by	stoichiometric	 SAHA	 (Fig.	 3.15C),	 suggesting	 that	 the	 IC50	 value	 is	 below	 150	 nM.	 	 The	MGCD0103-treated	 HDAC11,	 however,	 showed	 a	 maximum	 of	 ~50%	 loss	 of	 enzyme	activity	 at	 all	 concentrations	 of	 inhibitor	 (Fig.	 3.16).	 	 These	 data	 are	 consistent	 with	MGCD0103	 being	 an	 allosteric	 inhibitor	 that	 does	 not	 cause	 complete	 loss	 of	 activity.		Alternatively,	the	lack	of	complete	inhibition	could	be	caused	by	the	MGCD0103	solubility.	
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Figure	3.14:	Structures	of	SAHA	and	MGCD0103.	Chemical	structures	of	the	pan-HDAC	inhibitor	SAHA	(A)	and	the	isozyme	selective	inhibitor	MGCH0103	(B).		Metal	chelating	groups	are	colored	(hydroxamic	acid,	blue	and	benzamide	red).	
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Figure	3.15:	HDAC11	is	inhibited	by	SAHA	(A)	Progress	curves	for	HDAC11	(0.55	µM)	inhibition	of	deacetylation	by	increasing	concentrations	of	SAHA.		The	 BOC-Lys	 coumarin	 labeled	 substrate	 (50	 µM)	 was	 assayed	 as	 described	 in	 Figure	 3.12.	 	 (B)	 HDAC11	initial	 rates	plotted	against	SAHA	concentrations.	 	This	curve	 indicates	a	nearly	complete	 loss	of	activity	at	equimolar	concentrations	of	HDAC11	and	SAHA,	suggesting	that	the	IC50	<	0.5	µM.		(C)	HDAC11	inhibition	by	SAHA	was	assayed	at	a	lower	enzyme	concentration	(0.15	µM).	 	This	curve	shows	stoichiometric	inhibition,	suggesting	that	the	IC50	for	HDAC11	inhibition	by	SAHA	is	below	150	nM.	
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Figure	3.16:	HDAC11	is	partially	inhibited	by	MGCD0103	(A)	 Progress	 curves	 for	 HDAC11	 (0.55	 µM)	measured	 as	 in	 the	 figure	 legend	 of	 Fig.	 3.12,	 with	 increasing	concentrations	of	the	isozyme-selective	inhibitor	MGCD0103.		(B)	Percent	of	HDAC11	activity	as	a	function	of	the	concentration	of	MGCD0103.		This	curve	shows	that	40%	of	activity	is	lost	at	25	µM	inhibitor,	suggesting	a	high	 affinity	 interaction.	 	MGCD0103	 appears	 to	 bind	HDAC11	 tightly,	 but	 inhibition	hovers	 at	 about	 50%.		These	data	raise	the	possibility	that	MGCD0103	is	an	allosteric,	rather	than	competitive,	HDAC11	inhibitor.	
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Discussion		 HDAC11	is	the	most	recently	discovered	isozyme	in	this	family	of	enzymes,	and	it	is	the	 sole	member	 of	 the	 class	 IV	 deacetylases.	 	 Cell-based	 assays	 have	 demonstrated	 the	importance	 of	 HDAC11	 to	 immune	 function	 and	 inflammation	 control	 (68,	 85),	 brain	formation	 (67),	 and	 breast	 cancer	 (69).	 	 To	 date,	 however,	 in	 vitro	 biochemical	characterization	 of	HDAC11	 has	 been	 difficult.	 	 Here	we	 have,	 for	 the	 first	 time,	 directly	compared	 the	 activity	 of	 recombinant	 HDAC11	 expressed	 in	 E.	 coli,	 bacmid	 infection	 of	insect	cells,	and	HEK293	cell	cultures.		We	have	also	begun	a	basic	characterization	of	the	enzymology	of	HDAC11,	including	an	analysis	of	substrate	selectivity	and	inhibition	by	pan	and	proposed	HDAC11-selective	inhibitors.		 To	 date,	 there	 is	 no	 published	 data	 on	 the	 reactivity	 of	 HDAC11	 expressed	 and	purified	from	bacteria,	a	limiting	factor	in	the	biochemical	characterization	of	this	enzyme.		Our	 initial	 attempts	 to	 express	 recombinant	 HDAC11	 in	 bacteria	 unveiled	 two	 issues:	soluble	expression	of	HDAC11	was	low	and	one	of	the	most	abundantly	expressed	bacterial	proteins,	Ef-Tu,	displayed	similar	properties	to	HDAC11	(92).		The	two	proteins	are	within	a	 couple	 kDa	 in	 molecular	 weight,	 and	 due	 to	 parallels	 in	 pI,	 also	 run	 similarly	 on	 ion	exchange	columns.		Additionally,	native	Ef-Tu	binds	to	nickel	resin,	and	is	such	a	common	contaminant	that	there	is	an	effort	to	develop	a	strain	of	BL-21	cells	with	mutant	forms	of	this	 protein	 (93).	 	 By	 altering	 our	 expression	 methodology	 and	 HDAC11	 construct,	 we	developed	a	scheme	for	the	efficient	expression	of	HDAC11	in	E.	coli.			Interestingly,	 we	 demonstrated	 that	 soluble	 expression	 of	 HDAC11	 was	 not	improved	 by	 optimizing	 codon	 usage	 for	 bacterial	 expression,	 or	 by	 expression	 of	 the	enzyme	in	Rosetta	II	cells.		We	hypothesize	that	increasing	the	rate	of	translation	of	mRNA	
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to	amino	acids	is	unbeneficial,	leading	to	increased	aggregation	of	HDAC11,	resulting	in	the	low	 yield	 of	 soluble	 protein.	 	 The	 fusion	 of	 HDAC11	 with	 SUMO	 both	 slightly	 increases	soluble	protein	expression	and	shifts	the	molecular	weight	to	a	higher	value	than	Ef-Tu	(39	kDa	vs.	52	kDa).			We	 successfully	 increased	 soluble	 expression	 of	 HDAC11	 by	 co-expression	 of	 the	molecular	 chaperon	 trigger	 factor	 (tig).	 	 Soluble	 expression	 was	 not	 increased	 by	 co-expression	of	several	other	chaperones,	including	GroEL-GroES.		Tig	was	unique	among	the	chaperones	we	examined	(and	among	all	known	bacterial	 chaperones	 for	 that	matter)	 in	that	 it	 is	 a	 ribosome-associated	 chaperone	 (94).	 	Most	 bacterial	 chaperones	 catalyze	 the	folding	of	proteins	 in	 the	cytosol	 to	 their	 final,	native	 tertiary	 structure.	 	Tig,	 in	 contrast,	binds	 to	 and	 traps	 small	 regions	 of	 the	 nascent	 polypeptide	 at	 the	 ribosome,	 preventing	aggregation	of	potentially	‘sticky’	stretches	of	amino	acids	as	they	are	being	translated	(95).	We	were	 surprised	 to	 find	 that	 prokaryotic	 expression	 of	HDAC11	 yields	 enzyme	that,	in	our	in	vitro	assays,	does	not	display	catalytic	activity.		However,	HDAC11	expressed	in	and	purified	from	two	eukaryotic	cells,	HEK293	cells	and	sf9	insect	cells,	is	catalytically	activity.		The	reason	for	this	discrepancy	in	activity	is	not	yet	understood;	however,	the	42-dalton	increase	in	molecular	mass	for	HDAC11	expressed	in	sf9	insect	cells	compared	to	E.	
coli	 expression	 suggests	 that	 a	 post–translational	 modification	 of	 HDAC11	 occurs	 in	eukaryotic	 but	 not	 prokaryotic	 expression,	 and	 this	 PTM	may	 activate	 the	 enzyme.	 	We	hypothesize	that	this	modification	is	acetylation	of	a	lysine	residue.		This	PTM	is	consistent	with	the	observed	shift	in	molecular	mass.		Additionally,	proteolysis	of	HDAC11	expressed	in	sf9	and	E.	coli,	prior	 to	mass	spectroscopy	demonstrates	acetylated	peptides	unique	to	the	eukaryotic	expression.		This	hypothesis	is	explored	in	greater	detail	in	chapter	6.	
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Using	HDAC11	expressed	in	sf9	cells,	we	sought	to	understand	HDAC11	specificity	by	performing	the	first	screen	of	this	isozyme	against	a	small	library	of	peptide	substrates.		We	began	this	process	using	non-fluorinated	coumarin-labeled	peptides.	 	We	tested	three	of	these	fluorescently	labeled	peptides	and	found	that	two	of	the	three	showed	measurable	deacetylation	over	the	time	course	and	enzyme	concentrations	used.		The	first	that	reacted	with	HDAC11	was	a	very	simple	substrate,	an	acetyllysine	residue	with	an	N-terminal	BOC	protecting	group	and	a	C-terminal	methyl-coumarin.	 	The	second	two	peptides	sequences	were	based	on	p53;	the	inactive	Enzo	HDAC8	substrate	contains	two	acetyllysine	residues	adjacent	to	one	another,	while	the	active	substrate	(Enzo’s	Sirt1)	is	only	acetylated	at	one	of	these	lysines	(Fig.	3.11).		HDAC11	reacted	with	the	Sirt1	substrate	at	least	10-fold	faster	than	the	HDAC8	substrate.		These	results	suggest	that	HDAC11	may	have	a	preference	for	substrates	with	charged	residues	near	the	acetyllysine.			We	 also	 demonstrated	 that	 HDAC11	 catalyzes	 deacetylation	 of	 several	 unlabeled	peptides.		These	were	peptides	originally	designed	as	potential	HDAC8	substrates,	with	the	exception	of	one	peptide	from	the	DNA	replication	factor	Cdt1.	 	Cdt1	has	previously	been	shown	to	co-immunoprecipitate	with	Flag-tagged	and	GST-tagged	HDAC11	(71),	suggesting	that	it	might	be	an	in	vivo	substrate.		Additionally,	a	Histone	H4	lysine	16	(H4	K16)	peptide	was	tested.		This	peptide	has	been	used	to	assay	HDAC8	activity,	but	there	is	also	evidence	that	 HDAC11	 interacts	 with	 histone	 H4	 (68),	 making	 this	 a	 candidate	 for	 an	 in	 vivo	substrate	 as	 well.	 	 While	 HDAC11	 showed	 little	 catalytic	 activity	 with	 most	 of	 these	peptides	(less	than	10	M-1s-1),	the	top	two	candidates	proposed	from	the	in	vivo	pulldowns,	the	Cdt1	and	H4	K16	peptides,	were	deacetylated.		In	accordance	with	our	hypothesis	that	HDAC11	 favors	 substrates	 with	 charged	 amino	 acids,	 both	 of	 these	 peptides	 have	 an	
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abundance	of	polar	residues,	with	all	of	them	being	basic	(Arg,	Lys,	and	His).	 	We	showed	with	 the	 Sirt1	 substrate	 than	 an	 upstream	 positive	 charge	 was	 beneficial	 for	 HDAC11	catalysis.	 	With	these	peptides,	we	see	a	distribution	of	these	charged	residues,	occurring	both	upstream	and	downstream	of	the	acetyllysine.		This	trend	is	the	first	information	we	have	 on	 how	 HDAC11	 recognizes	 substrates,	 and	 how	 that	 recognition	 differs	 from	 the	well-characterized	isozyme	HDAC8.	While	 the	 majority	 of	 catalytic	 residues	 are	 conserved	 between	 HDAC8	 and	HDAC11,	 a	key	 residue	 involved	 in	 substrate	binding	at	 the	L2	 loop	of	HDAC8	 (Asp101),	and	all	class	I	HDACs,	is	not	conserved	in	HDAC11	(58);	sequence	alignments	show	that	this	residue	is	an	asparagine	in	HDAC11.		It	is	not	yet	understood	what	change	the	loss	of	this	positive	 charge	 would	 have,	 though	 one	 possibility	 is	 that	 this	 mutation	 eliminates	 one	point	 in	 the	 loop-substrate	 interaction,	 allowing	 the	 substrate	 to	 bind	 in	 a	 different	orientation.	 	 It	 is	 possible	 that	 this	 residue,	 along	 with	 small	 changes	 in	 the	 residues	responsible	for	forming	the	active	site	tunnel	(96),	are	responsible	for	HDAC11	specificity.		Of	 the	 six	 residues	 that	 form	 the	 HDAC8	 tunnel,	 5	 are	 conserved	 in	 HDAC11	 (based	 on	sequence	 alignment).	 	 The	 variable	 residue	 is	Met274,	which	 is	 a	 Leu	 in	 HDAC11.	 	 This	single	amino	acid	change	contributes	to	the	wider	active	site	tunnel	(based	on	modeling)	in	HDAC11	(96).		This	modeling	also	predicts	that	His142,	which	is	0.49	Å	from	the	active	site	divalent	metal	 in	HDAC8,	 is	 0.7	Å	 away	 in	HDAC11.	 	When	 the	 tunnel	 Leu	 in	HDAC11	 is	mutated	to	methionine,	that	distance	shrinks	to	0.44	Å,	suggesting	this	single	residue	may	play	a	large	role	in	the	geometry	of	the	catalytic	pocket	of	HDAC11	(96).	 	Consistent	with	our	current	hypothesis	that	HDAC11	is	selective	toward	substrates	with	localized	charged	residues,	a	subsequent	peptide	library	of	putative	HDAC11	substrates	(Chapter	4)	showed	
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that	 several	 of	 the	 fastest	 peptide	 substrates	 had	 an	 above	 average	 abundance	 of	 polar	residues.	We	have	demonstrated	here,	 for	the	 first	 time,	 that	purified	HDAC11	catalyzes	the	deacetylation	 of	 unlabeled	 (non-fluorinated)	 peptide	 substrates.	 	 HDAC11	 also	 shows	selectivity	 between	 these	 substrates.	 	 This	work	 demonstrates	 that	 the	 in	 vitro	 catalytic	activity	for	deacetylation	of	peptides	by	HDAC11	is	comparable	to	that	of	HDAC8	where	the	deacetylation	of	a	peptide	from	SMC3,	a	generally	in	vivo	HDAC8	substrate	(10),	has	a	rate	constant	of	about	60	M-1s-1	(61).		The	in	vitro	deacetylase	activity	of	HDAC11	with	a	peptide	from	the	DNA	replication	factor	Cdt1	supports	the	pull	down	data	suggesting	that	this	is	an	
in	vivo	substrate	of	HDAC11.		
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Chapter	4	
Development	of	an	on-chip	proteomics	method	for	identifying	full-length	HDAC	
substrates	
	
Introduction		 Lysine	acetyltransferases	(KATs)	and	histone	deacetylases	(HDACs)	are	two	families	of	 enzymes	 that	 catalyze	 the	 addition	 and	 hydrolysis,	 respectively,	 of	 acetyl	 moieties	attached	 to	 the	 Nε-position	 of	 lysine	 residues,	 respectively	 (97).	 	 The	 18	 histone	deacetylases	 are	 organized	 into	 four	 classes,	 based	 on	 both	 similarity	 to	 yeast	 homologs	and	 phylogeny	 (73).	 	 Class	 I,	 II,	 and	 IV	 HDACs	 are	metal-dependent	 enzymes,	 all	 with	 a	conserved	deacetylase	catalytic	domain.		Contrary	to	their	name,	HDACs	are	involved	in	the	deacetylation	and	regulation	of	thousands	of	proteins,	both	nuclear	and	cytoplasmic	(4,	73,	
98).				 In	 2009,	 a	 landmark	 global	 mass	 spectrometry	 approach	 was	 used	 to	 assess	 the	broad	impact	of	lysine	acetylation	on	virtually	every	cellular	process.		This	study	identified	roughly	 3,600	 acetylation	 sites	 on	 nearly	 2,000	 proteins	 (86).	 	 Today,	 the	 most	 recent	statistics	 in	 the	 phosphosite	 database	 (June,	 2016)	 show	 over	 20,000	 lysine	 acetylation	sites	 in	 humans,	 coming	 from	 over	 7,000	 proteins	 (6).	 	 As	 the	 acetylome	 continues	 to	expand,	 the	 importance	 of	 the	 function	 and	 specificity	 of	 individual	 HDAC	 isozymes	similarly	grows.		With	11	metal-dependent	HDACs,	deacetylation	must	be	a	combination	of	specificity	and	promiscuity.			
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	 To	 date,	 very	 little	 direct	 evidence	 has	 been	 produced	 linking	 specific	 HDAC	isozymes	to	substrate	proteins.	 	Perhaps	the	strongest	case	for	an	HDAC-substrate	pair	 is	HDAC1	 and	 the	 tumor	 suppressor	 p53,	 as	 evidenced	 by	 immunoprecipitation,	 in	 vitro	peptide	analysis,	and	co-expression	(99).		Additional	studies	have	used	similar	techniques,	identifying	 proteins	 that	 pull-down	 with	 specific	 HDAC	 isozymes.	 	 This	 approach	 has	yielded	 dozens	 of	 proteins,	 and	 has	 been	 applied	 to	 each	 of	 the	 11	 HDACs	 (40).		Additionally,	 Ed	 Holson’s	 group	 at	 the	 Broad	 Institute	 has	 recently	 used	 a	 SILAC	 mass	spectrometry-based	 approach	 to	 look	 for	 changes	 in	 protein	 acetylation	 after	 HDAC8-specific	 inhibition	 in	 cell	 culture	 (61).	 	 These	 are	 both	 powerful	 approaches	 that	 have	provided	 the	 field	with	new	avenues	 of	 research.	 	 They	do,	 however,	 have	 limitations	 in	their	 ability	 to	 identify	 isozyme-specific	 substrates.	 	 The	 pull-down	 experiments	 require	that	proteins	have	a	long	lasting,	stable	interaction	with	HDACs.	 	This	is	likely	to	increase	the	 identification	of	protein	partners	relative	 to	substrates	 in	 these	results.	 	Additionally,	while	 in	vivo	changes	 in	protein	acetylation	upon	HDAC-specific	 inhibition	are	strong	and	important	 pieces	 of	 evidence,	 they	 do	 not	 differentiate	 between	 a	 direct	 substrate	 and	 a	downstream	 effect.	 	 Furthermore,	 this	 strategy	 is	 reliant	 upon	 a	 protein’s	 relative	abundance,	and	ionizability	in	a	mass	spectrometer.				 Here,	 we	 present	 a	 novel	 and	 orthogonal	 method	 toward	 identifying	 HDAC	substrates.	 	 We	 have	 chosen	 to	 use	 both	 HDAC8	 (Class	 I)	 and	 HDAC11	 (Class	 IV)	 to	demonstrate	the	broader	abilities	of	 this	approach	to	the	HDAC	field	as	a	whole.	 	Using	a	chip-based	proteomics	approach,	we	report	 the	 identification	of	over	40	putative	HDAC8	substrates	 and	 over	 25	 putative	 HDAC11	 substrates.	 	 In	 collaboration	 with	 Phil	 Cole	 at	Johns	Hopkins	University,	we	used	a	recombinantly	expressed,	truncated	construct	of	the	
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lysine	acetyltransferase	p300	to	acetylate	proteins	immobilized	on	a	glass	slide.	 	We	then	exposed	these	slides	to	individual	HDAC	isozymes	and	monitored	changes	in	acetylation	by	immunochemistry.	 	 The	 immobilized	 proteins,	 roughly	 20,000,	 represent	 the	majority	 of	the	 human	 proteome.	 	 The	 HDAC	 protein	 substrates	 identified	 using	 this	 method	 are	largely	 novel	 targets,	 but	 several	 proteins	 that	 overlap	 with	 the	 results	 of	 previous	experimental	approaches	were	also	identified.		As	validation,	we	demonstrated	that	HDAC	catalyzes	deacetylation	of	peptides	corresponding	to	these	proteins.		We	also	use	unnatural	amino	 acid	 incorporation	 to	 show	 that	 HDAC8	 catalyzes	 deacetylation,	 in	 vitro,	 of	 singly	acetylated,	 full-length	 isocitrate	 dehydrogenase	 1	 (IDH1),	 marking	 the	 first	 time	 this	approach	has	been	used	successfully	on	a	non-histone	protein.		Taken	together,	these	data	demonstrate	that	IDH1	is	an	HDAC8	substrate	and	provide	validation	of	the	usefulness	of	this	method	in	identifying	HDAC-substrate	pairs.	
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Material	and	Methods11,12	
Reagents	Reagents	 used	 to	 prepare	 buffers	 were	 from	 Fisher	 or	 Sigma,	 unless	 otherwise	specified.	 	The	p300	plasmid	was	a	generous	gift	 from	Phil	Cole.	 	The	14mer	peptide	 for	expressed	 protein	 ligation	 was	 synthesized	 in	 the	 Cole	 laboratory.	 	 HuProt	 chips	 were	generated	 by	 Heng	 Zhu’s	 laboratory	 and	 CDI	 laboratories	 (100).	 	 The	 pEVOL	 plasmid	encoding	a	tRNA/tRNA	synthetase	pair	for	the	incorporation	of	acetyllysine	was	a	generous	gift	from	Wenshe	Lui.		
HDAC	expression	and	purification		 HDAC8	 and	 HDAC11	 were	 expressed	 and	 purified	 as	 described	 previously	 in	chapters	2	and	3,	respectively.		The	HDAC11	expression	was	in	sf9	insect	cells.		
p300	expression	and	purification	A	plasmid	encoding	the	catalytic	domain	of	p300	was	provided	by	Phil	Cole	(101).		This	 pTYB2	 plasmid	 encodes	 truncated	 p300	 including	 residues	 1287	 –	 1652,	 with	 two	mutations	 (M1652G	 and	K1637R)	 and	 deletion	 of	 the	 loop	 comprised	 of	 residues	 1523-1554.	 	The	gene	encoded	is	5’	-	p300	-	Sce	VMA	Intein	-	Factor	Xa	-	chitin	binding	domain	(CBD)	under	control	of	a	T7	promoter.		The	plasmid	was	transformed	into	z-competent	BL-21	 DE3	 cells	 (competency	 achieved	 using	 Zymo	 Mix	 and	 Go	 kit)	 and	 grown	 on	 an	 LB-ampicillin	 plate	 overnight	 at	 37˚C.	 	 The	 following	 morning,	 two	 single	 colonies	 were																																																									11	Purification	of	p300	for	EPL,	EPL,	p300	activity,	and	HDAC	catalyzed	deacetylation	on	proteome	chips	were	carried	out	in	Phil	Cole’s	laboratory.	12	Purification	of	p300	(and	EPL)	and	on-chip	enzyme	assays	were	performed	by	Eric	Sullivan	and	Beth	Zucconi.		Verification	of	p300	activity	using	a	radiolabeled	substrate	was	performed	by	Beth	Zucconi.	
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selected	 and	 inoculated	 into	 2,	 10	 mL	 tubes	 of	 2xYT	 (MP	 Biomedical)	 containing	 100	µg/mL	 ampicillin.	 	 Starter	 cultures	 were	 grown	 at	 37˚C	 with	 shaking	 (225	 rpm)	 for	approximately	4	hours,	until	 cultures	were	visibly	cloudy.	 	Each	culture	was	 then	diluted	into	 1	 L	 of	 freshly	 autoclaved	 2xYT	media	 containing	 ampicillin	 and	 grown	 at	 34˚C	with	shaking	(180	rpm).		At	O.D.600	=	0.4	the	cultures	were	induced	by	addition	of	1	mL	of	500	mM	Isopropyl	β-D-1-thiogalactopyranoside	(IPTG)	per	liter	of	culture	(final	concentration	=	0.		5	mM).		Cultures	were	grown	at	34˚C	with	shaking	(180	rpm)	for	5	hours.		Following	growth,	the	cultures	were	pelleted	by	centrifugation	for	20	minutes	at	6,000	x	g	(Beckman	JLA	8.1000).		Cell	pellets	were	kept	on	ice,	and	resuspended	into	p300	lysis	buffer	(25	mM	HEPES	pH	8.0,	500	mM	NaCl,	10%	glycerol).		Resuspended	cells	were	frozen	and	stored	at	-80˚C.				
Purification	of	p300	test	expression	(no	ligation)	Resuspended	 cells	 from	 1	 L	 of	 p300	 expression	 were	 thawed	 on	 ice.	 	 The	 cell	suspension	was	 lysed	by	 two	passes	 through	a	microfluidizer	 (DivTech	Equipment).	 	Cell	lysate	was	loaded	onto	a	5	mL	chitin	column	and	washed	with	20	column	volumes	(CV)	of	chitin	 binding	 buffer	 (25	mM	HEPES	pH	8.0,	 500	mM	NaCl).	 	 Cleavage	 of	 p300	 from	 the	chitin-binding	domain	was	catalyzed	by	addition	of	3	CV	of	chitin	cleavage	buffer	(25	mM	HEPES	 pH	 8.0,	 500	mM	NaCl,	 50	mM	 dithiothreitol	 (DTT)).	 	 The	 column	 flow	was	 then	stopped	and	the	cleavage	was	allowed	to	progress	for	16	hours	at	4˚C.		The	free	protein	was	then	eluted	with	5	CV	of	chitin	binding	buffer.		Cleavage	efficiency	was	determined	using	a	coomassie-stained	polyacrylamide	gel	following	sodium	dodecyl	sulfate	polyacrylamide	gel	electrophoresis	(SDS-PAGE)	(Fig.	4.1).	
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Figure	4.1:	Purification	of	unligated	p300	A	1	L	expression	of	p300	was	lysed	and	purified	on	a	5	mL	chitin	column.		The	p300-CBD	construct	is	76	kDa	before	cleavage.		Based	on	the	degree	of	total	protein	in	the	pellet	lanes,	lysis	may	have	been	incomplete.		The	wash	steps	appear	to	have	efficiently	removed	unbound	protein	from	the	column.		The	thiol-cleavage	product,	on	right,	is	a	pure	protein	corresponding	to	the	correct	molecular	weight	for	our	p300	construct	(38	kDa).	
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p300	Expressed	Protein	Ligation	and	purification	The	p300	cell	pellets	from	2	L	of	culture	were	thawed	on	ice	and	resuspended	in	60	mL	 of	 p300	 EPL	 lysis	 buffer	 (25	mM	HEPES	 pH	 7.9,	 500	mM	NaCl,	 10%	 glycerol,	 1	mM	phenylmethylsulfonyl	fluoride	(PMSF),	1	mM	MgSO4).		Cells	were	lysed	by	1	pass	through	a	French	Press.		The	lysate	was	cleared	by	centrifugation	at	27,000	x	g	for	30	minutes	in	a	J20	rotor.	 	Cleared	 lysate	was	 loaded	onto	a	15	mL	chitin	resin	bed,	 in	a	4˚C	cold	room.	 	The	loaded	resin	was	washed	with	5	CV	of	chitin	EPL	binding	buffer	(25	mM	HEPES	pH	7.9,	250	mM	NaCl,	1	mM	EDTA),	3	CV	of	chitin	EPL	buffer	B	(25	mM	HEPES	pH	7.9,	500	mM	NaCl,	1	mM	EDTA),	2	CV	chitin	binding	buffer,	and	2	CV	of	 ligation	buffer	(25	mM	HEPES	pH	7.4,	250	mM	NaCl,	1	mM	EDTA,	200	mM	2-mercaptoethanesulfonic	acid	(mesna)).	The	 C-terminal	 14mer	 peptide	 (29	 mg)	 (sequence:	 CMLVELHTQSQDRF)	 was	dissolved	 in	 4	 mL	 ligation	 buffer.	 	 This	 solution	 was	 applied	 to	 the	 top	 of	 the	 column,	followed	by	a	1	mL	ligation	buffer	stacker.		Cleavage	and	ligation	were	allowed	to	occur	for	3	hours	at	4˚C,	followed	by	16	hours	at	room	temperature.	After	 the	16-hour	 reaction,	 the	 column	was	 returned	 to	4˚C.	 	The	 ligation	product	was	eluted	with	4	CV	chitin	buffer.	 	The	eluent	 (35	mL)	was	added	 to	a	dialysis	 cassette	(20,000	Da	MWCO)	and	dialyzed	at	4˚C	for	2	hours	against	p300	dialysis	buffer	1	(20	mM	HEPES	pH	7.9,	500	mM	NaCl,	10	mM	DTT),	2	hours	against	p300	dialysis	buffer	2	(20	mM	HEPES	pH	7.9,	100	mM	NaCl,	5	mM	DTT),	and	2	hours	against	p300	dialysis	buffer	3	(20	mM	HEPES	pH	7.9,	 50	mM	NaCl,	 1	mM	DTT).	 	 The	protein	was	 then	 loaded	onto	 an	 SP-strong	cation	exchange	column	and	eluted	via	 fast	protein	 liquid	chromatography	(FPLC)	using	an	AKTA	pure	(GE	Healthcare).		The	column	was	equilibrated	with	10	CV	S-Buffer	A	(20	mM	Tris	pH	8.0,	50	mM	NaCl,	2	mM	DTT)	and	the	protein	sample	was	applied	using	a	
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superloop.		The	elution	gradient	was	as	follows:	0-30%	S-Buffer	B	(20	mM	Tris	pH	8.0,	1	M	NaCl)	over	25	CV,	 followed	by	30-60%	gradient	over	10	CV,	 and	 then	60-100%	gradient	over	 10	 CV.	 	 Protein	 elution	 and	 purity	 was	 confirmed	 by	 polyacrylamide	 gel	electrophoresis.	 	Fractions	containing	pure	p300	were	pooled	and	concentrated	 from	4.5	mL	 to	 <1	 mL	 via	 Amicon	 centrifugation	 tubes.	 	 Sample	 was	 then	 dialyzed	 for	 2	 hours	against	20	mM	HEPES	pH	7.9,	50	mM	NaCl,	1	mM	DTT,	10%	glycerol.	 	Following	dialysis,	protein	concentration	was	determined	by	the	micro	BCA	assay	(Pierce)	using	bovine	serum	albumin	 (BSA)	 as	 the	 standard,	 as	 well	 as	 by	 comparison	 to	 BSA	 on	 a	 denaturing	polyacrylamide	gel	.		
Proteome	Chip	Assays	The	 proteome	 chip	 experiments	 varied	 in	 amount	 of	 p300,	 HDAC8,	 and	 HDAC11	used	on	each	chip.		However,	the	general	protocol	was	consistent	for	each	chip	and	details	for	each	assay	are	described	below.	 	 In	all	cases,	chips	were	removed	 from	-80˚C	storage	and	 immediately	placed	 in	5	mL	blocking	solution	(5%	BSA	 in	phosphate-buffered	saline	with	0.5%	tween	20	(PBST)).				
p300	Reaction	Chips	were	blocked	for	1	hour	with	rocking	at	room	temperature.	 	Blocking	buffer	was	 then	removed	and	 the	chips	were	washed	 twice	 for	5	minutes	each	with	5	mL	p300	reaction	buffer	(50	mM	HEPES	pH	7.9,	50	mM	NaCl,	1	mM	TCEP).		During	washes,	the	p300	reaction	solution	was	prepared	on	ice	as	follows,	1x	p300	reaction	buffer,	8	µM	p300,	and	200	µM	acetyl-CoA	added	immediately	prior	to	using	the	reaction.		120	µL	of	reaction	was	
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pipetted	onto	the	appropriate	chips	and	coverslips	were	carefully	applied	using	tweezers	to	avoid	creating	air	pockets	beneath	them.		The	tray	containing	the	chips	was	wrapped	in	a	paper	 towel	moistened	with	water	 and	 clear	 plastic	wrap	 to	 prevent	 the	 reactions	 from	drying.	 	 The	 reactions	were	 incubated	 at	 30˚C	 for	 2	 hours.	 	 As	 this	 reaction	 progressed,	HDAC	 was	 reconstituted	 1:1	 with	 zinc.	 	 HDAC8	 was	 used	 at	 2	 and	 7.5	 µM	 final	concentrations	and	HDAC11	at	1	and	1.5	µM	final	concentrations.		The	p300	reactions	were	quenched	by	 two	10-minute	washes	with	5	mL	sodium	bicarbonate	wash	buffer	 (50	mM	NaHCO3-Na2CO3	pH	9.3).				
HDAC	reaction	After	blocking,	the	chips	were	washed	once	with	5	mL	of	20	µM	EDTA	in	0.5x	HDAC	reaction	buffer	(12.5	mM	HEPES	pH	8.0,	68.5	mM	NaCl,	1.5	mM	KCl)	for	5	minutes,	followed	by	two	washes	with	5	mL	0.5x	HDAC	reaction	buffer	for	10	minutes	each,	and	a	final	wash	of	5	mL	0.75x	HDAC	reaction	buffer	for	10	minutes.		HDAC	reaction	solutions	were	added:	in	round	1	experiments	120	µL	of	HDAC	reaction	solution	was	added	to	each	chip,	in	round	2	 experiments	 3	 mL	 of	 HDAC	 reaction	 solution	 was	 added	 to	 each	 chip,	 enough	 to	submerge	the	chips	completely.		The	chip	trays	were	again	wrapped	in	moist	paper	towels	and	 plastic	wrap	 and	 returned	 to	 30˚C	 for	 2.5	 hours.	 	 Following	 the	 reaction,	 the	HDAC	solution	was	removed	and	the	chips	were	washed	twice	with	p300	reaction	buffer	for	10	minutes	each.				
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Antibody	treatment	of	chips	Chips	were	washed	three	times	with	1%	SDS	in	tris-buffered	saline	with	0.5%	tween	20	 (TBST)	 for	 10	 minutes	 each.	 	 They	 were	 then	 washed	 four	 times	 with	 tris-buffered	saline	 (TBS)	 for	 15	 minutes	 each.	 	 Primary	 antibody	 (anti-acetyllysine	 from	 rabbit,	ThermoFisher)	was	diluted	1:5,000	in	TBST	with	5%	BSA	and	3.5	mL	were	added	to	each	chip	 and	 incubated	 at	 4˚C	 overnight.	 	 The	 primary	 antibody	was	 then	 removed	 and	 the	chips	were	washed	four	times	with	TBST	for	10	minutes	each.	 	Secondary	antibody	(anti-rabbit	Alexa	Fluor	647,	ThermoFisher)	was	diluted	1:10,000	in	TBST	with	5%	BSA	and	3.5	mL	 were	 added	 to	 each	 chip	 and	 incubated	 for	 1.5	 hours	 at	 room	 temperature.	 	 This	solution	was	poured	off	and	chips	were	washed	three	times	with	ultrapure	water	(Milli-Q,	Millipore)	for	10	minutes	each.		The	chips	were	then	dried	by	centrifugation	for	2	minutes	at	 1,000	 rpm	 and	 stored	 for	 1	 hour	 away	 from	 light	 at	 room	 temperature	 to	 complete	drying.				
Chip	Readout	Dry	chips	were	protected	from	light	until	ready	to	be	scanned.		Chips	were	read	one	at	 a	 time	 in	 a	 GenePix	 4000B	Microarray	 Scanner	 (Molecular	 Devices).	 	 This	 dual	 laser	scanner	 visualizes	 the	 acetyllysine	 secondary	 fluorophore	 at	 635	 nm	 and	 the	 GST	secondary	 fluorophore	 at	 532	 nm.	 	 The	 Pixel	 diameter	 was	 fixed	 at	 5	 µM	 and	 the	fluorescence	scans	were	always	performed	using	the	same	instrument	parameters	(power	and	gain).		
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Cloning	of	IDH1	Human	 IDH1	cDNA	(Dharmacon)	was	 cloned	 into	a	pET-M11	bacterial	 expression	vector.		Primers	were	designed	to	amplify	the	IDH1	cDNA	and	generate	an	N-terminal	NcoI	and	C-terminal	NotI	cleavage	sites	(Fig.	4.2A).	Polymerase	 chain	 reaction	 (PCR)	 amplification	 was	 performed	 in	 a	 thermocycler	using	 Q5	 HotStart	 DNA	 polymerase	 (New	 England	 Biolabs).	 	 The	 PCR	 products	 were	separated	 on	 a	 1%	 agarose	 gel.	 	 DNA	 was	 stained	 using	 Sybr	 Safe	 DNA	 stain	 (Thermo	Fisher)	and	the	band	corresponding	to	the	correct	size	for	the	desired	insert	was	excised	from	 the	 gel	 and	 cleaned	 using	 a	DNA	Gel	 Purification	Kit.	 	 Insert	 and	 vector	were	 both	digested	with	NcoI	 and	NotI	 (New	 England	 Biolabs)	 for	 4	 hours	 at	 37˚C	 to	 generate	 the	appropriate	sticky	ends.		The	restriction	digest	reactions	were	quenched	and	the	products	separated	using	a	second	agarose	gel,	followed	by	an	additional	DNA	Gel	Purification	step.		The	fragments,	at	a	3:1	insert	to	vector	ratio,	were	treated	with	Quick	T4	DNA	Ligase	and	Quick	Ligation	Buffer	 and	Mix	 (New	England	Biolabs)	on	 ice	 to	prepare	 the	new	circular	plasmid.	 	 The	 final	 construct	 was	 His6	 –	 TEV	 –	 IDH1	 in	 a	 pET	 M11	 vector	 encoding	kanamycin	 resistance	 (Fig.	 4.2B).	 	 This	 plasmid	 was	 transformed	 into	 XL1-Blue	 super	competent	 cells	 and	 plated	 on	 LB-Kan	 plates.	 	 The	 cells	 were	 grown	 overnight	 at	 37˚C.		Single	 colonies	 were	 then	 picked	 and	 10	 mL	 cultures	 were	 grown	 and	 treated	 with	 a	Promega	Wizard	Plus	SV	Miniprep	DNA	Purification	kit.	 	DNA	was	 sequenced	 to	 confirm	the	correct	gene	sequence.				
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A) 
Forward primer: 
5’- GCG TCC ATG GGT TCC AAA AAA ATC AGT GGC GGT TCT GTG GTA GAG 
 
Reverse primer: 
5’- CGC GCG GCC GCT TAA AGT TTG GCC TGA GCT AGT TTG ATC TT 
	
B) 
ATGAAACATCACCATCACCATCACCCCATGAGCGATTACGACATCCCCACTACTGAGAATCTTT
ATTTTCAGGGCGCCATGGGTTCCAAAAAAATCAGTGGCGGTTCTGTGGTAGAGATGCAAGGAGA
TGAAATGACACGAATCATTTGGGAATTGATTAAAGAGAAACTCATTTTTCCCTACGTGGAATTG
GATCTACATAGCTATGATTTAGGCATAGAGAATCGTGATGCCACCAACGACCAAGTCACCAAGG
ATGCTGCAGAAGCTATAAAGAAGCATAATGTTGGCGTCAAATGTGCCACTATCACTCCTGATGA
GAAGAGGGTTGAGGAGTTCAAGTTGAAACAAATGTGGAAATCACCAAATGGCACCATACGAAAT
ATTCTGGGTGGCACGGTCTTCAGAGAAGCCATTATCTGCAAAAATATCCCCCGGCTTGTGAGTG
GATGGGTAAAACCTATCATCATAGGTCGTCATGCTTATGGGGATCAATACAGAGCAACTGATTT
TGTTGTTCCTGGGCCTGGAAAAGTAGAGATAACCTACACACCAAGTGACGGAACCCAAAAGGTG
ACATACCTGGTACATAACTTTGAAGAAGGTGGTGGTGTTGCAATGGGGATGTATAATCAAGATA
AGTCAATTGAAGATTTTGCACACAGTTCCTTCCAAATGGCTCTGTCTAAGGGTTGGCCTTTGTA
TCTGAGCACCAAAAACACTATTCTGAAGAAATATGATGGGCGTTTTAAAGACATCTTTCAGGAG
ATATATGACAAGCAGTACAAGTCCCAGTTTGAAGCTCAAAAGATCTGGTATGAGCATAGGCTCA
TCGACGACATGGTGGCCCAAGCTATGAAATCAGAGGGAGGCTTCATCTGGGCCTGTAAAAACTA
TGATGGTGACGTGCAGTCGGACTCTGTGGCCCAAGGGTATGGCTCTCTCGGCATGATGACCAGC
GTGCTGGTTTGTCCAGATGGCAAGACAGTAGAAGCAGAGGCTGCCCACGGGACTGTAACCCGTC
ACTACCGCATGTACCAGAAAGGACAGGAGACGTCCACCAATCCCATTGCTTCCATTTTTGCCTG
GACCAGAGGGTTAGCCCACAGAGCAAAGCTTGATAACAATAAAGAGCTTGCCTTCTTTGCAAAT
GCTTTGGAAGAAGTCTCTATTGAGACAATTGAGGCTGGCTTCATGACCAAGGACTTGGCTGCTT
GCATTAAAGGTTTACCCAATGTGCAACGTTCTGACTACTTGAATACATTTGAGTTCATGGATAA
ACTTGGAGAAAACTTGAAGATCAAACTAGCTCAGGCCAAACTTTAA 
Figure	4.2:	Sequences	for	cloning	IDH1	cDNA	(A)	Human	wild-type	IDH1	cDNA	(Dharmacon)	was	amplified	using	the	listed	forward	and	reverse	primers.		These	primers	were	used	 in	a	PCR	reaction	to	prepare	an	IDH1	gene	with	an	N-terminal	NcoI	site	and	a	C-terminal	NotI	site.		(B)	DNA	sequence	coding	for	His6-TEV-IDH1	in	a	pET	M11	vector.		The	labeled	regions	are	polyhistidine	(blue),	TEV	recognition	site	(red),	start	of	IDH1	sequence	(orange),	and	lysine	residues	that	will	be	mutated	for	incorporation	of	acetyllysine	(highlighted	yellow).			
Expression	of	WT-IDH1	The	 plasmid	 encoding	 his-tagged	 IDH1	 was	 transformed	 into	 Rosetta	 2	 (DE3)	competent	 cells	 (Novagen),	 per	 the	manufacturer’s	 protocol.	 	 Briefly,	 cells	 (50	 µL)	were	thawed	on	ice	before	~100	ng	of	plasmid	DNA	was	added.		Cells	were	incubated	on	ice	for	5	
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minutes	before	30	seconds	of	heat	shock	in	a	42˚C	water	bath	and	finally	2	minutes	on	ice.		Following	 this,	 250	 µL	 of	 room	 temperature	 Super	 Optimal	 broth	 with	 Catabolite	repression	(S.O.C.)	medium	was	added	to	 the	cells	and	 incubated	 for	1	hour	at	37˚C	with	shaking.		This	solution	was	then	plated	on	LB-Kanamycin/Chloramphenicol	(50	µg/mL	and	34	µg/mL,	 respectively)	plates	and	grown	overnight	at	37˚C.	 	The	 following	day	colonies	were	 picked	 and	 used	 to	 inoculate	 10	 mL	 of	 2xYT	 media	 with	 kanamycin	 and	chloramphenicol	present	(at	the	above	concentrations).		These	starter	cultures	were	grown	for	~4	 hours	 before	 being	 diluted	 to	 1	 L	 (1:100	 dilution)	 in	 2xYT	with	 fresh	 antibiotics	present.		Cultures	were	grown	with	shaking	(175	rpm)	at	34˚C	until	an	O.D.600	of	0.5.		Then	the	cultures	were	cooled	to	18˚C	and	induced	by	addition	of	IPTG	to	a	final	concentration	of	0.5	mM.		The	cultures	were	grown	for	another	16	hours.		Following	growth,	the	cells	were	pelleted	by	centrifugation	at	6,000	x	g	for	20	minutes	in	a	Beckman	JA	8.1000	fixed	angle	rotor.		Cells	were	then	frozen	and	stored	at	-80˚C.		
Purification	of	WT-IDH1	The	IDH1	cell	pellet	was	thawed	on	ice	and	resuspended	in	30	mL	IDH1	Lysis	buffer	(50	 mM	 HEPES	 pH	 8.0,	 150	 mM	 NaCl,	 10%	 glycerol)	 with	 1	 Roche	 Complete	 protease	inhibitor	tablet	per	liter	of	cell	growth.		The	cell	solution	was	lysed	via	two	passes	through	a	chilled	micro-fluidizer.		Cell	lysate	was	then	treated	with	1	µL	of	DNase	I	and	incubated	on	ice	 for	 30	minutes.	 	 Lysate	was	 then	 cleared	 via	 centrifugation	 at	 27,000	 x	 g	 for	 1	 hour	(Sorvall	SS-34	rotor).	 	The	cleared	supernatant	was	decanted	and	passed	through	a	5	mL	nickel	affinity	column	(HisPur	Ni-NTA	resin,	Thermo)	using	gravity-flow.		The	column	was	then	washed	with	5	CV	of	IDH1	buffer	A	(50	mM	HEPES	pH	8.0,	150	mM	NaCl),	followed	by	
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elution	through	a	step-wise	gradient	of	increasing	imidazole	buffers,	from	0	mM	imidazole	to	250	mM	 imidazole	 (steps	 at	 0	mM,	50	mM,	 and	250	mM).	 	 Fractions	 containing	 IDH1	(determined	by	coomassie	staining	of	an	SDS-PAGE	gel)	were	pooled	and	 treated	with	of	TEV	 protease	 (1.5	 mg	 total).	 	 The	 protein	 was	 transferred	 to	 a	 Slide-A-Lyzer	 dialysis	cassette	and	dialyzed	overnight	at	4˚C	against	4	L	of	IDH1	buffer	A.		The	following	day,	the	protein	was	 removed	 from	dialysis	 and	again	passed	over	 a	5	mL	nickel	 affinity	 column,	run	in	the	same	fashion	as	the	first	Ni-column	(Fig.	4.3).		Fractions	containing	TEV-cleaved	IDH1	were	pooled	and	concentrated	using	Amicon	Ultra	 centrifugal	 filters.	 	 Final	protein	concentration	 was	 determined	 to	 be	 145	 µM	 by	 absorbance	 at	 A280	 using	 a	 nano-drop	spectrophotometer.		IDH1	was	aliquoted	and	flash	frozen	in	liquid	nitrogen,	then	stored	at	-80˚C.	 						
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Figure	4.3:	Purification	of	wild-type	IDH1	A	1-L	 IDH1	expression	was	purified	over	 two	nickel	columns.	 	The	 first	nickel	column	is	shown	on	the	 left.		IDH1	(46	kDa)	overexpression	is	seen	in	the	lysate	and	in	the	imidazole	gradient	with	protein	eluting	at	both	steps	 (50	mM	and	250	mM	imidazole).	 	After	a	TEV	protease	cleavage	step,	a	second	nickel	column	(right)	was	 run.	 	 Here,	 untagged	 IDH1	 elutes	 in	 the	 column	 flow	 through.	 	 The	 presence	 of	 an	 IDH1	 band	 in	 the	imidazole	gradient	suggests	that	TEV-cleavage	was	incomplete.	
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Generation	of	amber	stop	IDH1	mutants	Primers	were	designed	for	site-directed	mutagenesis	of	IDH1.		Four	lysine	residues	were	mutated,	 individually,	 to	amber	stop	codons,	 to	generate	 four	new	IDH1	constructs.		PCR	was	run	following	a	basic	QuikChange	II	(Agilent)	site-directed	mutagenesis	protocol,	using	Q5	HotStart	DNA	polymerase.		PCR	mutagenesis	products,	still	in	pET	M11	plasmids,	were	 incubated	 for	 1	 hour	 with	 DpnI,	 followed	 by	 transformation	 into	 XL1	 Blue	 super	competent	cells.		Cells	were	plated	on	LB-Kanamycin	plates	and	single	colonies	were	picked	and	sequenced	to	verify	incorporation	of	the	desired	mutants.				
Expression	of	truncated	IDH1	To	 verify	 that	 the	 mutant	 IDH1	 would	 express	 and	 terminate	 translation	 at	 the	desired	amber	stop	codons,	each	construct	was	 transformed	 into	Z-competent	BL21-DE3	and	grown	overnight	on	LB-Kan	plates.	 	Colonies	were	picked	and	 inoculated	 into	10	mL	2xYT	 starter	 cultures	 and	grown	with	 shaking	at	37˚C.	 	These	 cultures	were	diluted	 into	fresh	2xYT	at	1:100	and	grown	at	34˚C	until	an	O.D.600	of	0.5.		Cultures	were	then	cooled	to	18˚C	 and	 induced	 with	 IPTG	 at	 a	 final	 concentration	 of	 0.5	 mM.	 	 Cultures	 were	 grown	overnight	 with	 shaking.	 	 Cells	 were	 pelleted	 using	 the	 same	 centrifugation	 protocol	outlined	 above.	 	 A	 small	 portion	 of	 each	 cell	 pellet	 was	 lysed	 with	 B-PER	 II	 bacterial	extraction	reagent	(Thermo	Fisher),	as	per	the	manufacturer’s	protocol.		Briefly,	cells	were	resuspended	 in	 10	mL	 B-PER	 reagent	 and	 shaken	 at	 room	 temperature	 for	 10	minutes.		Insoluble	protein	was	then	pelleted	by	centrifugation	at	27,000	x	g	(Sorvall	SS-34	rotor)	for	15	 minutes.	 	 Soluble	 and	 insoluble	 fractions	 were	 fractionated	 using	 SDS-PAGE	 and	analyzed	 on	 a	 western	 blot	 probed	 with	 anti-Poly	 Histidine	 AP	 primary	 antibody	 and	
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visualized	by	colorimetric	change	upon	addition	of	5-bromo-4-chloro-3-indolyl-phospahte	(BCIP)	 and	nitro	blue	 tetrazolium	 (NBT)	 from	an	alkaline	phosphatase	 reagent	detection	kit	(EMD	Millipore).		
Preparation	of	a	pEVOL	Kac	plasmid	competent	cell	line	BL-21	 DE3	 z-competent	 cells	 were	 transformed	 with	 the	 pEVOL	 Kac	 plasmid	generously	provided	by	Wenshie	Lui,	 similar	 to	 that	used	 in(102,	103).	 	These	cells	were	plated	on	LB-Chloramphenicol	and	grown	overnight	at	37˚C.		Single	colonies	were	selected	and	 inoculated	 into	 10	 mL	 of	 LB	 culture	 with	 chloramphenicol	 present.	 	 These	 starter	cultures	were	allowed	to	grow	overnight	at	37˚C.		The	following	day,	1	mL	of	starter	culture	was	used	to	inoculate	100	mL	of	LB-chloramphenicol	medium.		This	culture	was	grown	at	34˚C	until	it	reached	an	OD600	of	0.4.		The	cells	were	immediately	incubated	on	ice	for	about	30	minutes.	 	The	following	procedure	to	prepare	calcium	competent	cells	was	performed	on	ice,	using	pre-chilled	buffers	and	chilled	centrifuge	rotors.		The	cell	culture	was	pelleted	by	 centrifugation	 at	 3,000	 x	 g	 for	 15	 minutes,	 and	 the	 supernatant	 was	 decanted	 and	disposed	 of.	 	 The	 cell	 pellet	 was	 resuspended	 in	 20	 mL	 MgCl2	 buffer	 (100	 mM	 MgCl2,	sterilized	by	autoclave).		The	cells	were	pelleted	again	by	centrifugation	at	2,000	x	g	for	15	minutes	and	the	supernatant	was	again	decanted.		Cells	were	resuspended	in	50	mL	CaCl2	buffer	A	(100	mM	CaCl2,	sterilized	by	autoclave).		The	cell	suspension	was	again	pelleted	by	centrifugation	 at	 2,000	 x	 g	 for	 15	 minutes	 and	 the	 supernatant	 decanted.	 	 Cells	 were	resuspended	in	10	mL	CaCl2	buffer	B	(100	mM	CaCl2,	15%	glycerol,	sterilized	by	autoclave).		The	cells	were	pelleted	by	centrifugation	at	1,000	x	g	for	15	minutes	and	the	supernatant	was	 decanted.	 	 The	 cell	 pellet	 was	 resuspended	 in	 0.5	 mL	 CaCl2	 buffer	 B.	 	 The	 cell	
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suspension	was	aliquoted	(50	µL)	and	flash	frozen	in	liquid	nitrogen.		Cells	were	stored	at	-80˚C.		
Expression	and	purification	of	singly	acetylated	IDH1	The	 Lysine	 to	 amber	 stop	mutants	 of	 IDH1	 (K81ac,	 K93ac,	 K224ac,	 and	 K321ac)	were	 transformed	 into	 calcium	 competent	 cells	 containing	 a	 pEVOL	 Kac	 plasmid	 that	encodes	a	tRNA/tRNA	synthetase	pair	for	acetyllysine	incorporation.		Briefly,	roughly	100	ng	of	 plasmid	DNA	 for	 each	 lysine	mutant	was	 added	 to	50	µL	of	 competent	 cells.	 	 Cells	were	incubated	on	ice	for	5	minutes,	followed	by	a	30	second	heat	shock	in	42˚C	water,	and	placed	back	on	 ice	 for	2	minutes.	 	S.O.C.	 	medium	was	then	added	to	each	aliquot	of	cells	(200	µL	of	S.O.C.)	and	the	cells	were	incubated	for	1	hour	with	shaking	at	37˚C.		Cells	were	then	 plated	 on	 LB-Kan/Chlor	 plates	 and	 grown	 overnight	 at	 37˚C.	 	 The	 expression	 of	mutant	IDH1	was	carried	out	using	a	similar	method	to	WT-IDH1	expression,	with	minor	differences.		Culture	sizes	were	limited	to	<500	mL	total.	 	After	cooling	the	cells	when	the	OD600	 reached	 0.5,	 the	 cells	 were	 treated	 with	 nicotinamide	 (final	 20	 mM)	 and	 then	continued	shaking	for	10	minutes.		Cells	were	then	treated	with	acetyllysine	(final	10	mM)	and	 the	 pEVOL	 plasmid	 was	 induced	 by	 addition	 of	 arabinose	 (final	 0.2%).	 	 After	 30	minutes,	IDH1	was	induced	by	addition	of	IPTG	(final	0.5	mM).			Following	expression,	mutant	IDH1	was	purified	over	two	nickel	columns,	according	to	 the	same	method	used	 for	WT-IDH1.	 	Acetylation	was	verified	by	western	blot	probed	with	an	anti-acetyllysine	primary	antibody.				
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HDAC8-catalyzed	deacetylation	of	full-length	IDH1	HDAC8	catalyzed	deacetylation	was	measured	for	all	four	IDH1	acetylation	mutants.		Reactions	were	done	under	single	turnover	conditions	([E]	>	[S]),	and	all	components	were	diluted	in	HDAC	reaction	buffer	(25	mM	HEPES	pH	8.0,	137	mM	NaCl,	3	mM	KCl).		HDAC8	was	 in	 excess	 of	 the	 acetylated	 IDH1	 substrate,	 which	 was	 assayed	 in	 the	 low-	 to	 sub-micromolar	 range.	 	An	 internal	 standard,	BSA,	was	used	 in	all	 reactions.	 	Reactions	were	carried	out	at	30˚C	 in	microcentrifuge	 tubes.	 	Reaction	aliquots	were	quenched	 into	SDS,	10%	HCl,	 or	 SAHA.	 	 Each	 time	 point	was	 then	 fractionated	 on	 a	 polyacrylamide	 gel	 and	transferred	to	a	nitrocellulose	membrane.	 	Western	blots	were	probed	with	primary	anti-acetyllysine	 antibody	 (rabbit,	 from	 Abcam)	 at	 a	 1:1000	 dilution	 for	 2	 hours	 at	 room	temperature.	 	 Horseradish	 peroxidase	 (HRP)	 -	 conjugated	 secondary	 antibody	was	 used,	followed	by	addition	of	SuperSignal	West	Pico	Chemiluminescent	substrate	(Thermo).		
Preparation	of	peptide	substrates	from	chip-based	hits	Acetylated	 peptides	 ranging	 from	 6-12	 amino	 acids	 were	 ordered	 from	 Synthetic	Biomolecules.	 	 Lyophilized	 peptides	 were	 resuspended	 in	 ultrapure	 water	 (Milli-Q,	Millipore).	 	 Those	 that	 would	 not	 dissolve	 in	 pure	 water	 were	 resuspended	 in	 water	containing	 DMSO,	 acetonitrile,	 sodium	 bicarbonate,	 or	 formic	 acid.	 	 To	 reduce	 metal	contamination	 in	 the	 peptides,	 50	 –	 100	 µL	 of	 a	 pre-washed	 Chelex-100	 resin	 (BioRad)	slurry	 in	Milli-Q	water	was	 added	 to	 each	peptide.	 	 The	peptides	were	 incubated	on	 ice,	with	 agitation	 once	 every	 5	 minutes	 for	 an	 hour.	 	 Chelex	 was	 then	 pelleted	 by	centrifugation	at	3000	x	g	and	supernatant	was	collected	and	transferred	to	clean,	metal-free	microcentrifuge	tubes.		Peptide	concentrations	were	determined	using	a	micro-BCA	kit	
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with	8	BSA	 standards	 and	3	 concentrations	of	 each	peptide.	 	Additionally,	 select	 peptide	concentrations	 were	 also	 measured	 by	 a	 fluorescamine-based	 assay	 as	 described	 in	Wolfson	et	al.	(76)	and	by	absorbance	measurements	at	A280.				
Measuring	turnover	of	acetylated	peptides	from	chip-hits	The	turnover	of	acetylated	peptides	was	measured	using	an	enzyme-coupled	assay,	as	described	in	Wolfson	et	al.,	(76).		In	summary,	peptides,	when	possible,	were	measured	at	100	µM.	 	 If	peptide	 stocks	did	not	 allow	 this,	 then	50	µM	peptide	 substrate	was	used.		HDAC8	was	reconstituted	with	cobalt	or	zinc	at	a	1:1	ratio	at	concentrations	ranging	from	0.5	–	1	µM.		HDAC11	was	reconstituted	with	zinc	at	a	1:1	ratio,	with	concentrations	ranging	from	0.2	–	0.5	µM.	 	Both	enzymes	were	assayed	at	34˚C.	 	Time	points	 ranged	 from	0	–	4	hours,	and	reactions	from	both	enzymes	were	quenched	into	10%	HCl.		Acidified	solutions	were	neutralized	by	addition	of	6%	sodium	bicarbonate	 immediately	before	analysis.	 	 In	Corning	3868	black	plates,	60	µL	of	neutralized	reactions	were	added	to	10	µL	of	a	coupled-enzyme	solution	 to	 catalyze	 the	 conversion	of	NAD+	 to	NADH	using	acetate	as	a	 starting	material	(as	previously	described).	 	Reaction	fluorescence	was	read	(ex.	 	340	nm	and	em.		460	nm)	at	short	time	intervals	(1-2	minutes)	until	the	coupled	enzyme	reactions	reached	completion,	in	less	than	2	hours.		
IDH1	activity	IDH1	was	assayed	with	75	µM	NADP+	and	200	µM	isocitrate.		Assays	were	run	in	50	–	100	µL	volumes	 in	a	black	Corning	3686	96-well	half-area	plate.	 	Progress	curves	were	measured	by	 fluorescence	with	 excitation	 at	 340	nm	and	 emission	 at	 460	nm	 (PolarStar	
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Fluorescence	 plate	 reader).	 	 IDH1	WT	 was	 assayed	 at	 5	 –	 50	 nM,	 and	 IDH1	 acetylated	mutants	were	assayed	at	10	nM	–	1	µM.						
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Results	
Expressed	Protein	Ligation	of	p300	generates	active	enzyme	and	results	in	acetylation	of	
proteins	‘on-chip.’	HuProt	chips,	developed	by	Zhu	and	coworkers	at	Johns	Hopkins	and	manufactured	by	CDI	Laboratories,	were	used	for	our	studies.		These	chips	contain	approximately	20,000	human	proteins,	 each	printed	 in	 duplicate	 in	 defined	 locations.	 	 The	proteins	 printed	 on	these	chips	all	contain	a	GST-tag,	used	both	in	their	purification	as	well	for	verification	of	protein	density	at	each	discrete	spot	on	the	chips.		Lysine	acetyltransferase	p300	was	used	to	 generate	 a	 pool	 of	 acetylated	 proteins	 on	 the	 chips.	 	 To	 acetylate	 a	 broader	 range	 of	proteins,	a	 truncated	 form	of	p300	was	used,	containing	 the	catalytic	domain	but	 lacking	the	 specificity	 domain.	 	 The	 truncated	 gene	 encodes	 amino	 acids	 1287-1652,	 with	 the	deletion	of	 an	auto-acetylation	 loop	 region	 (1523-1554)	 and	point	mutations	 at	M1652G	and	 K1637R	 (101).	 	 This	 construct	 yields	 a	 hypoacetylated,	 inactive	 p300,	 allowing	recombinant	expression	of	the	protein	in	E.	coli	without	toxicity	to	the	cells.		The	protein	is	then	activated	via	an	expressed	protein	 ligation	protocol	 to	extend	 the	C-terminus	by	14	amino	acids,	which	are	necessary	for	catalysis.		The	M1652G	mutation	increases	efficiency	of	the	ligation	reaction.	P300	 was	 expressed	 with	 a	 C-terminal	 Saccharomyces	 cerevisiae	 Vacuolar	Membrane	ATPase	(Sce	VMA)	intein	region	followed	by	a	chitin-binding	domain	(Fig.	4.4).		We	verified	expression	of	the	protein	in	BL-21	DE3	cells	via	a	one-column	purification	on	chitin	resin,	followed	by	thiol-induced	splicing	at	the	intein.		Protein	expression	and	purity	were	determined	by	Coomassie	staining	of	a	polyacrylamide	gel.		We	observed	a	yield	of	25	mg	of	p300	from	a	1-liter	expression	in	2xYT	media.	
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To	 generate	 active	 p300	 protein,	 expressed	 protein	 ligation	 (EPL)	 was	 used	 to	append	a	14mer	peptide	to	the	C-terminus	of	the	p300	construct.		EPL	was	carried	out	after	p300	was	bound	to	chitin	resin.		Instead	of	initiating	intein	cleavage	by	DTT	thiol	addition,	MESNA	reagent	was	used.		Cleaved	and	ligated	protein	was	further	purified	on	an	S-cation	exchange	 column.	 	 Activity	 of	 our	 p300	 enzyme	 was	 verified	 by	 Beth	 Zucconni,	 a	 post-doctoral	 research	 fellow	 in	 Phil	 Cole’s	 group,	 with	 experience	 assaying	 histone	acetyltransferase	activity.			To	acetylate	proteins	on	 the	HuProt	 chips,	p300	 (8	–	10	µM)	and	acetyl-CoA	(200	µM)	were	applied	to	the	chips	and	allowed	to	react	for	up	to	2	hours	at	30˚C.		A	limitation	to	this	type	of	experiment	is	that	the	pool	of	potential	substrate	proteins	is	‘pre-determined’	by	the	activity	of	the	KAT	enzyme.		Therefore,	our	objective	was	to	maximize	acetylation	of	chip-based	 proteins	 by	 using	 concentrations	 of	 enzyme	 and	 acetyl-CoA	 that	 were	intentionally	 above	 the	 range	 typically	 used	 for	 kinetic	 studies	 of	 p300.	 	 After	 reacting,	p300	was	quenched	with	an	ammonium	bicarbonate	buffer	and	the	chips	were	thoroughly	washed.	
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Figure	4.4:	p300	expression	vector	p300	construct	in	pTYB2	vector	from	New	England	Biolabs,	with	c-terminal	intein	and	chitin	binding	domain	(CBD).	 	This	p300	construct	encodes	amino	acids	1287-1652,	M1652G,	K1637R,	with	a	deletion	of	 the	 loop	from	1523-1554	(Created	using	SnapGene).	
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Developing	a	method	for	assaying	p300	and	HDAC	activity	on	proteome	chips	For	 our	 pilot	 round	 of	 chip-based	 assays,	 only	 HDAC8	 was	 used.	 	 Briefly,	 these	assays	 utilize	 chip-based	 libraries	 of	 20,000	 immobilized	 human	 proteins.	 	 Chips	 were	treated	 with	 differing	 combinations	 of	 KAT	 and	 HDAC,	 and	 differences	 in	 protein	acetylation	were	visualized.	 	HDAC8	was	reconstituted	with	cobalt	and	used	at	a	range	of	2.5	–	7.5	µM.	 	We	also	examined	 the	role	EDTA	treatment	of	 the	chips,	 to	 remove	excess	divalent	metals,	on	HDAC	activity	by	washing	a	subset	of	the	chips	with	an	EDTA	containing	buffer	after	acetylation	and	a	second	subset	of	chips	with	an	identical	buffer	lacking	EDTA.		Both	 sets	 of	 chips	were	 then	washed	with	HDAC	 reaction	 buffer	 to	 remove	 any	 residual	EDTA.	 	 HDAC8	 was	 applied	 to	 the	 surface	 of	 the	 chips	 (120	 µL)	 and	 a	 cover	 slip	 was	applied.	 	The	HDAC	reaction	was	allowed	to	proceed	for	2	hours	at	30˚C.	 	The	acetylation	state	of	individual	proteins	was	determined	by	anti-acetyllysine	immunofluorescence	with	excitation	at	635	nm	(Fig.	4.5A).			A	 second	 round	 of	 chip-based	 assays	was	 run,	 looking	 at	 the	 activity	 of	 both	 Zn-HDAC8	and	Zn-HDAC11	(Fig.	4.5B).		The	chips	were	handled	in	a	similar	manner,	but	some	adjustments	 were	made	 based	 on	 observations	 from	 the	 pilot	 experiment.	 	 HDAC8	was	used	at	a	 final	assay	concentration	of	2	µM,	and	HDAC11	was	used	at	1	and	1.5	µM.	 	For	these	chips,	HDAC	reaction	solutions	were	made	in	a	greater	volume.		Instead	of	applying	a	microliter	volume	of	enzyme	to	each	chip,	followed	by	a	coverslip,	we	added	3	mL	of	HDAC	solution,	 enough	 to	 submerge	 the	 HuProt	 chips	 and	 negate	 the	 need	 for	 a	 coverslip.	 	 In	doing	 so,	we	 sought	 to	 reduce	 background	 noise	 and	 increase	HDAC-chip	 interaction	 by	avoiding	the	formation	of	air	pockets	beneath	a	coverslip.			
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Figure	4.5:	Proteome	chip	assay	scheme	Proteome	 chips	 in	 both	 round	 1	 experiments	 (A)	 and	 round	 2	 experiments	 (B)	 that	 are	 labeled	 red	were	washed	with	EDTA	to	remove	divalent	metals	before	HDAC	application.		A.		The	first	round	of	proteome	chip	experiments	utilized	a	total	of	7	HuProt	chips.		p300	was	applied	to	chips	3-7,	as	shown.		HDAC8,	at	various	concentrations,	was	 then	 incubated	with	select	 chips.	 	B.	 	The	second	round	of	proteome	chip	experiments	utilized	8	HuProt	chips	and	measured	deacetylation	by	either	HDAC8	or	HDAC11.		p300	was	applied	to	chips	2-8,	as	shown.		Individual	HDAC	isozymes	were	then	applied	to	select	chips,	as	labeled.	
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HDAC8	catalyzes	deacetylation	of	proteins	on	HuProt	chips	To	 measure	 HDAC-catalyzed	 deacetylation	 of	 protein	 on	 the	 chips,	 we	 first	determined	which	proteins	were	acetylated	upon	incubation	with	the	p300	construct.		For	both	rounds	of	experiments,	we	first	manually	flagged	and	removed	artificial	spots	where	the	 antibody	 precipitated,	 which	 causes	 ‘firework’	 patterns.	 	 We	 then	 identified	 and	verified	that	control	proteins	were	successful	(landmarks,	rabbit-IgG,	etc.).	 	These	control	proteins	were	then	removed	before	analysis	of	acetylation	and	deacetylation	of	chip-based	substrates.	 	 For	 our	 pilot	 chips,	 identification	 of	 the	 acetylated	 proteins	was	 determined	using	 an	 anti-acetyllysine	 antibody	 and	 visualized	 via	 a	 fluorescent	 secondary	 antibody.		These	 data	 were	 then	 analyzed	 as	 histograms	 of	 foreground	 to	 background	 fluorescent	intensity	(f/b),	indicative	of	acetylated	lysines.		We	then	considered	proteins	with	f/b	more	than	 three	 standard	 deviations	 higher	 than	 the	 median	 value	 to	 be	 acetylated.		Furthermore,	 we	 required	 both	 copies	 of	 a	 given	 protein	 on	 the	 chip	 to	 be	 scored	 as	acetylated.	 	Using	this	method,	the	pilot	round	of	chips	identified	164	acetylated	proteins.		For	our	second	round	of	chip-based	experiments,	we	introduced	a	more	stringent	method	for	determining	acetylation.		Here	we	first	determined	the	average	f/b	ratio	for	all	proteins	on	the	chip.		If	no	acetylation	occurred,	a	plot	of	these	averages	would	yield	a	symmetrical	bell	curve.	 	Acetylation	 increases	 the	high	values	of	 f/b	on	this	curve.	 	To	correct	 for	 this	skew	when	 determining	 a	 standard	 deviation,	 we	 used	 the	 low	 f/b	 side	 of	 the	 curve	 to	recreate	a	symmetrical	bell,	which	we	refer	to	as	our	mirror	method.	 	From	this	modified	graph	we	 calculated	 standard	 deviation	 values.	 	 Here,	 we	 used	 two	 standard	 deviations	above	 average	 to	 determine	 KAT	 hits.	 	 Proteins	 had	 to	 meet	 these	 criteria	 in	 all	 four	replicates	(two	spots,	on	two	KAT	only	chips)	to	be	considered	acetylated.		In	this	round	of	
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experiments,	we	found	506	proteins	that	were	acetylated	twice	on	both	KAT	control	chips.		While	 there	 was	 some	 overlap	 in	 acetylated	 proteins	 between	 the	 two	 rounds	 of	experiments,	we	did	see	differences	(discussed	further	below).	Using	 these	 data	 to	 identify	 acetylated	 proteins,	 we	 then	 looked	 for	 a	 loss	 of	acetylation	in	the	HDAC-treated	chips.		For	our	pilot	experiment,	we	used	the	difference	in	f/b	of	the	KAT-only	chips	compared	to	the	KAT-HDAC	chips.		Proteins	with	a	greater	than	average	difference	between	these	conditions	were	considered	hits.		Analysis	of	these	chips	showed	 that	 43	 of	 the	 164	 acetylated	 proteins	 were	 deacetylated	 upon	 incubation	with	HDAC8.	 	 Further	 evaluation	 of	 these	 43	 hits	 by	 visually	 inspecting	 the	 raw	 fluorescent	images	suggested	that	8	were	false	positives	(i.e.	should	have	been	flagged	and	removed	as	antibody	precipitate	spots),	9	appeared	mediocre,	and	26	looked	to	be	good	hits	(Appendix	1,	 Table	 S1).	 	 These	 hits	 represented	 proteins	 from	 a	 diverse	 set	 of	 biological	 functions,	including	protein	folding	pathways,	metabolism,	and	the	cell	cycle.			For	our	second	round	of	chip-based	assays	we	used	a	more	stringent	methodology	to	identify	proteins	that	were	deacetylated	by	HDAC8.		We	used	three	separate	methods	to	identify	hits	from	these	chips.		The	first,	similar	to	the	pilot	experiment,	was	to	look	for	the	largest	 f/b	 differences	 between	 KAT-only	 and	 KAT-HDAC	 chips.	 	 We	 then	 repeated	 our	methodology	for	determining	p300	hits,	where	a	mirror	image	of	a	bell	curve	was	used	to	determine	standard	deviation.	 	Again,	proteins	two	standard	deviations	at	high	f/b	values	were	 considered	 acetylated.	 	 We	 compared	 KAT-only	 and	 KAT-HDAC	 chips	 using	 this	method,	 and	 looked	 for	 proteins	 that	 no	 longer	 met	 the	 acetylation	 threshold	 upon	treatment	with	an	HDAC.		Finally,	we	ran	t-tests	to	analyze	the	significance	of	f/b	changes	
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seen	between	each	occurrence	for	a	given	protein	on	the	chips.		For	HDAC8	treated	chips,	this	test	analyzed	a	total	of	10	spots	per	substrate	protein.	Using	the	mirror	method	of	analysis,	we	identified	228	proteins	that	fit	the	criteria	for	deacetylation	by	HDAC8.		These	proteins	showed	loss	of	f/b	for	the	duplicate	spots	on	one	 of	 the	 three	 HDAC8-treated	 chips.	 	 Of	 those	 228	 proteins,	 about	 half	 (109)	 were	identified	on	only	one	of	the	HDAC8-treated	chips,	67	of	them	were	identified	on	two	of	the	three	HDAC8-treated	chips,	and	52	were	identified	on	all	three	HDAC8-treated	chips.		Only	proteins	that	showed	loss	of	signal	on	all	 three	chips	were	analyzed	further.	 	Using	the	t-test	 statistical	 method,	 we	 identified	 347	 proteins	 that	 met	 a	 p<0.05	 cutoff	 and	 were	acetylated	on	 the	KAT-only	chips.	 	We	compared	 these	results	and	 identified	19	proteins	that	met	 the	 criteria	 for	 at	 least	 two	of	 the	 three	methods	 of	 determining	HDAC	 activity	(Appendix	1,	Tables	S2	and	S3).	We	 next	 analyzed	 the	 literature	 to	 determine	 which	 of	 these	 proteins	 have	documented	acetyllysine	sites,	and	found	that	11	of	the	26	hits	from	the	pilot	experiment	and	 11	 of	 the	 19	 hits	 from	 the	 second	 round	 experiment	were	 known	 to	 be	 acetylated.		Using	 the	 FlexPepBind	 algorithm	 developed	 by	 our	 collaborator	 Ora	 Furman	 (89),	 we	scored	 each	 known	 acetyllysine	 on	 these	 22	 proteins	 to	 perform	 as	 a	 first	 round	 of	validation.		The	FlexPepBind	algorithm	outputs	an	i_score,	a	prediction	of	the	likelihood	of	an	amino	acid	sequence	with	an	acetyllysine	being	an	HDAC8	substrate.		The	more	negative	a	score,	the	higher	the	chance	that	the	peptide	is	a	substrate.		Peptides	with	score’s	below	-17	are	considered	strong	candidates,	and	 -16	 to	 -17	are	considered	good	candidates,	but	with	 a	 greater	 chance	 of	 false	 positives.	 	 Our	 hits	 ranged	 from	 >0	 to	 <-20,	 suggesting	 a	
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number	of	the	sites	on	these	proteins	were	good	to	strong	candidates	to	be	deacetylated	by	HDAC8.				
HDAC11	deacetylates	an	overlapping	and	distinct	set	of	proteins	on	the	HuProt	chips	Chips	 treated	 with	 HDAC11	 (second	 round	 experiment	 only)	 were	 analyzed	according	to	the	same	method	as	the	HDAC8-treated	chips.	 	Using	the	mirror	method,	we	identified	 259	 proteins	 that	 met	 the	 criteria	 for	 deacetylation	 on	 both	 HDAC11-treated	chips	(4	spots	total).		Of	these	proteins,	96	were	also	identified	in	two	of	the	three	HDAC8-treated	 chips	 when	 analyzed	 using	 this	 same	method.	 	 Additionally,	 using	 the	 t-tests	 as	described	above,	364	proteins	met	a	p<0.05	and	were	previously	 identified	as	acetylated.		Of	the	364	proteins	that	passed	our	t-test	threshold,	70	also	had	f/b	intensity	differences	between	that	KAT-only	and	KAT-HDAC11	chips	of	0.5	or	greater	(f/b	intensity	of	acetylated	chip	minus	 f/b	 intensity	 of	 deacetylated	 chip	 ≥	 0.5).	 	When	 combined,	 we	 identified	 22	proteins	that	passed	all	three	of	our	criteria	and	3	additional	proteins	that	scored	highly	in	2	of	our	3	criteria.		Of	these	25	total	proteins,	14	are	known	to	be	acetylated	(Appendix	1,	Table	 S4).	 	 Unlike	HDAC8,	we	 have	 no	 computational	 substrate	 recognition	 algorithm	 to	triage	our	peptide	library	prior	to	in-solution	HDAC11	assays.		
MALDI-MS	makes	an	efficient	method	for	screening	large	batches	of	peptides		 Based	 on	 our	 FlexPepBind	 scores,	we	 ordered	 a	 library	 of	 short	 peptides	 (6	 –	 10	amino	acids)	based	on	 the	 local	 sequences	 surrounding	acetyllysines	on	 the	HDAC8	chip	hits.		In	total,	we	tested	16	peptides	from	our	pilot	round	of	chip	experiments.		Before	using	the	peptides	in	our	enzyme-coupled	assay,	we	ran	small-scale	reactions	(20	–	60-fold	less	
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volume	 than	 the	 enzyme-coupled	 assay)	where	 each	peptide	was	 incubated	with	HDAC8	and	spotted	time	points	on	a	polished	steel	MALDI-target.		We	looked	at	2	–	3	time	points	for	each	peptide,	from	a	zero	point	to	a	30-minute	point.		At	time	point	zero,	the	exact	mass	of	 the	peptide	 substrate	 is	observable.	 	At	 later	 time	points,	 a	peptide	 that	 is	 a	 substrate	should	show	a	new	peak	corresponding	 to	 the	peptide	minus	an	acetyl	group	(M-42	Da).		This	approach	provided	a	good	indication	of	which	peptides	would	be	highly	reactive	(Fig.	4.6).	 	 There	 were	 a	 few	 peptides,	 however,	 for	 which	 no	 peak	 corresponding	 to	 the	expected	parent	mass	was	observable.		While	there	were	some	outliers,	this	MALDI-based	pre-screen	 of	 HDAC8	 activity	 followed	 the	 same	 general	 trend	 predicted	 by	 the	FlexPepBind	algorithm.	 	The	most	 reactive	peptide	substrates	 following	 this	 screen	were	peptides	 #136	 and	 #138,	 corresponding	 to	 acetyllysine	 residues	 on	 isocitrate	dehydrogenase	(IDH1)	and	retinol	dehydrogenase	(RDH16);	at	30	minutes	only	a	product	peak	was	observable	in	the	mass	spectrum.		Peptide	#137	(IDH1)	was	the	next	best	peptide	as	 evaluated	 by	MALDI,	where	 the	 substrate	 and	 product	 peaks	were	 about	 equal	 at	 30	minutes.		Peptide	#135,	from	Aldo-keto	reductase	(AKR1C2),	also	gave	a	strong,	clean	peak	of	correct	mass.	 	However,	no	product	peak	appeared	over	the	time	course	tested.	 	As	we	moved	 from	 the	 best-scored	 to	 lowest-scored	peptides,	we	 found	no	 other	 peptides	 that	went	 to	 completion,	 but	 several	 that	 showed	 a	 product	 peak.	 	 The	data	 from	 the	MALDI	assay	 was	 largely	 consistent	 with	 the	 chip	 and	 FlexPepBind	 data,	 and	 informed	 our	selection	of	peptides	for	more	detailed	kinetic	analysis.		
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Figure	4.6:	Determination	of	HDAC8	activity	by	MALDI-MS	Peptides	(100	µM)	were	incubated	for	30	minutes	with	0.5	µM	HDAC8.		During	this	time,	a	total	of	three	time	points	were	quenched	into	10%	HCl.		The	first	time	point	(t=0	min.)	is	at	the	top	of	each	figure.		Moving	down,	t=15	min.		is	the	middle	frame,	and	t=30	min.		is	the	bottom	frame.		A.		Peptide	136	(Ac-RF(KAc)DIF-NH2)	is	a	positive	hit	by	MALDI	analysis,	where	the	parent	peptide	(909	Da)	decreases	by	42	Da	to	a	product	peak	(867	Da)	over	the	time	course.		B.		Peptide	135	(Ac-AK(KAc)HKR-NH2)	is	a	negative	hit,	where	the	parent	peptide	(851	Da)	does	not	give	way	to	an	observable	product	peak	over	the	time	course.	
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Peptide	assays	in	solution	are	consistent	with	HDAC	kinetic	trends	observed	in	MALDI	assay.		 To	 determine	 the	 rate	 constants	 for	 HDAC8-catalyzed	 deacetylation	 of	 these	peptides,	we	used	an	enzyme-coupled	assay	in	which	acetate	production	is	coupled	to	the	formation	 of	 NADH	 and	 visualized	 by	 fluorescence	 with	 ex.	 	 =	 340	 nm	 and	 em.	 	 =	 460	nm(76).		We	measured	activity	at	50	or	100	µM	peptide	concentrations	and	calculated	the	specificity	constant,	kcat/KM,	app,	for	HDAC8	catalysis	of	these	peptides.		This	calculation	was	done	under	the	assumption	that	our	substrate	concentration	was	below	KM.		The	measured	values	for	kcat/KM,	app	ranged	over	three	orders	of	magnitude,	from	100	–	102	M-1s-1	(Table	4.1).	 	The	largest	kcat/KM	value	was	observed	for	HDAC-catalyzed	deacetylation	of	peptide	#137,	 corresponding	 to	 IDH1.	 	 This	was	 followed	 by	 peptide	#136,	 also	 from	 IDH1,	 and	peptide	 #138	 from	 RDH16	 (Fig.	 4.7).	 	 These	 are	 the	 same	 three	 peptides	 that	 were	identified	as	the	best	substrates	in	the	MALDI	screen.		Not	only	did	IDH1	provide	the	fastest	peptide	 tested	 from	this	 round	of	 chip	experiments,	but	 three	of	 the	 four	sites	we	 tested	from	IDH1	showed	a	kcat/KM	>	20	M-1s-1.				
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Table	4.1:	Kinetics	of	HDAC8-catalyzed	deacetylation	of	peptides	from	Chip	set	1	
hits13,14	Table	arranged	by	peptide	#	and	I_score	
Peptide	#	 Protein	 Ac-Sequence-NH2	 I_score(89)	 kcat/KM	(M-1s-1)	
135	 AKR1C2	 AK(K-Ac)HKR -19.2	 <10	
136	 IDH1	 RF(K-Ac)DIF -18.3	 90	
137	 IDH1	 KLKQMW(K-Ac)SPN -18	 160	
138	 RDH16	 ERFL(K-Ac)SFLE -17.4	 54	
139	 PTEN	 HC(K-Ac)AGK -17.2	 <10	
140	 HSPA1L	 VE(K-Ac)ALR -17.1	 <10	
141	 AKR1C2	 LA(K-Ac)KHK -16.8	 20	
142	 IDH1	 YQ(K-Ac)GQE -16.3	 <10	
143	 AKR1C2	 YQ(K-Ac)GQE -16	 <10	
144	 CRIP1	 SLG(K-Ac)DWHR -15.8	 46	
145	 PTEN	 II(K-Ac)EIVSR -15.4	 <10	
146	 AKR1C2	 SV(K-Ac)RED -15.2	 12	
147	 RFK	 TK(K-Ac)SME -15.1	 34	
148	 RABL3	 EE(K-Ac)TYY -15.1	 <10	
149	 IDH1	 DE(K-Ac)RVE -15	 38	
150	 PTEN	 DK(K-Ac)GVT -14.6	 <10	
	
																																																								13	I_score	is	a	substrate	prediction	value	based	on	an	algorithm	developed	by	Alam	et	al.,	2016	14	Peptides	were	assayed	with	0.5	–	1	µM	zn-HDAC8	and	100	µM	substrate.		Assay	time	points	were	quenched	into	10%	HCl	and	developed	using	a	coupled-enzyme	assay.		The	listed	specificity	constant,	kcat/KM	is	an	apparent	value,	calculated	on	the	assumption	that	[S]	<	KM.	
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Figure	4.7:	HDAC8-catalyzed	deacetylation	of	chip-based	peptides	from	round	1	Progress	curves	for	peptides	identified	in	the	first	round	of	the	HDAC8	proteome	chip	experiments.		Peptides	are	representative	of	IDH1	(peptides	136	and	137)	and	RDH16	(peptide	138).		HDAC8	was	assayed	at	1	µM,	with	substrates	at	100	µM.		We	measured	activity	using	a	coupled-enzyme	assay.			
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HDAC8	and	HDAC11	both	deacetylate	peptides	from	the	second	round	of	chip	experiments.		 Using	 the	 same	 enzyme-coupled	 assay,	 we	 measured	 deacetylation	 of	 peptides	based	on	protein	hits	 identified	 in	 the	 second	 round	of	 chip-based	 experiments.	 	HDAC8	and	 HDAC11	 were	 both	 catalytically	 active	 against	 peptide	 substrates.	 	 In	 total,	 we	measured	 HDAC8	 deacetylation	 toward	 32	 peptides	 (from	 16	 proteins)	 and	 HDAC11	deacetylation	 toward	 18	 peptides	 (from	 9	 proteins).	 	 Both	 enzymes	 displayed	 apparent	
kcat/KM	values	ranging	from	100	–	102	M-1s-1	(Tables	4.2	and	4.3).		The	top	HDAC8	hit	from	this	 screen	 was	 a	 peptide	 corresponding	 to	 protein	 disulfide	 isomerase	 (P4HB),	 with	 a	
kcat/KM,	app	=	300	M-1s-1	(Fig.	4.8).		This	was	one	of	three	peptides	tested	from	P4HB,	but	the	only	one	that	showed	activity	greater	than	10	M-1s-1.				 The	HDAC11	set	of	peptides	is	the	first	library	of	HDAC11-specific	peptides	tested	to	date.	 	 Without	 the	 benefit	 of	 a	 predictive	 algorithm	 for	 HDAC11,	 peptides	 were	 chosen	based	 on	 trends	 we	 observed.	 	 Based	 on	 previous	 HDAC11-catalyzed	 deacetylation	 of	peptides	 (Chapter	 3),	 we	 hypothesized	 this	 isozyme	 might	 display	 a	 preference	 for	acetyllysines	surrounded	by	charged	residues.		Phosphosite	data	on	proteins	deacetylated	by	 HDAC11	 on	 our	 chips	 showed	 several	 acetyllysine	 residues	 flanked	 by	 charged	sequences.		When	proteins	had	multiple	acetylation	sites,	we	preferentially	included	those	found	in	charged	regions.		The	top	scoring	HDAC11	substrate	was	peptide	was	#215,	which	corresponds	to	an	acetyllysine	site	from	treacle	protein	(TCOF1),	with	a	kcat/KM	=	175	M-1s-
1	(Fig.	4.9).	
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TABLE	4.2:	HDAC8	Chip	set	2	Table	arranged	by	peptide	#	and	corresponding	protein	
peptide	#	 Protein	 Ac-Sequence-NH2	 I_score(89)	 kcat/KM	(M-1s-1)	
169	 PFKP	 TY(K-Ac)RLAIK -17.4	 <5	
171	 PFKP	 EL(K-Ac)KQT -16.6	 5	
172	 PFKP	 HRIP(K-Ac)EQW -18.3	 30	
175	 BOLL	 NY(K-Ac)DKK -17.0	 <5	
176	 ASAP2	 IR(K-Ac)VWQK -16.7	 <5	
177	 ASAP2	 WQ(K-Ac)RKC -18.3	 13	
178	 EIF4B	 ENPAS(K-Ac)FSSASK -17.4	 35	
179	 KLC2	 YL(K-Ac)QGKYQD -18.3	 <5	
181	 P4HB	 FK(K-Ac)FDE -18.2	 300	
182	 P4HB	 GL(K-Ac)KEE -17.4	 <5	
183	 P4HB	 WD(K-Ac)LGE    -17.8	 <5	
184	 PRDX4	 EF(K-Ac)ELK    -17.4	 15	
186	 TCOF1	 QA(K-Ac)KTR -18.3	 <5	
187	 TCOF1	 SG(K-Ac)SPR -16.7	 <5	
188	 TCOF1	 SR(K-Ac)RKL    -17.5	 <5	
189	 TCOF1	 RS(K-Ac)KKK    -18.2	 32				
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TABLE	4.3:	HDAC11	Chip	set	2	Table	arranged	by	peptide	#	and	corresponding	protein.		Charged	residues	are	highlighted	in	red	(acidic)	or	blue	(basic).	
peptide	#	 Protein	 Ac-Sequence-NH2	 kcat/KM	(M-1s-1)	
211	 TCOF1	 SM(K-Ac)EKA <5	
212	 TCOF1	 TG(K-Ac)TVA 60 
213	 TCOF1	 PG(K-Ac)VGD <5	
215	 TCOF1	 QV(K-Ac)AEK 175 
216	 TCOF1	 PG(K-Ac)TGPAVAK 8	
217	 TCOF1	 SAPG(K-Ac)VVT 33 
218	 TCOF1	 PA(K-Ac)ESP <5	
219	 TCOF1	 GA(K-Ac)DEP 9	
221	 EIF5	 EG(K-Ac)GNG 47 
222	 EIF5	 EGKGNGI(K-Ac)TVI 16 
225	 NIF3L1	 RPM(K-Ac)RIT 31 
226	 NIF3L1	 NTW(K-Ac)ER 10 
228	 GOT1	 DAE(K-Ac)RGLD 60 
229	 LUC7L	 EEIG(K-Ac)LLA 18 
230	 ZBTB21	 LAL(K-Ac)RPR <5	
231	 CNP	 DDL(K-Ac)KLK 31 
232	 CEBPZ	 KGGKQLN(K-Ac)YDPFSRN 51 
233	 C2orf47	 KEVLHAL(K-Ac)EKVTSLP 35 
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Figure	4.8:	HDAC8-catalyzed	deacetylation	of	chip-based	peptide	181	Progress	curve	for	deacetylation	of	peptide	181	(100	µM),	corresponding	to	protein	P4HB,	catalyzed	by	0.5	µM	HDAC8.		Data	is	fit	with	a	single	exponential	equation,	and	kcat/KM	was	calculated	to	be	300	M-1s-1	based	on	the	assumption	that	[S]	<	[KM].		This	progress	curve	and	the	measured	apparent	rate	constant	are	based	on	a	single	substrate	concentration.	
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Figure	4.9:	HDAC11-catalyzed	deacetylation	of	chip-based	peptides	Progress	curves	for	the	deacetylation	of	peptides	212	( )	and	215	( ),	corresponding	to	protein	TCOF1	and	peptide	228	( ),	corresponding	to	protein	GOT1.		These	peptides	were	deacetylated	with	some	of	the	highest	observed	kcat/KM	values	for	HDAC11.	These	assays	were	run	at	a	single	concentration	of	peptide.	
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Cloning	and	expression	of	WT	IDH1	and	amber	stop	mutants		 After	measuring	deacetylation	of	peptides	 from	our	 first	HDAC8	chips,	we	decided	to	further	examine	reactivity	of	HDAC8	with	the	top	substrate,	IDH1.		We	were	interested	in	HDAC8-catalyzed	deacetylation	of	 the	 full-length	protein.	 	While	 there	are	a	variety	of	methods	to	generate	acetylated	protein	substrates,	it	seemed	that	a	method	that	allows	for	the	controlled	insertion	of	single	acetylation	sites	would	provide	the	most	reproducible	and	reliable	 results.	 	 For	 this	 reason,	 we	 chose	 to	 express	 singly	 acetylated	 proteins	 by	incorporating	acetyllysine	as	an	unnatural	amino	acid.		We	acquired	a	pEVOL	plasmid	from	Wenshe	 Liu	 at	 Texas	 A&M	 encoding	 the	 required	 tRNA/tRNA	 synthetase	 pair	 for	acetyllysine	 incorporation.	 	We	 cloned	 the	 cDNA	 for	 human	 IDH1	 into	 a	 pET	 expression	vector	with	an	N-terminal	His6	 tag	 (Fig.	4.10),	 and	expressed	 the	WT	enzyme	 in	Rosetta	cells.	 	WT-IDH1	expressed	well	 and	was	 easily	purified	on	nickel-affinity	 resin	 (Fig.	 4.3),	resulting	 in	a	yield	of	about	25	mg/L.	 	We	used	QuikChange	site-directed	mutagenesis	 to	create	 four	additional	clones,	each	with	an	amber	stop	mutation	at	one	of	 the	 four	 lysine	residues	identified	as	acetylated	in	vivo	(K81	[pept.		#149],	K93	[pept.		#137],	K224	[pept.		#136],	K321	[pept.		#142])	(6).		We	transformed	the	pEVOL	plasmid	into	z-competent	BL-21	 DE3	 cells	 and	 grew	 a	 100	 mL	 culture.	 	 This	 culture	 was	 used	 to	 create	 a	 stock	 of	chemically	competent	cells.	 	We	 then	 transformed	the	plasmids	encoding	 the	amber	stop	IDH1	 mutants	 into	 this	 cell	 line,	 avoiding	 the	 need	 to	 perform	 a	 simultaneous	 dual	transformation.	 	 We	 observed	 significantly	 lower	 yields	 for	 these	 mutant	 proteins	 (<1	mg/mL),	and	 found	that	 they	showed	greatest	expression	 in	culture	sizes	below	500	mL.		Regardless,	we	were	 able	 to	 express	 and	 purify	 acetylated	 forms	 of	 IDH1,	 as	 verified	 by	anti-IDH1	and	anti-acetyllysine	western	blots.	
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	Figure	4.10:	IDH1	WT	and	acetylation	mutant	constructs	pET-M11	vector	with	an	IDH1	gene	insert.		Construct	has	an	N-terminal	His6	–	TEV	site.		Also	highlighted	are	the	 four	 lysine	 residues	 that	 were	 selected	 for	 unnatural	 amino	 acid	 incorporation	 (Constructed	 using	SnapGene).			
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IDH1	is	the	first	non-histone	full-length	protein	to	be	deacetylated	by	HDAC8	in	vitro		 To	assess	the	deacetylation	of	purified	IDH1	by	HDAC8,	we	ran	kinetic	assays	under	single	 turnover	conditions	 ([E]	>	 [S]).	 	The	assays	were	stopped	reactions,	 in	which	 time	points	were	quenched	into	either	SAHA	or	5x	SDS	gel	loading	dye	and	moved	onto	ice.		To	visualize	 changes	 in	 acetylation,	 we	 ran	 each	 time	 point	 on	 an	 SDS-PAGE	 gel	 and	transferred	 them	 to	 a	 nitrocellulose	 membrane.	 	 We	 then	 probed	 blots	 with	 an	 anti-acetyllysine	 antibody	 and	 visualized	 using	 an	 HRP-conjugated	 secondary	 antibody	 and	chemiluminescence.	 	 To	 account	 for	 possible	 differences	 in	 loading	 of	 samples,	transformation	efficiency,	etc.,	BSA	was	included	in	our	reaction	tubes.		This	BSA	standard	was	 also	 probed	 for	 on	 our	 blots	 and	 was	 used	 to	 calibrate	 our	 analysis	 of	 acetylation	changes.	 	 In	 our	 initial	 experiment,	 we	 used	 the	 5x	 SDS	 gel	 loading	 dye	 as	 our	 quench.		Using	 this	 assay,	 we	 found	 that	 all	 four	 IDH1	mutants	 (K81,	 K93,	 K224,	 and	 K321)	 are	deacetylated	by	HDAC8,	but	 to	differing	amounts	 (Fig.	4.11a).	 	From	 this	experiment,	we	saw	 changes	 in	 acetylation	 ranging	 from	 85%	 deacetylation	 (K321)	 to	 less	 than	 20%	deacetylation	 (K81)	 over	 the	 course	 of	 three	 hours	 (Fig.	 4.11b).	 	While	 K81	 showed	 the	smallest	 change	 over	 the	 time	 course,	 it	 also	 had	 the	 lowest	 starting	 intensity.	 	 This	suggested	 that	deacetylation	could	be	occurring	 rapidly	under	 these	conditions.	 	For	 this	reason,	we	carried	out	additional	assays	to	measure	deacetylation	of	the	singly	acetylated	IDH1	proteins.				 A	more	rigorous	assay	was	run	with	IDH1	acetylated	at	either	K81	or	K93,	in	which	we	took	a	total	of	six	time	points.		Again,	we	used	BSA	as	our	loading	control	and	5x	SDS	as	our	quench	solution.		Analysis	of	the	western	blots	showed	that	K93	was	80%	deacetylated	after	 the	 60-minute	 time	 course,	 with	 a	 kobs	 of	 0.35	 min-1	 (Fig.	 4.12A	 and	 Fig.	 4.13).		
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Analysis	 of	 K81	 was	 not	 as	 simple.	 	 There	 was	 no	 visible	 signal	 corresponding	 to	acetyllysine	in	any	of	the	K81	time	points	(Fig.	4.12BC).	 	However,	in	a	no-HDAC8	control	there	 was	 a	 clear	 acetyllysine	 signal	 in	 all	 time	 points.	 	 These	 data	 suggested	 that	 the	quench	 (5x	 SDS)	 might	 not	 inactivate	 HDAC8	 sufficiently,	 and	 that	 K81	 may	 have	 been	completely	 deacetylated.	 	 To	 address	 this	 issue,	 K81	was	 re-assayed	 using	 50	 µM	 (final)	SAHA	as	the	quench	for	each	time	point.		Over	the	15-minute	time	course,	we	saw	greater	than	50%	deacetylation	 in	15	minutes	(Fig.	4.14).	 	However,	even	with	the	SAHA-quench	method,	the	zero-time	point	has	only	60%	of	the	signal	generated	by	the	no-HDAC8	control	points.	 	 This	 suggests	 that	 even	 inactivation	 with	 SAHA	may	 not	 be	 a	 sufficiently	 rapid	quench	method.	
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Figure	4.11:	HDAC8-catazlyed	deacetylation	of	all	IDH1	acetyllysine	constructs	Singly-acetylated	IDH1	(0.3	µM	K81ac,	0.8	µM	K93ac,	4.7	µM	K224ac,	and	2.7	µM	K321ac)	was	incubated	with	HDAC8	(7.5	µM)	in	1x	HDAC8	assay	buffer	at	34˚C	for	a	time	course	of	three	hours.		Assays	were	run	at	single-turn	over	concentrations	([E]	>	[S]),	with	three	to	four	time	points	for	each	IDH1	variant.	 	A.	 	Western	blots	for	each	acetylated	IDH1	substrate	over	the	given	time	course.		Blots	were	probed	with	anti-acetyllysine	(left)	and	anti-BSA	(right)	primary	antibodies.		Blots	were	separately	treated	with	secondary	antibody	conjugated	to	 HRP	 and	 visualized	 by	 chemiluminescence.	 	 B.	 	 Quantification	 of	 the	 western	 blot	 band	 intensities	 for	acetylated	IDH1,	normalized	to	BSA	internal	standards.		Quantification	of	band	intensity	was	performed	using	ImageJ.		Loss	of	acetylation,	shown	as	a	decrease	in	intensity,	corresponds	to	HDAC8-catalyzed	deacetylation	of	the	target	protein.	
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Figure	4.12:	Time	course	of	HDAC8-catalyzed	deacetylation	of	IDH1	acetylated	at	
either	K81	or	K93	A.	 	 Quantification	 of	 IDH1	 K93ac	 (2.5	 µM)	 deacetylation	 by	 HDAC8	 (10	 µM)	 over	 a	 one	 hour	 time	 course	(quantified	using	 ImageJ).	 	Time	points	were	quenched	 in	5x	SDS	and	visualized	by	western	blot.	 	BSA	was	used	as	an	 internal	 standard,	and	all	quantification	was	normalized	 to	BSA.	 	By	one	hour,	 IDH1	K93ac	was	more	than	80%	deacetylated.		B.		IDH1	K81ac	incubated	with	HDAC8	(15	µM)	for	one	hour.		The	western	blot	was	probed	with	anti-acetyllysine	and	anti-BSA	antibodies.	 	 IDH1	and	BSA	bands	are	separated	and	labeled	on	 the	blot.	 	No	 IDH1	K81ac	 is	 seen	at	any	 time	point,	 including	 the	zero	 time.	 	This	 is	 in	contrast	 to	a	no-HDAC	control	 reaction	 (C)	with	 IDH1	K81ac	 that	does	 show	acetylated	 IDH1	 through	all	 time	points.	 	This	result	is	consistent	with	some	level	of	HDAC8	catalytic	activity	remaining	in	our	5x	SDS	quenches.	
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Figure	4.13:	Analysis	of	HDAC8	deacetylation	of	IDH1	K93ac	HDAC8	(10	µM)	catalyzed	deacetylation	of	 IDH1	K93ac	(2.5	µM),	as	described	 in	Figure	4.12A	 legend.	 	The	loss	of	substrate	(Y	axis)	over	time	is	shown	here,	fit	with	a	single	exponential.		We	determined	the	kobs	=	0.35	min-1.	 	One	point	(10	minutes,	open	circle)	was	determined	to	be	an	outlier	to	this	data,	based	on	a	Grubb’s	test	with	a	p	<	0.05	cutoff.	
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Figure	4.14:	Quenching	HDAC8	deacetylase	activity	toward	IDH1	K81ac	with	SAHA	Quantification	of	IDH1	K81ac	after	incubation	with	single-turn	over	concentrations	of	HDAC8	(black	bars)	or	with	1x	buffer	control	 (red	bars).	 	Quantification	 is	normalized	to	an	 internal	BSA	standard.	 	Acetylation	of	IDH1	 K81	 decreased	 to	 less	 than	 20%	 of	 the	 starting	 value	 over	 15	 minutes,	 while	 the	 no-HDAC	 control	reaction	remained	above	80%	of	the	starting	value	over	the	same	time	course.	
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Acetylation	inhibits	IDH1	activity		 To	 investigate	 the	 potential	 biological	 effects	 of	 acetylation	 on	 IDH1	 activity,	 we	assayed	WT	 and	mutant	 IDH1	 (Table	 4.4).	 	 Briefly,	 we	 used	 assay	 conditions	 of	 75	 µM	NADP+	and	200	µM	isocitrate,	both	above	their	published	KM	values(104).	 	We	found	that	IDH1	K81ac	showed	no	activity	at	 the	concentration	 tested,	and	was	at	 least	25-fold	 less	active	than	wild-type	enzyme	(Fig.	4.15).		Due	to	limitations	in	the	amount	of	IDH1	K81	we	had	available,	we	were	unable	to	test	higher	concentrations	to	get	a	more	accurate	sense	of	the	 inactivation	 caused	 by	 acetylation	 at	 this	 site.	 	 IDH1	K93	 and	K321	 both	 showed	no	activity	 at	 the	 concentrations	 tested	 (Fig	 4.15	 and	 Fig	 4.16).	 	 IDH1	 K224	 is	 the	 only	acetylation	mutant	to	show	activity	(Fig.	4.16).		It	is	reduced	about	650-fold	from	wild-type	IDH1	under	the	circumstances	tested.					
Table	4.4:	IDH1	catalytic	activity	change	with	acetylation	
IDH1	
mutant
Fold	decrease	
from	WT
K81ac 								>	25
K93ac 								>	5000
K224ac 650
K321ac 								>	2500
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Figure	4.15:	Progress	curves	for	WT	and	Acetylated	IDH1	IDH1	 was	 assayed	 using	 75	 µM	 NADPH	 and	 200	 µM	 isocitrate.	 	 Progress	 was	 determined	 by	 measuring	fluorescence	of	 the	NADP+	 reaction	product.	 	 IDH1	variants	were	 assayed	 at	 the	 following	 concentrations:	Wild-type	 (red)	at	20	nM,	K81ac	 (blue)	at	40	nM,	K93ac	 (green)	at	20	nM,	K224ac	 (purple)	 at	20	nM,	and	K321ac	(yellow)	at	20	nM.		No	activity	was	observed	for	acetylated	IDH1	at	the	concentrations	tested.	
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Figure	4.16:	Progress	curves	for	acetylated	IDH1	at	elevated	concentrations	Acetylated	IDH1	activity	was	assayed	at	the	higher	concentrations.		Concentrations	of	NADPH	and	isocitrate	remained	 75	 µM	 and	 200	 µM,	 respectively.	 	 IDH1	WT	 (red)	 was	 lowered	 to	 10	 nM.	 	 K93ac	 (green)	 was	assayed	at	150	nM,	K224ac	(purple)	at	1	µM,	and	K321ac	(yellow)	at	500	nM.		Only	K224ac	had	measurable	activity.	
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Discussion	Using	 a	 chip-based	 proteomics	method,	we	 have	 identified	 44	 proteins	 that	were	deacetylated	by	HDAC8	on	the	chips	and	25	that	were	deacetylated	by	HDAC11.		Of	the	44	proteins	 deacetylated	 by	 HDAC8,	 22	 have	 documented	 acetyllysine	 sites	 in	 literature.		Likewise,	for	the	25	HDAC11	hits,	14	have	documented	acetyllysine	sites.	 	Based	on	these	findings,	 we	 measured	 HDAC8	 and	 HDAC11	 catalyzed	 deacetylation	 of	 peptides	corresponding	 these	proteins	and	 found	that	 the	rate	constant	kcat/KM	ranged	 from	100	–	102	M-1s-1	for	both	HDAC	isozymes.	Of	the	novel	HDAC8	hits	that	we	continued	to	test	in	vitro,	IDH1	was	among	the	most	interesting	 putative	 substrates.	 	 IDH1	 has	 4	 known	 acetylation	 sites,	 one	 of	 which	corresponded	 to	 one	 of	 our	 best	 HDAC8	 peptide	 substrates.	 	 HDAC8-catalyzed	deacetylation	of	peptides	corresponding	to	these	sites	had	kcat/KM	values	ranging	from	<	10	M-1s-1	 to	 >	 150	 M-1s-1.	 	 IDH	 is	 a	 family	 of	 proteins,	 (IDH1,	 2,	 and	 3)	 involved	 in	 the	decarboxylation	of	citric	acid.		These	enzymes	require	either	NADP+	(IDH1,	IDH2)	or	NAD+	(IDH3)	as	a	cofactor	(105,	106).	 	Additionally,	 IDH2	and	IDH3	are	mitochondrial	proteins	(106),	 while	 IDH1	 is	 cytosolic	 (105).	 	 IDH1	mutations	 have	 been	 linked	 to	 gliobastomas	(104),	with	more	 than	80%	of	 secondary	 glioblastoma	patients	 testing	positive	 for	 these	mutations	(107).			We	continued	investigating	the	role	of	HDAC8	catalysis	on	the	deacetylation	of	IDH1	by	 expressing	 four	 different	 singly	 acetylated	 mutants.	 	 Our	 data	 is	 consistent	 with	 the	hypothesis	 that	 HDAC8	 does	 catalyze	 deacetylation	 of	 this	 protein,	 from	 a	 substrate	prediction	 algorithm	 to	 in	 vitro	 activity	 with	 peptides	 to	 activity	 with	 purified,	 singly	acetylated	full-length	IDH1.		Additionally,	we	show	that	deacetylation	is	not	uniform	across	
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all	 four	 acetyllysine	mutants;	HDAC8	 has	 specificity	 for	 select	 sites	 on	 the	 protein.	 	 This	marks	 the	 first	 time	 a	 singly	 acetylated	 non-histone	 protein	 has	 been	 deacetylated	 by	HDAC8	in	vitro.	While	 IDH1-acetylation	 has	 been	 documented,	 the	 functional	 role	 of	 this	modification	 is	 not	 yet	 understood.	 	 We	 sought	 to	 address	 this	 question	 by	 assaying	acetylated	 IDH1	 mutants	 in	 comparison	 to	 WT-enzyme.	 	 Interestingly,	 we	 found	 that	acetylation	significantly	decreases	IDH1	activity,	with	some	acetylation	sites	having	greater	than	 103	 fold	 loss	 of	 activity.	 	 The	 only	 IDH1	 variant	 with	 measurable	 activity	 was	acetylated	at	K224,	but	activity	loss	was	in	the	range	of	650-fold.		These	observations	are	in	agreement	 with	 the	 observed	 inactivation	 of	 acetylated	 IDH2	 (108).	 	 Upon	 addition	 of	HDAC8	to	IDH1-K224ac,	we	did	not	see	an	increase	in	IDH1	activity.		We	hypothesized	that	this	 could	 be	 due	 to	 a	 protein-protein	 interaction	 between	 IDH1	 and	 HDAC8.	 	 Upon	addition	of	saturating	SAHA,	we	observe	a	moderate	recovery	of	IDH1	activity.		Addition	of	HDAC8	 to	WT-IDH1	 also	 yields	 a	 decrease	 in	 IDH1	 activity,	 consistent	with	 our	 protein-protein	interaction	hypothesis.			Understanding	 the	 role	 of	 each	 HDAC	 isozyme	 is	 crucial	 for	 understanding	 and	developing	 potent	 and	 selective	 therapeutics,	 and	 the	 acetylation	 field	 has	 developed	methods	identify	putative	HDAC-substrate	pairs.		The	majority	of	data	on	this	topic	comes	from	 pull-down	 experiments	 or	 analysis	 of	 proteins	 after	 treating	 cells	 with	 an	 HDAC	inhibitor.	 	 A	 recent	 study	 identifying	 protein-protein	 interactions,	 established	 via	immunoaffinity	 purification	 of	 eGFP	 tagged	 HDACs,	 identified	 dozens	 of	 proteins	 that	interact	with	specific	HDAC	 isozymes	(40).	 	These	 included	15	proteins	 that	pulled	down	with	 HDAC8	 and	 124	 proteins	 that	 pulled	 down	 with	 HDAC11.	 	 These	 HDAC8	 proteins	
	 145	
included	 members	 of	 the	 structural	 maintenance	 of	 chromosomes	 (SMC)	 family,	 among	others.		The	HDAC11	hits	represented	proteins	from	a	large	diversity	of	both	function	and	localization,	highlighting	possible	roles	in	chromatin	modification	and	gene	expression,	as	well	as	RNA	editing.		It	is	of	note,	though,	that	this	method	looks	for	stable	protein-protein	interactions.	 	 It	 does	 not	 bias	 the	 result	 toward	 substrate	 proteins,	 and	 there	 is	 no	requirement	that	the	proteins	identified	must	undergo	any	change	in	acetylation.	 	Indeed,	one	 could	 imagine	 that	 potentially	 transient	 interactions	 between	 HDAC8	 and	 its	substrates	might	not	be	seen.		 A	 subsequent	 study,	 from	 Ed	 Holson	 at	 the	 Broad	 Institute,	 utilized	 a	 mass	spectrometric	 approach	 to	 identify	 putative	 HDAC8	 substrates	 (61).	 	 Here,	 researchers	treated	 cells	with	 an	 HDAC8-specific	 inhibitor	 and	 utilized	 a	 SILAC	 approach	 to	 identify	changes	in	protein	acetylation.		This	approach	identified	several	additional	putative	HDAC8	substrates,	as	well	as	a	 few	proteins	 that	were	very	near	 the	arbitrary	cutoffs	used.	 	The	only	 overlapping	 protein	 between	 this	 method	 and	 the	 immunoaffinity	 purification	 was	SMC3.	 	 This	 technique	 requires	 that	 identified	 proteins	 must	 undergo	 a	 change	 in	acetylation	between	control	and	treated	cells,	 that	 the	acetylated	peptides	pulldown	with	anti-acetyllysine	antibodies,	and	that	they	are	in	sufficient	concentration	to	be	identified	by	mass	spectrometric	analysis.	 	 It	does	not,	however,	require	that	acetylation	changes	are	a	direct	effect	of	HDAC8	inhibition.	 	Downstream	effects	would	likely	have	introduced	false	positives	 into	 the	 results.	 	 Subsequent	 in	 vitro	 analysis	 of	 peptides	 based	 on	 these	 hits	showed	that	ARID1A	and	CSRP2BP	were	the	strongest	substrate	candidates	(61).		 The	method	outlined	here	is	based	on	the	HDAC-catalyzed	deacetylation	of	purified	full-length	human	proteins.	 	These	proteins	are	immobilized,	in	duplicate,	in	a	microarray	
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format	on	a	functionalized	glass	surface.	 	We	incubated	this	proteome	library	with	a	KAT	protein,	 p300,	 to	 acetylate	 chip-based	 proteins.	 	 This	 introduces	 perhaps	 the	 most	significant	 limitation	 of	 this	 assay.	 	 Acetylation	 by	 p300	 is	 required	 for	 a	 protein	 in	 our	assay	 to	 then	 be	 deacetylated	 by	 an	 HDAC.	 	 To	 reduce	 the	 impact	 of	 this	 limitation,	 we	chose	 to	 use	 a	 p300	 construct	 containing	 the	 acetyltransferase	 domain	 but	 lacking	 the	specificity	domain,	and	supplied	excess	acetyl-CoA	to	the	acetyltransferase	reaction.			This	setup	allows	for	the	in	vitro	assaying	of	thousands	of	proteins	simultaneously.		Any	HDAC	 isozyme	 can	 be	 incubated	with	 the	 acetylated	 chips	 to	measured	 deacetylase	activity.	 	 Visualization	 of	 acetylation	 and	 deacetylation	 is	 based	 on	 reactivity	 of	 protein	acetyllysine	 sites	with	 an	 anti-acetyllysine	 antibody.	 	 This,	 as	was	 also	 the	 case	with	 the	SILAC	method,	requires	that	the	antibody	recognizes	these	sites.	 	This	technique	does	not	select	for	proteins	based	on	their	tendency	to	complex	or	pull	down	with	HDACs,	nor	does	it	identify	downstream	effects	of	HDAC	catalysis.				 Of	 the	 15	 proteins	 identified	 via	 eGFP-HDAC8	 immunoprecipitation,	 only	 one	 of	these	 proteins	was	marked	 as	 acetylated	 on	 our	 proteome	 chips.	 	 This	 protein,	 gamma-adducin	 (ADD3),	 is	 involved	 in	 cytoskeleton	 assembly	 (109).	 	 It	 was	 identified	 as	deacetylated	by	HDAC8	 in	one	of	 the	 three	methods	used	 to	evaluate	HDAC8	hits	on	 the	chips,	 but	 failed	 to	 meet	 the	 criteria	 in	 our	 other	 analysis	 methodology.	 	 It	 was	 a	requirement	 in	 choosing	 our	 top	 HDAC8	 hits	 that	 they	 be	 identified	 by	 at	 least	 two	methods.		For	this	reason,	it	was	not	marked	as	an	HDAC8	hit.		Additionally,	at	the	time	of	this	document,	ADD3	had	no	acetylation	sites	scored	by	FlexPepBind.		However,	due	to	its	appearance	 in	multiple	 approaches,	 ADD3	 should	 be	 kept	 in	mind	 as	 a	 potential	HDAC8	substrate.			
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	 From	the	handful	of	proteins	identified	by	the	SILAC	method,	only	one	of	the	targets	was	 acetylated	 on	 the	 proteome	 chips,	 CSRP2BP.	 	 Additionally,	 treacle	 protein	 (TCOF1),	which	 met	 the	 thresholds	 for	 acetylation	 change	 in	 their	 study	 but	 was	 considered	insignificant	(p	=	0.05	instead	of	p	<	0.05),	was	acetylated	on	our	proteome	chips.		CSRP2BP	is	 a	 member	 of	 the	 acetyltransferase	 complex	 ATAC,	 and	 has	 weak	 acetyltransferase	activity	itself	(110).		Like	ADD3,	CSRP2BP	was	identified	in	only	one	of	the	three	methods	used	 to	 select	HDAC8	hits	 from	our	 proteome	 experiment.	 	 A	 scan	 of	 known	 acetylation	sites	through	FlexPepBind	does	show	that	CSRP2BP	has	three	acetylation	sites	that	score	<	-16.5,	suggesting	that	they	may	be	good	substrates	in	vitro.		The	second	protein,	TCOF1,	is	known	 for	 its	 role	 as	 the	host	 gene	 for	mutations	 leading	 to	Treacher	Collins	 Syndrome.		TCOF1	 is	 believed	 to	 undergo	 extensive	 post-translational	 modification	 (111),	 and	 is	involved	 in	 ribosomal	 biogenesis	 (112).	 	 TOCF1	 was	 deacetylated	 on	 HDAC8	 proteome	chips,	 and	was	 identified	 as	 a	 top-scoring	 hit.	 	 This	 protein	 also	 has	 several	 acetylation	sites,	some	of	which	are	predicted	by	FlexPepBind	to	be	good	HDAC8	substrates.		A	peptide	from	this	protein	(peptide	#189	in	Table	4.2)	was	among	the	top	scoring	peptides	from	the	proteome	chip	experiments.			As	 mentioned,	 the	 immunoaffinity	 purification	 method	 was	 also	 used	 to	 identify	proteins	that	associate	with	HDAC11	(40).		Of	the	124	proteins	identified,	4	were	acetylated	on	the	proteome	chips.	 	Of	 those	 four,	3	were	 identified	as	deacetylated	on	our	HDAC11-treated	proteome	chips.		These	were	CCAAT/enhancer-binding	protein	zeta	(CEBPZ),	DnaJ	homolog	subfamily	B	member	2	(DNAJB2),	and	an	uncharacterized	protein	(C2orf47).		Two	of	these	three	proteins	had	known	acetylation	sites,	CEBPZ	and	C2orf47.		CEBPZ	stimulates	a	 transcriptional	 promoter	 for	 HSP70	 (113).	 	While	 acetylation	 of	 CEBPZ	 has	 been	 seen	
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across	 multiple	 studies	 (86,	 114),	 the	 role	 of	 this	 modification	 is	 not	 yet	 understood.		C2orf47	is	an	uncharacterized	protein.		While	it	is	expressed	in	the	cytoplasm,	according	to	the	Human	Protein	Atlas,	it	appears	to	localize	to	the	mitochondria.		Analysis	by	TargetP’s	prediction	server	also	suggests	the	presence	of	a	mitochondrial	localization	peptide.	 	This	distinction,	 between	 expressed	 in	 the	mitochondria	 vs.	 localized	 in	 the	mitochondria,	 is	important.	 	 Evidence	 suggests	HDAC11	 is	present	 in	both	 the	nucleus	and	 the	 cytoplasm	(24,	40,	115),	but	there	is	no	record	of	HDAC11	in	the	mitochondria.		So	while	C2orf47	may	localize	 to	 the	 mitochondria,	 the	 potential	 for	 modification	 exists	 before	 this	 protein	reaches	that	final	location.			Taken	 together,	 there	were	 three	 proteins	 that	 were	 acetylated	 on	 the	 proteome	chips	and	also	identified	as	potential	HDAC8	substrates	in	published	literature.		All	three	of	these	proteins	were	identified	as	deacetylated	in	at	least	one	of	the	analysis	methods	used	on	our	chips.	 	One	of	 the	 three	was	 identified	by	multiple	analysis	methods,	and	upon	 in	
vitro	 peptide	 testing	 it	 was	 shown	 that	 a	 peptide	 representing	 an	 acetyllysine	 from	 this	protein,	 TCOF1,	 was	 turned	 over	 by	 HDAC8.	 	 Additionally,	 of	 the	 4	 proteins	 that	 were	acetylated	 on	 our	 chips	 and	 previously	 identified	 as	 interacting	 partners	 with	 HDAC11,	three	were	also	deacetylated	by	HDAC11	in	our	chip	experiments.		Two	of	these	had	known	acetylation	 sites,	 and	 we	 found	 that	 peptides	 from	 both	 proteins	 were	 turned	 over	 by	HDAC11	 in	 subsequent	 in	 vitro	 testing.	 	 These	 results	 bolstered	 our	 confidence	 in	 the	multitude	of	novel	protein	targets	identified	using	this	new	on-chip	proteomics	method.			In	summary,	we	have	shown	that	HDAC	deacetylase	activity	from	multiple	isozymes	can	be	observed	with	proteins	immobilized	on	a	proteome	chip	microarray.		This	data	set	has	 led	 to	 the	 identification	of	several	new	putative	substrates	 for	both	HDACs	8	and	11.		
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Using	 an	 in	 vitro	 enzyme-coupled	 assay,	 we	 have	 verified	 HDAC	 activity	 against	 several	peptides	 corresponding	 to	 these	 proteins.	 	 Finally,	 we	 have	 shown	 that	 HDAC8	 can	deacetylate	recombinantly	expressed	and	purified	singly-acetylated	IDH1	in	vitro,	marking	a	 first	 for	 the	 HDAC	 field.	 	 We	 hope	 the	 techniques	 presented	 here	 will	 continue	 to	 be	applied,	in	conjunction	with	current	methods,	to	additional	HDAC	isozymes	to	further	our	understanding	of	this	family	of	enzymes.		
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Chapter	5	
Dual-Mode	HDAC	Prodrug	for	Covalent	Modification	and	Subsequent	Inhibitor	
Release15,16	
Introduction	Transcription	 is	 a	 tightly	 regulated	biological	process	 that	 is	 the	 first	 step	 in	gene	expression	 (19,	 116,	 117).	 	 In	 eukaryotic	 cells,	 sequence-	 specific	 DNA	 binding	 factors	control	the	flow	of	genetic	information	from	DNA	to	RNA,	thereby	regulating	transcription.		In	cells,	DNA	is	tightly	compacted	into	chromatin,	a	highly	organized	and	dynamic	complex	between	 DNA	 and	 proteins.	 	 When	 gene	 transcription	 is	 activated,	 the	 DNA	 is	 made	accessible	 to	 transcription	 factors	 via	 nucleosome	 modification	 (19,	 116)	 The	 local	architecture	 of	 chromatin,	 which	 is	 influenced	 by	 post-translational	 modifications	 of	histones,	 can	 regulate	 gene	 expression.	 	 These	 modifications	 include	 methylation,	phosphorylation,	 and	 acetylation	 of	 core	 histones.	 	 Histone	 acetylation	 occurs	 at	 the	 ε-amino	groups	of	conserved	 lysine	residues	near	 the	N-termini.	 	Acetylation	 levels	of	core	histones	are	a	result	of	the	balance	between	histone	acetyltransferases	(HATs)	and	histone	deacetylases	 (HDACs)	 (19,	116–118)	 Increased	 levels	of	histone	acetylation	are	generally	
																																																								15	Revised	from	Daniel,	K.		B.,	Sullivan,	E.		D.,	Chen,	Y.,	Chan,	J.		C.,	Jennings,	P.		A.,	Fierke,	C.		A.,	and	Cohen,	S.		M.		(2015)	Dual-Mode	HDAC	Prodrug	for	Covalent	Modification	and	Subsequent	Inhibitor	Release.,	J.		Med.		Chem.		
58,	4812–21.		16	Project	developed	by	Kevin	Daniel.		Eric	Sullivan	expressed	and	purified	WT	and	Cys153Ala	HDAC8.		Eric	Sullivan	carried	out	the	PCR	and	generated	the	HDAC8	Cys153Ala	mutant.		Eric	Sullivan	determined	kinetics	of	inhibition	for	SAHA,	SAHA-TAP,	and	SAHA-OBn	using	WT-HDAC8	and	Cys153Ala	HDAC8.		Kevin	Daniels,	Eric	Sullivan,	Seth	Cohen,	and	Carol	Fierke	wrote	and	edited	the	manuscript.	
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associated	with	transcriptional	activity,	whereas	decreased	levels	of	histone	acetylation	are	associated	with	repression	of	transcription.		Additionally,	acetylation	of	specific	lysines	on	histone	tails	facilitates	the	recruitment	of	bromodomain-containing	chromatin	remodeling	factors	 (119,	 120)	 Furthermore,	 acetylated	 lysines	 have	 been	 observed	 in	many	 cellular	proteins,	indicating	that	HATs	and	HDACs	do	not	function	solely	to	modify	histones	(86)	Histone	 deacetylase	 inhibitors	 (HDACi)	 have	 been	 developed	 as	 a	 class	 of	 therapeutic	agents	 intended	 to	 target	 aberrant	 epigenetic	 states	 associated	 with	 a	 variety	 of	pathologies,	 most	 notably	 cancer	 (121)	 Recent	 findings	 have	 shown	 that	 the	 relief	 of	oncogenic	transcriptional	repressors	by	HDACi	can	lead	to	cell	cycle	arrest	and	apoptosis	(19,	 116–118)	 This	 is	 because	 many	 cancers	 have	 evolved	 such	 that	 pro-apoptotic	pathways	 are	 transcriptionally	 repressed	 via	 histone	 deacetylation.	 	 HDACi	 prevent	deacetylation	 of	 the	 lysine	 residues	 of	 the	 histone	 tails,	 which,	 in	 turn,	 leads	 to	transcriptional	activation,	gene	expression,	and	cell	death	(19,	121)		The	development	of	HDACi	has	been	ongoing,	and	>10	candidates	have	progressed	to	 clinical	 trials	 (117)	 HDACi	 can	 be	 subdivided	 into	 structural	 classes	 including	hydroxamic	 acids,	 cyclic	 peptides,	 aliphatic	 acids,	 and	 benzamides	 (122)	 The	 HDACi	Vorinostat	(suberoylanilide	hydroxamic	acid,	SAHA)	received	approval	by	the	United	States	Food	 and	 Drug	 Administration	 (FDA)	 in	 2006	 for	 the	 treatment	 of	 cutaneous	 T-cell	lymphoma	(CTCL)	(123)	Crystallization	of	SAHA	with	HDAC8	supported	a	model	involving	the	linkage	of	a	metal-binding	pharmacophore	(MBP)	to	a	capping	group	designed	to	form	favorable	 interactions	with	 amino	 acid	 residues	 at	 the	 entrance	 to	 the	 active	 site	 tunnel	(Figure	 5.1a)	 (124)	 Three	 other	 HDACi	 have	 been	 approved	 by	 the	 FDA,	 including	Panobinostat	 and	 Belinostat,	 both	 broad-spectrum,	 hydroxamate-based	 HDACi	 for	 the	
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treatment	 of	 multiple	 myeloma	 or	 relapsed/refractory	 peripheral	 T-cell	 lymphoma,	respectively	(Figure	5.1a)	(125,	126)	Romidepsin	(FK228),	a	cyclic	peptide	HDACi	that	uses	a	thiol	group	to	coordinate	the	active	site	metal	ion,	is	approved	for	CTCL	treatment	(Figure	5.1a)	(123)		SAHA,	 Romidepsin,	 and	 Panobinostat	 act	 to	 inhibit	 most	 isoforms	 of	 the	 metal-dependent	 HDAC	 family	 and	 are	 regarded	 as	 broad-spectrum	 HDAC	 inhibitors.	 	 Despite	promising	 clinical	 results	 for	HDACi,	 these	drugs	have	not	been	effective	 in	 clinical	 trials	involving	solid	tumors.	 	 In	 fact,	 these	FDA-approved	drugs	have	been	associated	with	the	onset	 of	 serious	 side	 effects,	 including	 fatigue,	 gastrointestinal	 issues	 (diarrhea,	 nausea,	vomiting),	and	hematologic	complications	(thrombocytopenia,	anemia,	neutropenia)	(121,	
123)	 Both	 SAHA	 and	 Romidepsin	 have	 also	 been	 associated	 with	 cardiotoxicity(121)	Clinical	studies	in	humans	determined	the	major	metabolic	pathways	of	SAHA	degradation	involve	 glucoronidation	 by	 UDP-glucoronosyltransferases	 (UGTs)	 to	 generate	 inactive	 1	(Figure	 5.1b).	 	 Alternatively,	 hydrolysis	 of	 SAHA	 to	 the	 carboxylic	 acid	 analogue	 (2)	followed	by	β-oxidation	generates	the	inactive	metabolite	4-anilino-4-oxobutanoic	acid	(3,	Figure	 5.1b)	 (123,	 127)	 Clinical	 studies	 determined	 that	 the	 mean	 steady-state	 serum	exposures	of	1	and	2	were	4-	and	13-fold	higher	than	SAHA,	respectively.		Additionally,	the	apparent	t1/2	of	SAHA	in	human	serum	was	∼1.5	h	for	patients	receiving	single	doses	of	400	mg	of	SAHA	(121,	123,	127)	The	poor	pharmacokinetic	(PK)	properties	of	SAHA	are	similar	for	 other	 hydroxamic	 acid-based	 compounds	 and	 involve	 chemical	 instability	 and	 rapid	elimination	(121,	128)	In	fact,	the	FDA	has	approved	SAHA	for	CTCL	only	in	patients	with	persistent	 or	 recurrent	 disease	who	have	 already	 followed	 two	 systemic	 therapies	 (121)	Similarly,	the	FDA	has	only	approved	Romidepsin	for	CTCL	treatment	in	patients	who	have	
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received	at	 least	one	prior	systemic	 therapy,	and	Panobinostat	 is	administered	only	after	two	prior	standard	therapies	have	failed	(129)	The	onset	of	these	deleterious	side	effects	is	proposed	to	originate,	in	part,	from	the	lack	of	selectivity	of	these	drugs	for	a	specific	HDAC	isozyme	(121)		
	
Figure	5.1:	FDA-approved	HDAC	inhibitors.	(A)	 The	 hydroaxamic	 acid	 and	 sulfhydryl	 MBP	 donor	 atoms	 of	 SAHA,	 Panobinostat,	 and	 Romidepsin	 are	shown	 in	 red.	 	 (B)	Metabolism	of	 SAHA.	 	Upon	 systemic	 circulatin,	UGT	 enzymes	 localized	 in	 the	 liver	 can	convert	 SAHA	 to	 a	 SAHA	 b-D-glucuronide	 (1),	 rendering	 the	 drug	 inactive.	 	 A	 different	 pathway	 involves	initial	hydrolysis	of	SAHA	to	the	corresponding	carboxylic	acid	(2),	followed	by	oxidation	to	3.			 Chemically	modified	 versions	 of	 active	 drugs	 have	 been	 developed	 in	 an	 effort	 to	overcome	barriers	 to	drug	 formulation	and	delivery.	 	The	modified,	 latent	version	of	 the	drug,	 termed	 the	 prodrug,	 undergoes	 a	 transformation	 in	 the	 presence	 of	 a	 desired	chemical	or	enzymatic	stimulus	in	vivo	to	generate	the	active	agent	(130,	131)	The	chemical	group	appended	to	 the	active	drug	rendering	 it	 inactive	 is	 termed	the	promoiety.	 	Only	a	handful	 of	 reports	 have	 investigated	 HDAC	 prodrugs,	 with	 most	 studies	 focused	 on	developing	acyl	derivatives	of	SAHA	or	similar	hydroxamic	acid-based	HDACi	 to	enhance	
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cell	permeability	and	hydrolytic	stability	(132).		As	expected,	these	prodrugs	showed	little	activity	as	HDAC	inhibitors,	and	biochemical	assays	suggest	that	the	acylated	prodrugs	are	more	cell-permeable	than	the	hydroxamic	acid	parent	drugs.		A	similar	report	investigated	a	carbamate	prodrug	concept	for	hydroxamate	HDACi	(including	SAHA)	to	improve	drug-like	 properties,	 including	 cellular	 permeability	 (133).	 	 However,	 both	 of	 these	 strategies	rely	 on	 hydrolysis	 in	 vivo	 to	 release	 the	 active	 drug	 and	 do	 not	 improve	 drug−target	specificity	for	selected	disease	states	or	sites	of	disease.			Initially,	 we	 sought	 to	 develop	 new	HDAC	 inhibitor	 prodrugs	 (proinhibitors)	 that	become	activated	 in	the	presence	of	 thiols	such	as	glutathione	 in	 its	reduced	form	(GSH),	which	 is	 frequently	more	abundant	at	 the	site	of	disease	 (e.g.,	 cancer)	 (134).	 	Previously,	Huang	and	co-workers	reported	the	development	of	a	 long-wavelength	fluorescent	probe	involving	 a	 quinone-methide	 reaction	 that	 can	 detect	 physiologically	 relevant	 thiols	including	GSH	(135).		Although	the	quinone	promoiety	functions	as	an	electrophilic	Michael	acceptor,	 it	was	determined	that	other	biologically	relevant	nucleophiles,	 including	serine	and	lysine,	were	unreactive	with	this	functionality.		Our	prodrug	approach	considered	the	covalent	appendage	of	this	quinone	promoiety	to	the	hydroxamate	of	an	HDACi,	since	the	alkylation	 of	 hydroxamates	 has	 been	 shown	 to	 be	 effective	 in	 improving	 PK	 properties	including	hydrolytic	stability,	cellular	permeability,	and	glucoronidation	(132,	136,	137).			As	 described	 below,	 even	 in	 the	 absence	 of	 nucleophilic	 thiols,	 we	 observed	activation	of	our	prodrug	(SAHA-TAP);	sequence	homology	analysis	revealed	that	a	single	cysteine	(Cys)	residue	is	conserved	in	all	metal-dependent	HDAC	isoforms,	which	we	found	was	 reactive	 with	 our	 prodrug	 (Appendix	 2,	 Figure	 S1)	 (138).	 	 The	 crystal	 structure	 of	HDAC8	 complexed	 with	 SAHA	 reveals	 that	 the	 conserved	 Cys	 (Cys153	 for	 HDAC8)	 is	
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located	in	the	catalytic	active	site	pocket	∼5.6	Å	away	from	the	hydroxamic	acid	moiety	of	SAHA	(Figure	5.2).		Thus,	we	have	concluded	that	our	prodrug	is	cleaved	by	the	sulfhydryl	moiety	 of	 the	 conserved	 Cys	 of	 HDAC,	 leading	 to	 drug	 activation	 and	 a	 dual	 mode	 of	inhibition:	 covalent	 modification	 of	 the	 conserved	 Cys	 leading	 to	 the	 formation	 of	 an	inactive,	covalently	modified	enzyme	and	release	of	the	competitive	inhibitor	SAHA.		
	
	
Figure	5.2:	Protein	crystal	structure	of	HDAC8	complexed	with	SAHA.	The	 distance	 between	 the	 sulfhydryl	 moiety	 of	 Cys153	 and	 the	 nitrogen	 atom	 of	 the	 MBP	 of	 SAHA	 was	determined	 to	be	5.6	Å.	 	 SAHA	and	Cys153	are	shown	as	sticks	 in	color	code	 (carbon,	gray;	nitrogen,	blue;	oxygen,	red;	sulfur,	yellow),	and	the	Zn2+	ion	is	shown	as	an	orange	sphere	(PDB:	1T69).	
	
relevant thiols including GSH.22 Although the quinone
promoiety functions as an electrophilic Michael acceptor, it
was determined that other biologically relevant nucleophiles,
including serine and lysine, were unreactive with this
functionality. Our prodrug approach considered the covalent
appendage of this quinone promoiety t the hydroxamate of an
HDACi, since the alkylation of hydroxamates has been shown
to be effective in improving PK properties including hydrolytic
stability, cellular permeability, and glucoronidation.19,23,24
As described below, even in the absence of nucleophilic
thiols, we observed activation of our prodrug (SAHA-TAP);
sequence homology analysis revealed that a single cysteine
(Cys) residue is conserved in all metal-dependent HDAC
isoforms, which we found was reactive with our prodrug
(Supporting Information, Figure S1).25 The crystal structure of
HDAC8 complexed with SAHA reveals that the conserved Cys
(Cys153 for HDAC8) is located in the catalytic active site
pocket ∼5.6 Å away from the hydroxamic acid moiety of SAHA
(Figure 2). Thus, we have concluded that our prodrug is
cleaved by the sulfhydryl moiety of the conserv d Cys of
HDAC, leading to drug activation and a dual mode of
inhibition: covalent modification of the conserved Cys leading
to the formation of an inactive, covalently modified enzyme and
release of the competitive inhibitor SAHA.
■ RESULTS AND DISCUSSION
Development of a Unique HDACi Prodrug. SAHA was
chosen as the drug of interest because it is FDA-approved for
the treatment of CTCL and has been well-studied. A prodrug
of SAHA containing a quinone-based, thiol-sensitive promoiety
was designed, termed SAHA-TAP (TAP, thiol activated
prodrug) (Figure 3). To develop SAHA-TAP, the promoiety
was first synthesized using a modified literature procedure.22
The promoiety was appended to SAHA under basic conditions
to generate SAHA-TAP. The activation of SAHA-TAP by
reaction with GSH is summarized in Figure 3a. A control
compound, SAHA-OBn, was synthesized in a similar manner.
This compound contains a benzyl moiety appended to SAHA
via the N-hydroxyl functionality. SAHA-OBn was designed to
have a similar structure as that of SAHA-TAP but to be
unreactive toward nucleophilic thiols.
Assessment of SAHA-TAP Reactivity with GSH. To
evaluate the reactivity of SAHA-TAP and SAHA-OBn with
nucelophilic t iols, analytical HPLC was utilized under
simulated physiological conditions (50 mM HEPES, pH 7.4).
SAHA-TAP was treated with GSH (2 mM, 2 equiv) to confirm
that the prodrug is indeed reactive with thiols. After incubation
of SAHA-TAP with GSH, three distinct peaks were apparent in
the HPLC chromatogram (Figure 3b). Liquid chromatogra-
phy−mass spectrometry (LC-MS) confirms that the identity of
the first peak (tR = 10.5 min) is the quinone-methide side
product, the second peak is SAHA (tR = 10.7 min), and the
third peak is unreacted SAHA-TAP (tR = 14.7 min). Treatment
of SAHA-OBn with GSH under the same conditions resulted in
no change in the HPLC chromatogram, indicative of the
expected lack of reactivity (Figure 3c). Having shown that
SAHA-TAP reacts rapidly with GSH, the aqueous stability of
SAHA-TAP was evaluated under simulated physiological
conditions (50 mM HEPES, pH 7.4). An HPLC chromatogram
was obtained immediately after preparation in aqueous buffer,
and a second trace was collected after incubation at 37 °C for
24 h. SAHA-TAP was determined to be >97% stable to
hydrolysis in the absence of thiols (Figure S2).
HDAC Inhibition by SAHA-TAP. To determine the
efficacy of the SAHA-TAP prodrug strategy, the ability of
SAHA-TAP and SAHA-OBn to inhibit HDAC-1, -2, -3, -6, and
-8 was evaluated using an optimized homogeneous fluo-
rescence-based assay (BPS Bioscience). Surprisingly, even in
the absence of exogenous thiols, SAHA-TAP was an effective
inhibitor of all HDACs tested, with an apparent IC50 value that
is slightly less potent (2- to 50-fold) than that of the parent
inhibitor, SAHA (Table S1). This result was unexpected
because the metal-binding ability of the hydroxamic acid MBP
of SAHA-TAP is blocked by the promoiety, which should
render the drug nearly inactive. Recent studies indicate that the
metal-free form of HDAC8 has a low affinity for SAHA
analogues, further demonstrating the importance of metal
binding for HDAC inhibition.26 To determine if a component
of the biochemical assay resulted in SAHA-TAP activation,
analytical HPLC was utilized. SAHA-TAP was incubated with
either BSA (5 mg/mL) or trypsin (5 mg/mL) at 37 °C for 2 h;
however, SAHA-TAP was found to be >95% stable in the
presence of either of these assay components (data not shown).
Because SAHA-TAP is a larger molecule than SAHA and the
metal-binding hydroxamate group is blocked, it is feasible that
the promoiety may be positioned very close to Cys153 when
bound to HDAC8. This positioning could be ideal for
nucleophilic attack by the sulfhydryl moiety, leading to covalent
modification and SAHA release. We hypothesized that the
Cys153 residue of HDAC8 reacts with bound SAHA-TAP,
resulting in a covalent modification of the protein and
subsequent release of SAHA, a competitive inhibitor (Figure
S3). It is important to note that there are many other Cys
residues in the metal-dependent HDAC isoforms (e.g., 10 Cys
residues in HDAC8), and activation of SAHA-TAP by these
residues may also be responsible, in part, for the release of
SAHA that we observe (vide supra).
Mass Spectrometry Analysis. To investigate whether the
active site Cys153 is covalently modified by the SAHA-TAP
promoiety, mass spectrometry (MS) techniques were utilized.
Digestion of wild-type (WT) HDAC8 with trypsin yields an 18
Figure 2. Protein crystal structure of HDAC8 complexed with SAHA.
The distance between the sulfhydryl moiety of Cys153 and the
nitrogen atom of the MBP of SAHA was determined to be 5.6 Å.
SAHA and Cys153 are shown as sticks in color code (carbon, gray;
nitrogen, blue; oxygen, red; sulfur, yellow), and the Zn2+ ion is shown
as an orange sphere (PDB: 1T69).
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Results	and	Discussion	
Development	of	a	Unique	HDACi	Prodrug.			SAHA	 was	 chosen	 as	 the	 drug	 of	 interest	 because	 it	 is	 FDA-approved	 for	 the	treatment	of	CTCL	and	has	been	well-studied.	 	A	prodrug	of	SAHA	containing	a	quinone-based,	 thiol-sensitive	 promoiety	 was	 designed,	 termed	 SAHA-TAP	 (TAP,	 thiol	 activated	prodrug)	(Figure	5.3).		To	develop	SAHA-TAP,	the	promoiety	was	first	synthesized	using	a	modified	 literature	procedure	 (135).	 	The	promoiety	was	appended	 to	SAHA	under	basic	conditions	 to	 generate	 SAHA-TAP.	 	 The	 activation	 of	 SAHA-TAP	 by	 reaction	with	 GSH	 is	summarized	in	Figure	5.3a.		A	control	compound,	SAHA-OBn,	was	synthesized	in	a	similar	manner.	 	This	compound	contains	a	benzyl	moiety	appended	to	SAHA	via	the	N-hydroxyl	functionality.		SAHA-OBn	was	designed	to	have	a	similar	structure	as	that	of	SAHA-TAP	but	to	be	unreactive	toward	nucleophilic	thiols.			
	
Assessment	of	SAHA-TAP	Reactivity	with	GSH.			To	 evaluate	 the	 reactivity	 of	 SAHA-TAP	 and	 SAHA-OBn	 with	 nucelophilic	 thiols,	analytical	HPLC	was	utilized	under	simulated	physiological	conditions	(50	mM	HEPES,	pH	7.4).	 	 SAHA-TAP	 was	 treated	 with	 GSH	 (2	 mM,	 2	 equiv)	 to	 confirm	 that	 the	 prodrug	 is	indeed	reactive	with	thiols.	 	After	 incubation	of	SAHA-TAP	with	GSH,	three	distinct	peaks	were	 apparent	 in	 the	 HPLC	 chromatogram	 (Figure	 5.3b).	 	 Liquid	 chromatography−mass	spectrometry	 (LC-MS)	 confirms	 that	 the	 identity	 of	 the	 first	 peak	 (tR	 =	 10.5	min)	 is	 the	quinone-methide	side	product,	the	second	peak	is	SAHA	(tR	=	10.7	min),	and	the	third	peak	is	unreacted	SAHA-TAP	(tR	=	14.7	min).		Treatment	of	SAHA-OBn	with	GSH	under	the	same	conditions	resulted	in	no	change	in	the	HPLC	chromatogram,	indicative	of	the	expected	lack	
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of	 reactivity	 (Figure	 5.3c).	 	 Having	 shown	 that	 SAHA-TAP	 reacts	 rapidly	 with	 GSH,	 the	aqueous	stability	of	SAHA-TAP	was	evaluated	under	simulated	physiological	conditions	(50	mM	HEPES,	pH	7.4).		An	HPLC	chromatogram	was	obtained	immediately	after	preparation	in	 aqueous	 buffer,	 and	 a	 second	 trace	 was	 collected	 after	 incubation	 at	 37	 °C	 for	 24	 h.		SAHA-TAP	 was	 determined	 to	 be	 >97%	 stable	 to	 hydrolysis	 in	 the	 absence	 of	 thiols	(Appendix	2,	Figure	S2).				
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Figure	5.3:	Treatment	of	SAHA-TAP	with	GSH		(A)	Activation	of	SAHA-TAP	by	GSH.		In	the	presence	of	GSH,	the	sulfhydryl	moiety	can	attack	the	electrophilic	quinone	 moiety.	 	 Subsequent	 rearrangement	 releases	 SAHA	 along	 with	 the	 quinone-methide	 adduct.	 	 (B)	HPLC	trace	of	SAHA	(black),	SAHA-TAP	(blue),	and	SAHA-TAP	after	treatment	with	GSH	(2	mM,	2	equiv.)	for	2	h	at	37˚C	(red).		Retention	times	are	10.7	min.		for	SAHA	and	14.7	min.		for	SAHA-TAP,	and	10.5	min.		for	the	quinone-methide	GSH	adduct	generated	from	the	reaction.		(C)	HPLC	trace	of	SAHA	(black),	SAHA-OBn	(blue),	and	SAHA-OBn	after	incubation	in	HEPES	(50	mM,	pH	7.4)	for	24	h	at	37˚C	(red).	 	Retention	times	are	10.7	min.		for	SAHA	and	14.9	min.		for	SAHA-OBn.		
HDAC	Inhibition	by	SAHA-TAP.			To	determine	 the	 efficacy	of	 the	 SAHA-TAP	prodrug	 strategy,	 the	 ability	of	 SAHA-TAP	and	SAHA-OBn	to	inhibit	HDAC-1,	-2,	-3,	-6,	and	-8	was	evaluated	using	an	optimized	homogeneous	 fluorescence-based	 assay	 (BPS	 Bioscience).	 	 Surprisingly,	 even	 in	 the	absence	of	exogenous	thiols,	SAHA-TAP	was	an	effective	inhibitor	of	all	HDACs	tested,	with	
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an	 apparent	 IC50	 value	 that	 is	 slightly	 less	 potent	 (2-	 to	 50-fold)	 than	 that	 of	 the	 parent	inhibitor,	SAHA	(Table	S1).	 	This	result	was	unexpected	because	the	metal-binding	ability	of	 the	 hydroxamic	 acid	 MBP	 of	 SAHA-TAP	 is	 blocked	 by	 the	 promoiety,	 which	 should	render	the	drug	nearly	inactive.		Recent	studies	indicate	that	the	metal-free	form	of	HDAC8	has	 a	 low	 affinity	 for	 SAHA	 analogues,	 further	 demonstrating	 the	 importance	 of	 metal	binding	for	HDAC	inhibition(139).	 	To	determine	if	a	component	of	the	biochemical	assay	resulted	 in	SAHA-TAP	activation,	analytical	HPLC	was	utilized.	 	SAHA-TAP	was	 incubated	with	either	BSA	(5	mg/mL)	or	trypsin	(5	mg/mL)	at	37	°C	for	2	h;	however,	SAHA-TAP	was	found	 to	 be	 >95%	 stable	 in	 the	 presence	 of	 either	 of	 these	 assay	 components	 (data	 not	shown).			Because	 SAHA-TAP	 is	 a	 larger	 molecule	 than	 SAHA	 and	 the	 metal-binding	hydroxamate	 group	 is	 blocked,	 it	 is	 feasible	 that	 the	 promoiety	may	 be	 positioned	 very	close	 to	Cys153	when	bound	 to	HDAC8.	 	 This	 positioning	 could	be	 ideal	 for	 nucleophilic	attack	 by	 the	 sulfhydryl	moiety,	 leading	 to	 covalent	modification	 and	 SAHA	 release.	 	We	hypothesized	that	the	Cys153	residue	of	HDAC8	reacts	with	bound	SAHA-TAP,	resulting	in	a	 covalent	 modification	 of	 the	 protein	 and	 subsequent	 release	 of	 SAHA,	 a	 competitive	inhibitor	 (Appendix	2,	 Figure	S3).	 	 It	 is	 important	 to	note	 that	 there	 are	many	other	Cys	residues	 in	 the	 metal-dependent	 HDAC	 isoforms	 (e.g.,	 10	 Cys	 residues	 in	 HDAC8),	 and	activation	of	SAHA-TAP	by	these	residues	may	also	be	responsible,	in	part,	for	the	release	of	SAHA	that	we	observe	(vide	supra).				
Mass	Spectrometry	Analysis.			To	 investigate	whether	 the	active	site	Cys153	 is	covalently	modified	by	 the	SAHA-
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TAP	promoiety,	mass	spectrometry	(MS)	techniques	were	utilized.	 	Digestion	of	wild-type	(WT)	HDAC8	with	trypsin	yields	an	18	amino	acid	peptide	containing	Cys153,	which	can	be	used	 to	 monitor	 the	 modification	 via	 mass	 spectrometry	 (Figure	 5.4a).	 	 If	 a	 covalent	modification	occurs	at	this	position	after	treatment	of	WT	HDAC8	with	SAHA-TAP,	then	the	expected	MS	ion	for	this	peptide	fragment	will	be	different	from	the	unmodified	parent	ion.			HDAC8	(WT,	with	or	without	incubation	with	a	12-fold	excess	of	SAHA-TAP	for	60	min	at	37	°C)	was	digested	with	trypsin,	and	the	resulting	peptides	were	analyzed	by	LC-MS.		The	expected	parent	ion	for	the	WT	HDAC8	Cys153	peptide	was	consistent	with	a	peak	at	 tR	 =	 84.5	 min	 (Figure	 5.4b).	 	 Similarly,	 a	 peak	 at	 tR	 =	 88.5	 min	 corresponds	 to	 the	expected	 parent	 ion	 for	 the	 covalently	modified	 Cys153	HDAC8	 peptide	 after	 SAHA-TAP	treatment	(Figure	5.4c).		To	eliminate	other	digestion	products	that	could	account	for	this	ion,	 further	MS	 techniques	were	applied	 to	verify	 that	 these	 ion	peaks	correspond	 to	 the	peptide	sequence	of	interest.			Tandem	 mass	 spectrometry	 (MS2	 or	 MS/MS)	 is	 routinely	 used	 in	 proteomics	 to	characterize	 amino	 acid	 sequences	 of	 proteins,	 where	 peptides	 undergo	 further	fragmentation	to	amino	acid	aggregates	(140).		The	fragmentation	patterns	observed	in	the	MS/MS	 spectra	 of	 tryptic	 peptides	 for	 WT	 HDAC8	 and	 SAHA-TAP	 treated	 HDAC8	 were	investigated	 to	 obtain	 additional	 insight	 into	 the	 possibility	 of	 covalent	 modification	 of	Cys153.		The	expected	monoisotopic	masses	for	the	y	ion	series	in	both	WT	HDAC8	and	the	SAHA-TAP	treated	sample	are	summarized	in	Table	S2.	 	The	expected	y	fragment	ions	for	both	 peptides	 align	 until	 Cys153	 (y12),	 where	 this	 ion	 and	 each	 subsequent	 ion	 have	different	masses.	 	 Indeed,	 the	MS/MS	 fragmentation	spectrum	 for	 the	WT	HDAC8	 tryptic	peptide	 (parent	 ion	 m/z	 =	 1006.98,	 [M	 +	 2H]2+)	 shows	 many	 of	 the	 expected	 y	 ions	
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(Appendix	2,	Figure	S4).		Similarly,	the	MS/MS	fragmentation	spectrum	for	the	SAHA-TAP	treated	HDAC8	tryptic	peptide	(parent	ion	m/z	=	1059.53	[M	+	2H]2+)	shows	many	y	ions,	including	the	characteristic	peak	of	m/z	=	1511.82	(Appendix	2,	Figure	S5).	 	This	peak	 is	indicative	 of	 a	 covalent	 modification	 of	 m/z	 =	 162.1	 for	 the	 HDAC8	 tryptic	 fragment	 at	Cys153.		These	data	prove	that	the	covalent	modification	of	Cys153	is	occurring	to	form	an	adduct	containing	the	SAHA-TAP	promoiety,	as	shown	in	Appendix	2,	Figure	S3.			MS	analysis	 also	 indicated	 that	Cys102,	Cys244,	 and	Cys314	could	be	modified	by	the	 TAP	moiety	 from	 SAHA-TAP.	 	 Importantly,	 the	 peptides	 containing	 surface	 cysteines	(Cys275	 and	 Cys352)	 were	 not	 modified	 with	 TAP,	 suggesting	 that	 activation	 is	 not	nonspecific.	 	Nonetheless,	 the	hypothesized	mechanism	of	activation	 involving	a	covalent	modification	of	Cys	residues	in	HDAC8,	 including	Cys153,	was	observed,	which	can	aid	in	explaining	 the	 inhibition	 of	 HDACs	 by	 SAHA-	 TAP	 even	 in	 the	 absence	 of	 exogenous	nucleophilic	thiols,	as	observed	in	the	in	vitro	assays.				
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Figure	5.4:	HDAC8	tryptic	fragment	MS	data.			(A)	Expected	HDAC8	Cys153	peptide	upon	digestion	with	trypsin	(Cys153	in	bold).		The	expected	MS	ion	for	the	WT	protein	 is	shown	along	with	the	expected	 ion	 for	 the	peptide	 including	the	covalent	addition	of	 the	TAP	 promoiety	 on	 Cys153.	 	 (B)	 The	 tryptic	 fragment	 of	WT	HDAC8	 (tR	=	 84.5	min)	 is	 consistent	with	 the	expected	 [M	 +	 2H]2+	 ion.	 	 (C)	 After	 treatment	 of	 HDAC8	 with	 SAHA-	 TAP	 (12	 equiv)	 and	 digestion	 with	trypsin,	a	peak	aligning	with	the	expected	[M	+	2H]2+	ion	is	observed	(tR	=	88.5	min).				
In	vitro	Time	Dependence	of	SAHA-TAP	HDAC	Inhibition.			With	 the	 MS	 data	 in	 hand	 confirming	 covalent	 modification	 of	 Cys	 residues	 in	HDAC8,	we	 sought	 to	 investigate	 the	kinetics	of	 inhibition	of	HDAC8	by	SAHA-TAP	using	the	Fluor-de-Lys	activity	assay	(Enzo	Life	Sciences).		A	previous	study	determined	that	the	catalytic	 activity	 and	 thus	 inhibition	of	HDAC8	 is	dependent	on	 the	 identity	of	 the	 active	site	metal	ion	(e.g.,	Co2+,	Fe2+,	Zn2+,	and	Ni2+)	(57).		To	obtain	the	most	accurate	results,	apo-
TAP using the Fluor-de-Lys activity assay (Enzo Life Sciences).
A previous study determined that the catalytic activity and thus
inhibition of HDAC8 is dependent on the identity of the active
site metal ion (e.g., Co2+, Fe2+, Zn2+, and Ni2+).28 To obtain the
most accurate results, apo-HDAC8 (human, recombinant) was
initially prepared before the addition of Zn2+ in a 1:1
stoichiometry. An initial test of HDAC8 inhibition by
preincubation of the enzyme with SAHA-TAP demonstrated
that activity loss occurred within the first 0.5 h (data not
shown). To determine the kinetics for the time-dependent
Figure 4. HDAC8 tryptic fragment MS data. (a) Expected HDAC8 Cys153 peptide upon digestion with trypsin (Cys153 in bold). The expected MS
ion for the WT protein is shown along with the expected ion for the peptide including the covalent addition of the TAP promoiety on Cys153. (b)
The tryptic fragment of WT HDAC8 (tR = 84.5 min) is consistent with the expected [M + 2H]
2+ ion. (c) After treatment of HDAC8 with SAHA-
TAP (12 equiv) and digestion with trypsin, a peak aligning with the expected [M + 2H]2+ ion is observed (tR = 88.5 min).
Figure 5. Time dependence of HDAC8 inhibition. (a) WT HDAC8 (0.5 μM) progress curves at varying concentrations (0−20 μM) of SAHA-TAP.
Dependence of both the (b) initial rate, v0, and (c) kobs on the concentration of SAHA-TAP. (d) C153A HDAC8 (2 μM) progress curves at varying
concentrations (0−20 μM) of SAHA-TAP.
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HDAC8	 (human,	 recombinant)	was	 initially	prepared	before	 the	 addition	of	Zn2+	 in	 a	1:1	stoichiometry.	 	 An	 initial	 test	 of	 HDAC8	 inhibition	 by	 preincubation	 of	 the	 enzyme	with	SAHA-TAP	demonstrated	that	activity	loss	occurred	within	the	first	0.5	h	(data	not	shown).		To	 determine	 the	 kinetics	 for	 the	 time-dependent	 inhibition	 by	 SAHA-TAP,	 HDAC8	progress	curves	were	measured	 through	a	range	of	 inhibitor	concentrations	(Figure	5.5).		For	these	reactions,	the	Fluor-de-Lys	HDAC8	substrate	(150	μM)	and	SAHA-TAP	(0−20	μM)	were	added	to	each	assay	prior	to	initiating	the	reactions	with	WT	HDAC8	(0.5	μM).		Over	a	time	 course,	 aliquots	 of	 the	 reactions	 were	 stopped	 by	 dilution	 into	 a	 solution	 of	trichostatin	A	and	trypsin,	and	product	formation	was	analyzed	from	the	resulting	change	in	 fluorescence.	 	 Analysis	 of	 the	 HDAC8	 progress	 curves	 in	 the	 presence	 of	 increasing	concentrations	of	SAHA-TAP	demonstrates	a	nonlinear	formation	of	product	with	respect	to	 time.	 	 Equation	 5.1,	 which	 describes	 the	 time-dependent	 decrease	 in	 initial	 velocity	under	steady-state	turnover	conditions	(141,	142),		was	fit	to	the	progress	curves			
(Equation 5.1) 	where	P	represents	production	 formation,	vs	and	v0	represent	 final	and	 initial	velocities,	respectively,	 t	 is	 time,	 C	 is	 the	 initial	 fluorescent	 ratio,	 and	 kobs	 is	 the	 rate	 constant	describing	 the	 transition	 from	 the	 initial	 velocity	 to	 the	 final	 steady-state	 velocity,	reflecting	the	time-dependent	enzyme	inactivation.			This	 fit	 reveals	 that	both	 the	 initial	velocity	and	 the	rate	constant	 for	 inactivation,	
kobs,	have	a	hyperbolic	dependence	on	the	concentration	of	SAHA-TAP	(Figures	5.5b,c).		The	initial	 velocity	 decreases	 with	 an	 apparent	 Ki	 =	 7	 ±	 4	 μM,	 and	 the	 rate	 constant	 for	
€ 
P = (vs ∗ t )+ (v 0 −vs )∗ [1−exp(−kobs ∗ t )]kobs +C
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inactivation	 increases	with	 a	k1/2	 =	8	±	2	μM	 to	 a	maximal	 rate	 constant	of	 0.0013	 s-1	 at	saturating	 SAHA-TAP.	 	 This	 type	 of	 inhibition	 is	 characteristic	 of	 a	 two-step	mechanism	(Scheme	5.1)	 in	which	a	rapid	reversible	step,	such	as	binding	of	SAHA-TAP	to	HDAC8,	 is	followed	 by	 a	 time-dependent	 step,	 consistent	 with	 irreversible	 inactivation	 (141,	 142).		These	 data	 demonstrate	 that	 the	 prodrug,	 SAHA-TAP,	 is	 capable	 of	 binding	 to	 and	inhibiting	HDAC8.		The	time-dependent	decrease	in	activity	is	consistent	with	the	MS	data	demonstrating	the	formation	of	a	covalent	enzyme	adduct.			 (Scheme	5.1)		 For	 comparison,	 progress	 curves	 for	 inhibition	 of	 HDAC8	 with	 the	 competitive	inhibitor	 SAHA	 and	 a	 negative	 control,	 SAHA-OBn,	 were	 evaluated.	 	 These	 assays	 were	performed	 in	 the	 same	manner	 as	 the	 SAHA-TAP	 progress	 curves,	 where	 substrate	 and	inhibitor	were	added	to	the	assay	prior	to	the	addition	of	HDAC8	to	initiate	the	reaction.		In	contrast	 to	the	data	with	SAHA-TAP,	 these	progress	curves	are	 linear	with	no	observable	curvature	 for	 all	 concentrations	 of	 SAHA	 (Appendix	 2,	 Figure	 S6a)	 and	 SAHA-OBn	(Appendix	2,	Figure	S6b).		As	expected,	HDAC8	(0.5	μM)	is	inhibited	>90%	by	SAHA	in	the	concentration	range	tested	(2−8	μM),	which	is	 in	agreement	with	the	250	nM	Ki	reported	for	Zn2+-HDAC8.		SAHA-OBn	(2−10	μM)	does	not	inhibit	the	activity	of	HDAC8.		The	lack	of	inhibition	by	SAHA-	OBn	is	consistent	with	previous	IC50	data	(Table	S1).		Taken	together,	these	 data	 show	 that	 SAHA-TAP	 has	 a	 unique	 mode	 of	 inhibition	 for	 HDAC8	 when	compared	to	SAHA.		This	inhibitor	functions	both	as	a	competitive	inhibitor	and	as	a	time-dependent	inactivator,	in	contrast	to	the	linear,	time-	independent	inhibition	observed	for	SAHA.			
E + I E I E I
KI kobs
	 165	
To	 determine	 the	 role	 of	 Cys153	 in	 the	 time-dependent	 inhibition	 of	 HDAC8,	 a	Cys153Ala	 (C153A)	 HDAC8	 mutant	 was	 prepared	 and	 purified.	 	 In	 vitro	 assays	 for	 the	mutant	were	conducted	under	the	same	conditions	used	for	WT	HDAC8.	 	Progress	curves	for	 these	 assays	 reveal	 dose-responsive	 inhibition	 with	 Ki	 =	 8	 ±	 4	 μM	 for	 SAHA-TAP	(Figures	5.5d	and	Appendix	2,	Figure	S7).	 	Furthermore,	 these	progress	curves	are	 linear	for	 all	 concentrations	 of	 inhibitor,	 showing	 a	 loss	 of	 the	 time-dependent	 inhibition	observed	with	WT	HDAC8.		This	data	suggests	that	SAHA-TAP,	containing	the	same	linker	spacer	and	capping	group	as	SAHA,	can	bind	HDAC8	 in	a	noncovalent	manner,	 inhibiting	the	 enzyme	 (Scheme	 5.1).	 	 The	 linear	 progress	 curves	 also	 demonstrate	 that	 Cys153	 is	important	 for	 the	 time-dependent	 inactivation,	 eliminating	 an	 alternate	 explanation	 that	the	 time-dependent	 inhibition	 is	 due	 to	 the	 slow	 formation	 of	 SAHA	 from	 SAHA-TAP.		Progress	curves	with	C153A	HDAC8	measured	with	SAHA	and	SAHA-OBn	data	reveal	that	the	 HDAC8	 mutant	 remains	 susceptible	 to	 inhibition	 by	 SAHA	 and	 not	 SAHA-OBn	(Appendix	2,	Figure	S8).			Collectively,	these	data	indicate	both	that	SAHA-TAP	binds	noncovalently	to	HDAC8	to	inhibit	the	activity	and	that	the	time-dependence	mainly	reflects	the	reaction	of	SAHA-TAP	with	Cys153.		Although	the	MS	data	suggests	that	SAHA-TAP	can	react	with	other	Cys	residues	 in	HDAC8,	 leading	 to	 SAHA	 release,	 C153A	HDAC8	 is	 not	 inactivated	 in	 a	 time-dependent	manner,	demonstrating	the	importance	of	this	particular	Cys	in	the	mechanism	of	 inhibition	 for	 the	WT	 enzyme.	 	 The	 combination	 of	 the	 enzyme	 kinetics	 and	MS	 data	provides	 evidence	 that	 the	 inactivation	 of	 HDAC8	 by	 SAHA-TAP	 involves	 two	 steps:	noncovalent	binding	of	SAHA-TAP	to	HDAC8	followed	by	covalent	modification	of	Cys153.				
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Figure	5.5:	Time	dependence	of	HDAC8	inhibition.			(A)	WT	HDAC8	(0.5	μM)	progress	curves	at	varying	concentrations	(0−20	μM)	of	SAHA-TAP.		Dependence	of	both	the	(B)	initial	rate,	v0,	and	(C)	kobs	on	the	concentration	of	SAHA-TAP.		(d)	C153A	HDAC8	(2	μM)	progress	curves	at	varying	concentrations	(0−20	μM)	of	SAHA-TAP.				
Plasma	Stability.			As	mentioned	 earlier,	 SAHA	 suffers	 from	poor	PK	properties,	 including	hydrolytic	instability	 with	 t	 ∼1/2	 1.5	 h.	 	 To	 determine	 the	 stability	 of	 SAHA-TAP	 in	 a	 biologically	relevant	 model,	 human	 plasma	 stability	 studies	 were	 conducted	 as	 previously	 reported	(143).		After	incubating	SAHA	or	SAHA-TAP	in	human	plasma,	aliquots	were	withdrawn	at	various	time	points	(0,	15,	30,	60,	and	120	min),	quenched	with	acetonitrile,	 filtered,	and	evaluated	via	analytical	HPLC.	 	The	percent	parent	compound	remaining	was	determined	by	integrating	the	area	under	the	curve	and	comparing	this	number	with	the	initial	sample	
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of	 parent	 compound	 at	 an	 incubation	 time	 of	 0	min.	 	 Approximately	 72%	 of	 SAHA-TAP	remained	 after	 1	 h	 incubation	 at	 37	 °C,	 whereas	 only	 ∼60%	 of	 SAHA	 remained	 under	identical	 conditions.	 	 Only	 ∼50%	 of	 either	 parent	 compound	 remained	 after	 a	 2	 h	incubation	at	37	°C	(Figure	5.6a).	 	After	2	h	 incubation	at	37	°C,	the	HPLC	trace	of	SAHA-	TAP	showed	 that	 the	major	degradation	peak	 (∼23%)	corresponds	 to	SAHA,	with	∼52%	SAHA-TAP	 remaining	and	∼25%	other	products.	 	This	 suggests	 that	hydrolysis	of	 SAHA-	TAP	to	SAHA	is	a	major	component	of	the	degradation	process	in	human	plasma	(Appendix	2,	 Figure	 S9).	 	 For	 comparison,	 after	 a	 2	 h	 incubation	 in	 human	 plasma	 under	 identical	conditions,	 the	 HPLC	 chromatogram	 for	 SAHA	 shows	 the	 emergence	 of	 a	 series	 of	 new	unidentifiable	peaks	(∼45%),	with	∼55%	SAHA	remaining	(Appendix	2,	Figure	S9).	 	Even	though	SAHA-TAP	gradually	degrades	over	this	2	h	period,	it	is	relatively	slow	and	results	in	the	release	of	 the	active	drug	SAHA.	 	Efforts	to	 identify	other	product	peaks	via	LC-MS	were	inconclusive.		Overall,	this	study	indicates	that	SAHA-TAP	has	a	moderately	improved	stability	profile	than	SAHA	in	human	plasma.				
Cell	Proliferation	Studies.			With	the	kinetics	of	activation	and	plasma	stability	of	SAHA-TAP	elucidated,	we	then	studied	the	effect	of	SAHA-TAP	on	the	proliferation	of	a	variety	of	cell	lines.		Because	SAHA	is	FDA-approved	for	CTCL,	we	selected	HH	(CTCL)	and	Jurkat	(T-cell	leukemia)	cell	lines	for	analysis.		The	viability	of	NIH/3T3	(mouse	embryo	fibroblast)	was	also	tested	to	determine	the	toxicity	of	each	compound	for	a	noncancer	cell	 line.	 	The	EC50	values	of	SAHA,	SAHA-TAP,	and	SAHA-OBn	are	shown	in	Figure	5.6b	for	each	cell	line.		The	observed	EC50	values	of	 SAHA	 for	 HH	 and	 for	 Jurkat	 cell	 lines	 were	 1.03	 ±	 0.21	 μM	 and	 1.66	 ±	 0.14	 μM,	
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respectively,	consistent	with	previously	reported	data	(144,	145).		SAHA-TAP	is	∼3−4-fold	less	potent	 than	SAHA,	but	 it	 is	 still	 an	 active	 compound,	with	 calculated	EC50	values	of	3.38	±	0.30	μM	and	6.05	±	0.14	μM	for	HH	and	Jurkat	cells,	respectively.		This	difference	in	potency	may	be	 attributed	 to	 the	 alkylated	Cys	 affecting	 the	binding	of	 SAHA	 to	HDAC8;	further	structural	studies	are	needed	to	confirm	this	hypothesis.		Interestingly,	SAHA	also	is	toxic	 for	NIH/3T3	cell	 lines,	with	a	calculated	EC50	of	4.80	±	0.99	μM.	 	Other	studies	also	report	cytotoxicity	of	healthy	kidney	cells	(Vero)	after	treatment	with	SAHA	(EC50	=	5.20	±	0.96	 μM)	 (57).	 	 Unfortunately,	 cell	 proliferation	 studies	 indicate	 that	 SAHA-TAP	 is	 also	slightly	 toxic	 for	 NIH/	 3T3	 cells	 with	 an	 apparent	 EC50	 value	 of	 9.37	 ±	 1.21	 μM.	 	 As	expected,	cell	proliferation	is	unaffected	by	the	addition	of	SAHA-OBn	for	all	cells	studied.			
	
Intracellular	Target	Validation.			With	the	cell	proliferation	data	 in	hand	for	both	 Jurkat	and	HH	cells,	we	sought	 to	validate	 the	 intracellular	 target	 of	 SAHA-TAP	 using	western	 blotting	 techniques.	 	 Broad-spectrum	 HDACi	 are	 known	 to	 increase	 the	 steady-state	 accumulation	 of	 tubulin,	 an	endogenous	HDAC	substrate	and	a	common	marker	for	intracellular	HDAC6	activity	(146,	
147).		For	these	experiments,	SAHA	was	used	as	a	positive	control,	since	it	has	been	shown	to	 dramatically	 increase	 tubulin	 acetylation	 in	 a	 variety	 of	 cells	 (145,	 148).	 	 Indeed,	 we	observed	that	SAHA-TAP	increased	tubulin	acetylation	in	both	Jurkat	and	HH	cells	without	disturbing	 actin	 levels	 (Figure	 5.6c),	 suggesting	 that	 the	 antiproliferative	 mechanism	 of	action	for	SAHA-TAP,	like	SAHA,	involves	nonspecific	HDAC	inhibition.		
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Figure	5.6:	SAHA-TAP	cell	proliferation	and	potency		(a)	Plasma	stability	for	SAHA	(red	circles)	and	SAHA-TAP	(black	squares)	over	time	(mean	±	SD).		(b)	Cellular	EC50	values	(μM)	obtained	from	the	MTS	cell	proliferation	assay.		NI,	no	inhibition	at	50	μM.		(c)	Western	blot	analysis	 of	 tubulin	 acetylation	 for	 Jurkat	 (lanes	 1−5)	 and	 HH	 (lanes	 6−10)	 cells.	 	 Lane	 1,	 control	 (no	treatment);	 lane	2,	SAHA	(1.5	μM);	 lane	3,	SAHA	(20	μM);	 lane	4,	SAHA-TAP	(6	μM);	 lane	5,	SAHA-TAP	(20	μM);	lane	6,	control	(no	treatment);	lane	7,	SAHA	(1.5	μM);	lane	8,	SAHA	(20	μM);	lane	9,	SAHA-TAP	(6	μM);	lane	10,	SAHA-	TAP	(20	μM).				
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Conclusions	A	 thiol-sensitive	 prodrug	 of	 the	 FDA-approved	 HDACi	 SAHA	 has	 been	 developed	that	displays	a	time-dependent	inhibition	of	HDAC8.		SAHA-TAP	functions	as	a	dual-mode	HDAC	inhibitor	with	both	a	covalent	modification	and	a	noncovalent,	conventional	mode	of	action.		SAHA-TAP	is	susceptible	to	nucleophilic	attack	by	Cys	residues	on	the	target	HDAC,	particularly	 the	 conserved	Cys153	 residue	 in	 the	 catalytic	 domain	 of	HDAC8.	 	 These	Cys	residues	are	covalently	modified	with	the	promoiety,	inactivating	the	enzyme,	followed	by	the	 release	 of	 the	 competitive	 inhibitor	 SAHA.	 	 Proteomic	 MS	 confirms	 that	 this	modification	 occurs	 at	 Cys153,	 and	 the	 kinetics	 of	 inhibition	 show	 unambiguous	 time-dependent	 inhibition	 of	HDAC8	 by	 SAHA-TAP,	 indicative	 of	 a	 covalent	modification	with	release	of	SAHA.		The	HDAC8	C153A	mutant	retains	the	noncovalent	mode	of	inhibition	by	SAHA-TAP	(Scheme	5.1),	whereas	the	time-dependent	mode	of	inhibition	disappears.		This	result	demonstrates	the	importance	of	the	active	site	Cys	in	the	inactivation	of	HDAC8	by	SAHA-TAP.	 	 The	 stability	 of	 SAHA-TAP	 in	 human	 plasma	 is	 slightly	 improved,	with	 slow	conversion	to	SAHA	observed.	 	 In	contrast,	SAHA	is	rapidly	degraded	to	several	products	under	 identical	 conditions,	 consistent	 with	 previous	 literature	 studies.	 	 Finally,	 cellular	proliferation	 studies	 show	 a	 clear	 dose−response	 relationship	 with	 SAHA-TAP	 for	 two	distinct	 cancer	 cell	 lines,	 with	 only	 moderately	 inferior	 EC50	 values	 compared	 to	 SAHA;	immunoblotting	 confirms	 that	 the	 antiproliferative	 mechanism	 of	 action	 of	 SAHA-TAP	involves	HDAC	inhibition.		To	the	best	of	our	knowledge,	SAHA-TAP	is	the	first	dual-mode	HDAC	proinhibitor	 that	exploits	 the	modification	of	endogenous,	 conserved	Cys	 residues,	namely,	 the	 catalytic	 site	 Cys153	 residue	 in	 HDAC8,	 to	 generate	 a	 covalent	 adduct	 in	addition	to	releasing	a	competitive	inhibitor.	
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Experimental	Section	
Enzyme	Inhibition	Assays.			HDAC-1,	 -2,	 -3,	 -6,	 and	 -8	 activity	 was	 determined	 in	 vitro	 with	 an	 optimized	homogeneous	assay	performed	in	a	384-well	plate.		Recombinant,	full-length	HDAC	protein	(BPS	 Biosciences)	 was	 incubated	 with	 fluorophore-conjugated	 substrate,	 MAZ1600	 and	MAZ1675,	at	[substrate]	=	Km	(MAZ1600;	11	μM	for	HDAC1,	18	μM	for	HDAC2,	9	μM	for	HDAC3,	 4	 μM	 for	HDAC6;	MAZ1675;	 263	 μM	 for	HDAC8).	 	 Reactions	were	 performed	 in	assay	 buffer	 (50	 mM	 HEPES,	 100	 mM	 KCl,	 0.001%	 Tween-20,	 0.05%	 BSA,	 pH	 7.4,	 and	additional	200	μM	TCEP	was	added	for	HDAC6)	and	followed	by	fluorogenic	release	of	7-amino-4-	methylcoumarin	from	substrate	upon	deacetylase	and	trypsin	enzymatic	activity.		Flourescence	measurements	were	obtained	every	5	min	using	a	multilabel	plate	reader	and	plate	 stacker	 (Envision;	PerkinElmer).	 	 Each	plate	was	 analyzed	by	plate	 repeat,	 and	 the	first	 derivative	 within	 the	 linear	 range	 was	 imported	 into	 analytical	 software	 (Spotfire	DecisionSite).	 	 Replicate	 experimental	 data	 from	 incubations	 with	 inhibitor	 were	normalized	 to	 DMSO	 controls	 ([DMSO]	 <	 0.5%).	 	 IC50	 values	 are	 determined	 by	 logistic	regression	with	unconstrained	maximum	and	minimum	values.			
	
Mass	Spectrometry	Experiments.			Preparation.	 	 An	 aliquot	 of	 HDAC8	 (1.7	 μM)	 was	 incubated	 with	 SAHA-TAP	 (12	equiv,	 20	 μM)	 at	 37	 °C	 for	 1	 h.	 	 The	 protein	 was	 purified	 by	 SDS-PAGE	 followed	 by	Coomassie	staining	prior	to	analysis.			
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In	Gel	Digest.			The	gel	slices	of	interest	were	cut	to	1	mm	cubes	and	destained	three	times	by	first	washing	 with	 100	 mM	 ammonium	 bicarbonate	 (100	 μL)	 for	 15	 min	 followed	 by	 the	addition	of	ACN	 (100	μL)	 for	15	min.	 	The	 supernatant	was	 collected,	 and	 samples	were	dried	in	a	SpeedVac.		The	samples	were	then	reduced	by	the	addition	of	100	μM	ammonium	bicarbonate/10	 mM	 DTT	 (200	 μL)	 and	 incubated	 at	 56	 °C	 for	 30	 min.	 	 The	 liquid	 was	removed,	and	100	mM	ammonium	bicarbonate/55	mM	iodoacetamide	(200	μL)	was	added	to	 gel	 pieces	 and	 incubated	 at	 RT	 in	 the	 dark	 for	 20	 min.	 	 After	 the	 removal	 of	 the	supernatant	 and	 one	 wash	 with	 100	 mM	 ammonium	 bicarbonate	 for	 15	 min,	 the	 same	volume	of	ACN	was	added	to	dehydrate	the	gel	pieces.		The	solution	was	then	removed,	and	the	samples	were	dried	 in	a	SpeedVac.	 	For	digestion,	enough	solution	of	 ice-cold	trypsin	(0.01	μg/mL)	in	50	mM	ammonium	bicarbonate	was	added	to	cover	the	gel	pieces,	which	were	 then	 incubated	 on	 ice	 for	 30	min.	 	 After	 complete	 rehydration,	 the	 excess	 trypsin	solution	was	removed,	replaced	with	fresh	50	mM	ammonium	bicarbonate,	and	incubated	overnight	at	37	°C.		The	peptides	were	extracted	twice	by	the	addition	of	0.2%	formic	acid	and	5%	ACN	(50	μL)	and	vortex	mixing	at	RT	for	30	min.	 	The	supernatant	was	removed	and	saved.		A	total	of	50	μL	of	50%	ACN/0.2%	formic	acid	was	added	to	the	sample,	which	was	vortexed	again	at	RT	for	30	min.	 	The	supernatant	was	removed	and	combined	with	the	supernatant	from	the	first	extraction.		The	combined	extractions	were	analyzed	directly	by	LC-MS.			
	 173	
	
LC-MS/MS.			Trypsin-digested	 peptides	 were	 analyzed	 by	 HPLC	 coupled	 with	 tandem	 mass	spectrometry	 (LC-MS/MS)	 using	 nanospray	 ionization.	 	 The	 nanospray	 ionization	experiments	were	performed	using	a	TripleTOF	5600	hybrid	mass	 spectrometer	 (SCIEX)	interfaced	with	nanoscale	reversed-phase	HPLC	(Tempo)	using	a	10	cm	×	100	μm	i.d.		glass	capillary	 packed	 with	 5	 mm	 C18	 Zorbax	 beads	 (Agilent	 Technologies).	 	 Peptides	 were	eluted	from	the	C18	column	into	the	mass	spectrometer	using	a	linear	gradient	(5−	60%)	of	ACN	at	a	flow	rate	of	250	μL/min	for	1	h.		The	buffers	used	to	create	the	ACN	gradient	are	buffer	A	(98%	H2O,	2%	ACN,	0.2%	formic	acid,	and	0.005%	TFA)	and	buffer	B	(0.2%	formic	acid	and	0.005%	TFA	in	ACN).		MS/MS	data	were	acquired	in	a	data-	dependent	manner	in	which	the	MS1	data	was	acquired	for	250	ms	at	m/z	of	400	to1250	Da	and	the	MS/MS	data	was	acquired	from	m/z	of	50	to	2000	Da.		Independent	data	acquisition	(IDA)	parameters	were	MS1-TOF	250	ms	followed	by	50	MS2	events	of	25	ms	each.		The	IDA	criteria	were	as	follows:	 over	 200	 counts	 threshold,	 charge	 state	 +2−4,	 with	 4	 s	 exclusion.	 	 Finally,	 the	collected	data	were	analyzed	using	MASCOT	(Matrix	Sciences).			
	
Protein	Expression	and	Purification.			Recombinant	 human	 HDAC8	 in	 a	 pET-20b-derived	 plasmid	 with	 an	 added	 C-terminal	TEV	protease	cleavage	site	and	His6	tag	(termed	pHD)	was	expressed	and	purified	in	Escherichia	coli	BL21(DE3)	according	to	Gantt	and	co-workers	(57),	with	the	following	modification:	 elution	 from	 the	 nickel	 columns	 was	 performed	 using	 a	 linear	 gradient	(10−250	mM	imidazole).		In	the	preparation	of	apo-enzyme,	HDAC8	was	dialyzed	twice	at	4	
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°C	against	4	L	of	25	mM	MOPS,	1	mM	EDTA,	5	mM	KCl,	1	mM	TCEP,	pH	7.5,	followed	by	four	times	against	2	L	of	25	mM	MOPS,	5	mM	KCl,	1	mM	TCEP,	pH	7.5.		All	components	were	free	of	transition	metals,	and	dialysis	occurred	in	plasticware	that	had	been	washed	with	EDTA	and	rinsed	with	Milli-Q	ddH2O.		Apo-	enzyme	was	stored	at	−80	°C	in	the	same	metal-free	buffer.	 	The	Cys153Ala	HDAC8	mutant	was	constructed	in	a	pHD4	TEV-His	plasmid,	using	the	 QuikChange	 site-directed	 mutagenesis	 protocol	 and	 kit,	 and	 the	 mutation	 was	confirmed	by	the	UM	DNA	sequencing	facility.	 	This	construct	was	expressed	and	purified	in	the	same	manner	as	wild-type	enzyme.			
	
HDAC8	Time-Course	Inhibition	Experiments.			Recombinant	WT	or	C153A	mutant	human	HDAC8	was	reconstituted	for	1	h	on	ice	at	a	1:1	stoichiometry	(at	10	μM)	with	Zn2+	in	1×	HDAC	assay	buffer	(25	mM	HEPES,	3	mM	KCl,	 137	mM	NaCl,	 pH	 8.0).	 	 The	 5	 and	 50	mM	 SAHA-TAP,	 SAHA-OBn,	 and	 SAHA	 stocks	were	serially	diluted	into	decreasing	concentrations	of	DMSO	to	maintain	solubility	of	the	compounds.	 	 Reaction	 mixtures	 of	 1×	 HDAC	 assay	 buffer,	 150	 μM	 Fluor-de-Lys	 peptide	substrate	 (R−H−K(Ac)−K(Ac)−fluoro-	 phore)	 (Enzo	 Life	 Sciences),	 and	 various	concentrations	of	inhibitors	(SAHA-TAP,	SAHA-OBn,	or	SAHA)	were	prepared	and	allowed	to	equilibrate	at	30	°C.		The	final	DMSO	content	was	<1%.		Assays	were	initiated	by	addition	of	 wild-type	 (0.5	 μM)	 or	 Cys153Ala	 mutant	 (2	 μM)	 HDAC8.	 	 At	 various	 time	 points,	 a	reaction	aliquot	(5	μL)	was	diluted	into	a	Fluor-de-Lys	quench	solution	(45	μL)	containing	trypsin	and	trichostatin	A	(TSA).		Assays	were	read	in	96-well	plates	(Corning	3686)	using	a	PolarStar	fluorescent	plate	reader.		The	fluorescence	corresponding	to	product	formation	(λex	=	340	nm,	λem	=	450	nm)	and	remaining	substrate	(λex	=	340	nm,	λem	=	380	nm)	was	
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measured,	 and	 the	 ratio	 of	 product	 formed/remaining	 substrate	 is	 reported.	 	 Standard	curves	 demonstrate	 that	 this	 fluorescent	 ratio	 linearly	 reflects	 product	 under	 these	conditions.			
Cell	Proliferation	Studies.			HH	and	Jurkat	cell	lines	were	obtained	from	ATCC	(Manassas,	VA,	USA)	and	grown	in	RPMI	1640	medium	supplemented	with	10%	 fetal	bovine	 serum	(Gibco,	Grand	 Island,	NY,	USA).		The	NIH/3T3	cell	line	was	kindly	donated	by	Dr.	Richard	Klemke	and	grown	in	DMEM	medium	supplemented	with	10%	fetal	bovine	serum	(Gibco,	Grand	Island,	NY,	USA)	at	 37	 °C	 in	 an	 incubator	 with	 5%	 CO2.	 	 The	 CellTiter	 96	 aqueous	 one	 solution	 cell	proliferation	 assay	 (MTS)	 kit	 was	 purchased	 from	 Promega	 (Madison,	 WI,	 USA).	 	 Cell	viability	was	measured	using	the	MTS	assay	according	to	the	manufacturer’s	protocol.		To	start	the	assay,	cells	were	counted	with	a	hemocytometer,	diluted	with	fresh	medium	to	the	proper	concentration,	and	seeded	in	96-well	plates	(5000	cells/well	for	NIH/	3T3	and	20	000	 cells/well	 for	 HH	 and	 Jurkat).	 	 Jurkat	 and	 HH	 cells	 were	 then	 directly	 incubated	 in	media	 containing	 the	 various	 concentrations	 of	 drugs	 for	 70	 h	 (ranging	 from	0.5	 to	 128	μM).	 	NIH/3T3	cells	were	first	incubated	at	37	°C	with	5%	CO2	for	16	h	prior	to	the	drug	treatment	for	cell	attachment.		The	cells	were	then	treated	with	various	concentrations	of	drugs	for	70	h.		The	CellTiter	96	aqueous	one	solution	was	added	(20	μL	per	well),	and	the	plate	was	incubated	at	37	°C	for	2	h	(NIH	3T3)	or	4	h	(HH	and	Jurkat).		The	absorbance	was	recorded	at	490	nm	using	the	BioTek	Synergy	HT	microplate	reader.		Each	concentration	of	drug	treatment	was	conducted	in	triplicate	for	each	trail,	with	2−3	trials	conducted.			
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Plasma	Stability.			The	plasma	stability	of	SAHA	and	SAHA-TAP	was	 investigated	with	pooled	normal	human	 plasma	 (Innovative	 Research,	 Novi,	 MI).	 	 In	 duplicate,	 plasma	 (1.0	 mL)	 was	preincubated	for	2	min	at	37°C	followed	by	the	addition	of	20	μL	of	a	5.0	mM	stock	solution	(DMSO).		Aliquots	(100	μL)	were	withdrawn	at	0,	15,	30,	60,	and	120	min	and	immediately	quenched	 with	 100	 μL	 of	 ACN	 to	 precipitate	 the	 proteins.	 	 The	 samples	 were	 vortexed	thoroughly	and	centrifuged	for	2	min	at	13	000	rpm.	 	The	supernatant	was	collected	and	centrifuged	 through	0.2	μm	spin	 filters	 (Corning)	 for	5	min	 at	8000	 rpm.	 	 Samples	were	then	 frozen	 until	 analyzed	 by	 HPLC	 with	 the	 following	 method:	 analytical	 HPLC	 was	performed	 on	 a	 HP	 Series	 1050	 system	 equipped	 with	 a	 Poroshell	 120	 reverse-phase	column	(EC-C18,	4.6	×	100	mm,	2.7	μm).		Separation	was	achieved	with	a	flow	rate	of	1	mL	min−1	and	the	following	mobile	phase:	2.5%	ACN	+	0.1%	formic	acid	in	H2O	(A)	and	0.1%	formic	acid	in	ACN	(B).		Starting	with	95%	A	and	5%	B,	a	linear	gradient	was	run	for	15	min	to	a	 final	solvent	mixture	of	5%	A	and	95%	B,	which	was	held	 for	5	min	before	ramping	back	down	to	95%	A	and	5%	B	over	the	course	of	2	min,	with	constant	holding	at	this	level	for	4	additional	min.			
	
Western	Blot	Analysis.			Log	 phase	 growing	 HH	 and	 Jurkat	 cell	 lines	 were	 cultured	 until	 70%	 percent	confluent	 and	 treated	 with	 specified	 concentrations	 of	 compounds	 for	 4	 h	 prior	 to	harvesting.	 	 Cells	 were	 spun	 at	 250g	 and	 washed	 with	 DPBS	 buffer	 (Life	 Technologies)	before	lysis	using	RIPA	buffer	(50	mM	Tris-HCl	(pH	7.5),	150	mM	Na2EDTA,	1%	Nonidet	P-40,	1%	sodium	deoxycholate,	0.1%	sodium	dodecyl	sulfate)	supplemented	with	complete	
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protease	inhibitor	cocktail	(Roche)	for	30	min	on	ice.		Samples	were	then	spun	at	12	000g	before	quantification	of	total	protein	concentration	using	a	BCA	assay	(Thermo).		Dilutions	were	made	to	normalize	total	protein	concentration	for	each	gel	sample.		Diluted	samples	were	then	run	on	a	10%	SDS-PAGE	gel	at	100	V	for	2	h	before	transfer	onto	Immobilon-P	PVDF	Membrane	(EMD	Millipore)	at	100	V	for	45	min	before	blocking	in	5%	(v/v)	Casein-TBST	 (Tris-buffered	 saline	 Tween-20;	 0.05%	 Tween-20	 v/v)	 at	 4	 °C.	 	 Blots	 were	 then	incubated	with	monoclonal	mouse	 anti-acetylated	 tubulin	 (Life	Technologies),	 polyclonal	rabbit	 anti-tubulin	 (Sigma),	 or	 anti-actin−HRP	 (Santa	 Cruz)	 in	 5%	 (v/v)	 BSA-TBST	 at	dilutions	 according	 to	 manufacturer’s	 instructions	 overnight	 at	 4	 °C.	 	 Blots	 were	 then	washed	 by	 three	 5	 min	 washes	 in	 TBST	 (0.05%	 v/v);	 anti-acetylated	 tubulin	 and	 anti-tubulin	antibodies	were	 then	 incubated	with	HRP-conjugated	anti-mouse	 (Santa	Cruz)	or	anti-rabbit	 (Pierce)	 antibodies.	 	 Detection	 was	 performed	 using	 SuperSignal	 West	 pico	substrate	(Pierce)	with	10%	(v/v)	SuperSignal	West	femto	substrate	(Pierce)	and	imaged	on	ChemiDoc	XRS+	System	with	Image	Lab	Software	(Bio-Rad).			
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Chapter	6	
Conclusions	and	Future	Directions	
Overview	The	acetylome	has	grown	from	histone	 tails	at	 its	discovery	 in	 the	early	1960’s	 to	almost	 2,000	 proteins	 in	 2009	 (86,	 149,	 150).	 	 In	 the	 7	 years	 since,	 that	 number	 has	continued	to	grow,	and	acetylation	has	now	been	documented	on	over	7,000	proteins	(6).		Acetylation	 is	 known	 to	 affect	 proteins	 in	 virtually	 every	 cellular	 process,	 including	 cell	cycle,	metabolism,	and	gene	expression	(86).		With	the	acetylome	expanding,	research	has	also	 increased	 into	 understanding	 the	 regulation	 of	 this	 dynamic	 post-translational	modification.	 	 The	 catalysts	 of	 lysine	 acetylation	 and	 deacetylation	 are	 the	 lysine	acetyltransferases	and	histone	deacetylases,	respectively.	 	The	first	human	HDAC,	HDAC1,	was	annotated	more	than	30	years	after	the	discovery	of	histone	acetylation	(151).		Today,	there	are	18	deacetylases	capable	of	the	negative	regulation	of	lysine	acetylation.		Of	these,	there	are	11	metal-dependent	enzymes,	the	Class	I,	II,	and	IV	HDACs	(73).		 While	 research	 is	 rapidly	expanding	 the	knowledge	on	 the	 function	of	HDACs,	 the	field	is	complex	and	still	evolving.		In	this	thesis	I	have	presented	a	body	of	work	that	not	only	 improves	 upon	 the	 understanding	 of	 HDAC8	 and	 HDAC11,	 but	 perhaps	 equally	importantly,	also	describes	a	set	of	methods	and	techniques	that	can	be	applied	to	any	of	the	HDAC	isozymes.				
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Deacetylase	activity	on	peptides	Deacetylation	 of	 peptide	 substrates	 has	 been,	 and	 remains,	 a	 rapid	 and	 effective	method	of	assaying	HDAC	catalysis.		Peptide-based	HDAC	assays	are	useful	methods	when	addressing	a	variety	of	questions,	including	isozyme-specificity	of	inhibitors	(35),	substrate	selectivity	 of	 a	 single	 isozyme	 (152),	 and	 selectivity	 of	 multiple	 HDAC	 isozymes	 against	individual	 substrates	 (61).	 	 HDAC	 catalysis	 on	 peptides	 has	 historically	 involved	methyl-coumarin	labeled	peptides	(87).		Here	we	reported	on	the	advancement	of	several	peptide	substrate-based	methods	 that	do	not	 require	 fluorophore-labeled	peptide,	 allowing	more	freedom	 in	 peptide	 length	 and	 sequence.	 	 These	 various	 techniques	 differ	 in	 their	advantages	 and	 disadvantages,	 making	 some	 more	 useful	 for	 specific	 applications	 than	others.			Previous	 work	 in	 the	 Fierke	 laboratory	 developed	 an	 enzyme-coupled	 assay	 for	HDAC	activity	that	measures	acetate	production	in	a	stopped	format	(76).		I	optimized	this	assay	 so	 that	 it	 can	 be	 run	 as	 a	 continuous	 assay.	 	 In	 doing	 so,	 the	 amount	 of	 time	 and	materials	required	was	reduced.		However,	this	assay	is	now	sensitive	to	the	activity	of	the	coupling	 enzymes	 and	 requires	 that	 HDAC	 deacetylation	 be	 the	 rate-limiting	 step	 of	 the	coupled	 reactions.	 	 This	 continuous	 assay	 is	 well	 suited	 for	 quantifying	 the	 function	 of	HDAC	 inhibitors	 in	 a	 high-throughput	 manner,	 since	 the	 maximum	 rate	 of	 the	 HDAC	reaction	 is	predetermined.	 	 I	also	demonstrated	 that	 two	mass	spectrometry	approaches,	Q-TOF	 HPLC-MS	 and	 MALDI-TOF,	 could	 be	 used	 to	 assay	 HDAC	 deacetylation.	 	 Both	methods	provide	direct	 evidence	 for	HDAC-catalyzed	deacetylation	 of	 peptide	 substrates	by	 determining	 the	 exact	mass	 of	 the	 substrate	 and	 product.	 	 Q-TOF	HPLC-MS	 provides	
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quantifiable	 deacetylation	 data,	 but	 due	 to	 variation	 in	 elution	 times	 and	 the	 differing	ionizability	of	peptides,	multiple	standard	curves	are	needed.	 	The	MALDI-TOF	approach,	while	not	easily	quantitative,	only	requires	a	calibration	curve	of	known	molecular	weight	standards.		This	technique	is	rapid	and	suitable	for	small-volume	reactions.		This	makes	the	MALDI-TOF	approach	best	suited	for	preliminary	screening	of	large	substrate	libraries.	The	ability	to	quickly	and	accurately	measure	HDAC	catalysis	on	unlabeled	peptide	substrates	 was	 instrumental	 to	 the	 initial	 biochemical	 characterization	 of	 HDAC11	(Chapter	 2)	 and	 to	 the	 validation	 of	 substrates	 identified	 for	 both	 HDAC8	 and	 HDAC11	(Chapter	3).	 	 These	methods	 should	 continue	 to	be	useful	 tools	 for	understanding	HDAC	catalysis	and	specificity.				
Expression	and	characterization	of	HDAC11		 HDAC11	 is	 the	 most	 recently	 identified	 and	 one	 of	 the	 most	 poorly	 understood	HDACs	(24).	 	 I	successfully	expressed	and	purified	HDAC11	from	E.	coli,	 insect	cells	(sf9),	and	 human	 HEK293	 cells.	 	 To	 achieve	 sufficient	 expression	 levels	 and	 soluble	 yields	 of	HDAC11	from	bacteria,	I	fused	the	gene	encoding	HDAC11	to	SUMO.		I	also	tested	a	panel	of	molecular	 chaperones	 and	 observed	 that	 co-expression	 of	 SUMO-HDAC11	 with	 trigger	factor	significantly	improved	soluble	yield	of	HDAC11.		Interestingly,	and	perhaps	a	factor	in	 the	 limited	 understanding	 of	 this	 isozyme,	 HDAC11	 expressed	 in	 bacteria	 is	 inactive,	while	HDAC11	expressed	in	insect	cells	and	HEK293	cells	is	catalytically	active.		 Using	 HDAC11	 expressed	 and	 purified	 from	 insect	 cells,	 I	 demonstrated	 that	HDAC11	catalyzes	 the	deacetylation	of	both	methyl-coumarin-labeled	peptides	as	well	as	unlabeled	peptides.	 	 I	measured	activity	with	multiple	unlabeled	peptides	and	 found	that	
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two	peptides	proposed	in	literature	as	substrates	through	pull-down	methods	had	among	the	 most	 rapid	 rates	 of	 deacetylation	 of	 those	 tested.	 	 These	 peptides	 correspond	 to	sequences	 from	 the	DNA	 replication	 factor	Cdt1	 and	histone	H4	K16.	 	We	 also	 observed	that	 the	 best	 HDAC11	 substrates	 from	 this	 initial	 screen	were	 positively	 charged.	 	 After	measuring	 additional	 peptides,	 based	 on	 proteins	 identified	 on	 the	 proteome	 chips	(Chapter	 4),	 the	 data	 suggest	 that	 the	 charge	 at	 the	 +1	 position	 downstream	 of	 the	acetyllysine	may	have	an	impact	of	the	reactivity	of	the	peptide	with	HDAC11	(Table	6.1).		The	 total	 charge	 of	 the	 peptide	 and	 the	 charge	 at	 the	 -1	 positions	 do	 not	 demonstrate	 a	trend.	 	 These	 data,	 based	 on	 rate	 constants	 determined	 for	 HDAC11-catalyzed	deacetylation	of	21	peptides,	refined	our	hypothesis	from	HDAC11	favors	substrates	with	a	positive	 charge	 to	 HDAC11	 favors	 substrates	 with	 a	 positive	 charge	 immediately	downstream	of	the	acetyllysine.	 	A	fit	of	the	dependence	of	Log	(kcat/KM)	on	the	charge	at	the	+1	position	shows	a	trend	toward	increasing	peptide	reactivity	with	positive	charges,	but	the	R-factor	is	not	significant.		The	data	suggest	that	positive	charges	at	the	+1	position	enhance	 reactivity,	 but	 there	 are	 clearly	 more	 determinants	 in	 HDAC11	 specificity.		Measuring	HDAC11-catalyzed	deacetylation	of	a	peptide	 library	with	variability	at	 the	+1	and	 -1	 positions,	 as	 has	 been	 done	 with	 HDAC8,	 will	 help	 to	 elucidate	 the	 role	 of	 local	charges	on	HDAC11	substrate	selectivity.		
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Table	6.1:	Peptide	substrates	used	to	assay	HDAC11	catalytic	activity	Peptides	all	contain	an	acetylated	N-terminus	and	an	amidated	C-terminus.	 	Charged	residues	are	shown	in	red	 (acidic)	 or	 blue	 (basic).	 	 Table	 is	 sorted	 by	 charge	 of	 the	 amino	 acid	 at	 the	 +1	 position,	 immediately	downstream	of	the	acetyllysine.		Proteins	with	multiple	acetylation	sites	tested	are	labeled	with	a	suffix	(a,	b,	
c,	etc.)	
Protein Peptide	Sequence
kcat/KM	
(M-1s-1)
+1	Position	
Charge
GOT1 DAE(K-Ac)RGLD 60 1
H4	K16 KGGA(Kac)RHR 50 1
NIF3L1a RPM(K-Ac)RIT 31 1
CNP DDL(K-Ac)KLK 31 1
Cdt1	K49 GSR(Kac)RAR 30 1
ZBTB21 LAL(K-Ac)RPR 5 1
TCOF1a QV(K-Ac)AEK 175 0
TCOF1b TG(K-Ac)TVA 60 0
CEBPZ KGGKQLN(K-Ac)YDPFSRN 51 0
EIF5a EG(K-Ac)GNG 47 0
TCOF1c SAPG(K-Ac)VVT 33 0
LUC7L EEIG(K-Ac)LLA 18 0
EIF5b EGKGNGI(K-Ac)TVI 16 0
TCOF1d PG(K-Ac)TGPAVAK 8 0
IDH1 KLKQMW(Kac)SPN 7 0
TCOF1e PG(K-Ac)VGD 5 0
C2orf47 KEVLHAL(K-Ac)EKVTSLP 35 -1
NIF3L1b NTW(K-Ac)ER 10 -1
TCOF1f GA(K-Ac)DEP 9 -1
TCOF1g SM(K-Ac)EKA 5 -1
TCOF1h PA(K-Ac)ESP 5 -1 			 Using	 intact	 protein	 mass	 spectra,	 we	 observed	 that	 the	 molecular	 weight	 of	HDAC11	expressed	and	purified	from	insect	cells	was	42	daltons	heavier	than	the	predicted	mass	 based	 on	 amino	 acid	 sequence.	 	 We	 hypothesize	 that	 a	 post-translational	modification,	 occurring	 in	 eukaryotic	 expression	 of	 HDAC11	 but	 not	 in	 prokaryotic	expression,	is	activating	the	enzyme.		A	mass	gain	of	42	daltons	is	consistent	with	both	an	acetyl	 moiety	 and	 trimethylation,	 among	 others.	 	 Post-translational	 modifications	 have	
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been	 identified	 on	 other	 HDAC	 isozymes,	 including	 lysine	 acetylation	 and	 lysine	methylation	of	HDAC1	(86,	153).				 We	collaborated	with	the	Martin	laboratory	to	use	a	bottom-up	mass	spectrometry	approach	 to	 evaluate	 differential	 modifications	 on	 HDAC11	 expressed	 in	 E.	 coli	 and	HDAC11	expressed	in	insect	cells.		We	digested	purified	HDAC11	from	bacterial	and	insect	cells	 with	 Asp-N	 and	 Trypsin,	 separately.	 	 We	 identified	 multiple	 sites	 of	 acetylation	(lysine)	and	methylation	(lysine,	arginine,	glutamine,	glutamate,	and	histidine)	present	on	HDAC11	 expressed	 and	 purified	 from	 insect	 cells	 that	 were	 not	 present	 on	 HDAC11	expressed	and	purified	from	bacteria.		We	also	observed	two	sites	of	methylation	unique	to	
E.	coli	(Table	6.2).		It	is	difficult	to	quantify	the	fraction	of	HDAC11	that	is	modified	in	each	sample.		Based	on	our	intact	protein	spectra,	we	predicted	one	main	modification	but	have	not	yet	observed	this	using	the	bottom-up	approach.		Additionally,	neither	the	Asp-N	digest	nor	 the	 trypsin	 digest	 achieved	 100%	 sequence	 coverage	 of	 HDAC11	 (45%	 and	 80%,	respectively,	with	a	combined	85%).		The	effect	of	post-translational	modifications	at	these	positions	 is	not	 yet	understood;	we	hypothesize	 that	one	or	more	of	 these	modifications	may	activate	HDAC11.		
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Table	6.2:	Unique	PTMs	identified	on	HDAC11	expressed	and	purified	from	sf9	insect	
cells	and	E.	coli	bacterial	cells.	HDAC11	expressed	and	purified	from	sf9	insect	cells	and	E.	coli	bacterial	cells	was	digested	with	Asp-N	and	trypsin.		This	table	includes	only	modifications	unique	to	one	expression	system.		The	modified	residues	are	highlighted	(red).	
protease modification sf9 E.	coli
Asp-N acetylation	(K) DKVERNIKKSLQEHLP -
Asp-N acetylation	(K) DRLGGLSISPAGIVKR -
trypsin acetylation	(K) VINFLKEEK -
trypsin mono-methylation	(K) VINFLKEEK -
Asp-N di-methylation	(K) - DKVERNIKKSLQEHLP
Asp-N di-methylation	(K) - DKVERNIKKSLQEHLP
trypsin tri-methylation	(K) ATIIDLDAHQGNGHERDFMDDK -
trypsin mono-methylation	(E) FLFERVEGISR -
trypsin mono-methylation	(R) FLFERVEGISR -
trypsin mono-methylation	(R) MLHTTQLYQHVPETRWPIVYSPR -
trypsin mono-methylation	(R) LLSDSMLVEAR -
trypsin di-methylation	(R) LLSDSMLVEAR -
trypsin di-methylation	(QH) MLHTTQLYQHVPETRWPIVYSPR - 			 To	 completely	 elucidate	 the	 role	 of	 these	 post-translational	 modifications,	 the	modifications	should	be	inserted	into	HDAC11	expressed	and	purified	from	E.	coli,	followed	by	 measurement	 of	 the	 changes	 in	 HDAC11	 catalytic	 activity	 for	 comparison	 with	 the	activity	 and	 specificity	 of	 HDAC11	 expressed	 in	 sf9	 or	 HEK293	 cells.	 	 Insertion	 of	 the	modifications	 at	 specific	 positions	 could	 be	 accomplished	 through	 the	 incorporation	 of	unnatural	 amino	 acids	 representing	 these	 modifications	 into	 the	 primary	 sequence	 of	HDAC11.		To	this	end,	we	have	used	site-directed	mutagenesis	to	replace	one	lysine,	based	on	those	identified	in	table	6.2,	in	HDAC11	with	an	amber	stop	codon,	and	are	currently	in	the	process	of	using	a	modified	tRNAacK/tRNAacK	synthetase	pair	to	incorporate	acetyllysine	at	 that	 site.	 	 We	 plan	 to	 use	 this	 method	 to	 determine	 the	 effects	 of	 modifications	 at	multiple	 sites.	 	 Identification	 of	 an	 activating	 modification	 on	 HDAC11	 would	 provide	
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insight	into	the	in	vivo	regulation	of	this	enzyme.		It	would	also	provide	a	method	by	which	active	 HDAC11	 could	 be	 expressed	 and	 purified	 from	 E.	 coli,	 allowing	 for	 more	 rapid	expression	 of	 HDAC11	 than	 from	 insect	 cells,	 and	 point	 mutations	 can	 be	 more	 easily	prepared	 and	 expressed	without	 the	need	 to	 create	baculovirus	 stocks	 for	 each	HDAC11	construct.		
Chip-based	substrate	identification	Using	a	chip-based	format,	we	observed	HDAC	catalyzed	deacetylation	on	a	library	of	full-length	human	proteins	in	collaboration	with	the	Cole	laboratory.		This	method	is	an	advance	 in	 the	 field	 for	 identification	 of	 substrate;	 it	 does	 not	 rely	 upon	 stable	 protein-protein	interactions	(pulldowns)	or	the	ability	to	immunoprecipitate	peptides	with	an	anti-acetyllysine	antibody.		Instead,	it	is	an	assay	based	on	changes	in	protein	acetylation	upon	incubation	 with	 an	 HDAC	 isozyme,	 visualized	 by	 fluorescence	 of	 an	 anti-acetyllysine	antibody.	 	 Using	 this	 method	 we	 identified	 44	 putative	 substrates	 of	 HDAC8	 and	 25	putative	 substrates	 of	 HDAC11.	 	 We	 identified	 proteins	 involved	 in	 various	 cellular	pathways,	 including	metabolism	and	gene	 transcription.	 	These	putative	 substrates	were	predominantly	novel	HDAC	targets,	though	some	have	been	identified	previously	(40,	61).		We	found	that	CSRP2BP	and	TCOF1,	both	identified	as	likely	HDAC8	substrates	in	a	SILAC-based	method	(61),	were	also	deacetylated	by	HDAC8	on	the	proteome	chips.	One	 of	 the	 most	 promising	 HDAC8	 substrates	 identified	 through	 the	 chip-based	screen	is	isocitrate	dehydrogenase	1	(IDH1).		I	measured	HDAC8-catalyzed	deacetylation	of	4	peptides	from	this	protein,	and	found	rate	constants	varying	from	less	than	10	to	greater	than	150	M-1s-1.		To	further	validate	IDH1	as	an	HDAC8	substrate,	I	expressed	and	purified	
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five	constructs	of	recombinant	 IDH1,	using	non-natural	amino	acids	to	 incorporate	single	acetyllysine	 residues	 into	 the	 protein	 (IDH1	WT,	 K81ac,	 K93ac,	 K224ac,	 and	 K321ac).	 	 I	incubated	acetylated	IDH1	with	HDAC8	and	observed	changes	in	acetylation	with	time	by	visualizing	 IDH1	 acetylation	 with	 an	 anti-acetyllysine	 antibody.	 	 IDH1	 is	 now	 the	 first	singly-acetylated	full-length	non-histone	protein	demonstrated	to	be	deacetylated	 in	vitro	by	HDAC8.				 To	further	validate	IDH1	as	an	HDAC8	substrate,	I	would	like	to	see	in	vivo	evidence	demonstrating	an	 increase	 in	 IDH1	acetylation	upon	specific	 inhibition	of	HDAC8	in	cells.		IDH1	 acetylation	 could	 be	 verified	 by	 mass	 spectrometry,	 as	 was	 used	 in	 the	 SILAC	experiments,	 or,	 if	 protein	 concentration	 is	 high	 enough,	 it	 could	 be	 pulled-down	 and	verified	by	probing	a	western	blot	with	an	anti-acetyllysine	antibody.		 The	effect	of	acetylation	on	IDH1	is	not	currently	known.		To	address	this	question	we	assayed	IDH1	catalytic	activity	with	isocitrate.	 	We	found	that	acetylation	significantly	reduces	the	activity	of	IDH1,	with	some	acetylation	sites	causing	a	decrease	of	over	103-fold	in	activity.	 	These	data	suggest	that	IDH1	activity	is	negatively	regulated	by	acetylation	 in	
vivo,	and	that	HDAC8	may	function	as	the	deacetylase	that	restores	IDH1	activity	through	site-specific	 deacetylation.	 	 I	 attempted	 to	 rescue	 activity	 of	 acetylated	 IDH1	 in	 vitro	 by	addition	 of	 HDAC8	 (Fig.	 6.1).	 	 Unexpectedly,	 I	 found	 that	 addition	 of	 HDAC8	 did	 not	increase	the	activity	of	acetylated	IDH1.		One	possible	explanation	is	that	HDAC8	and	IDH1	undergo	a	protein-protein	interaction	that	prevents	IDH1	catalysis.		In	agreement	with	this	hypothesis,	 adding	HDAC8	 to	WT	 IDH1	decreases	 IDH1	catalytic	activity.	 	Furthermore,	 I	found	that	adding	saturating	concentrations	of	SAHA	after	adding	HDAC8	to	an	acetylated	IDH1	reaction	resulted	in	an	increase	in	IDH1	activity.		It	is	worth	noting	that	these	data	are	
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a	 preliminary	 finding.	 	 To	 continue	 exploring	 this	 hypothesis,	 these	 reactions	 should	 be	repeated	with	additional	controls.		For	example,	longer	time-course	controls	need	to	be	run	simultaneously	with	 the	HDAC8	 rescue	 experiment.	 	 Additionally,	 pulldown	 experiments	may	provide	evidence	for	an	IDH1-HDAC8	protein	complex.	Finally,	 the	 chip-based	assay	 requires	 that	proteins	 are	acetylated	by	 the	 catalytic	domain	of	p300	in	order	to	be	considered	as	an	HDAC	substrate.		This	will,	inherently,	limit	the	pool	of	potential	substrates.		To	determine	a	more	complete	picture	of	isozyme-specific	HDAC-catalyzed	deacetylation	of	 the	proteome	 chips,	 additional	 lysine	 acetyltransferases	such	as	GCN5	may	need	to	be	used	in	addition	to,	or	in	place	of,	p300.							
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Figure	6.1:	Effect	of	HDAC8	on	acetylated	IDH1	activity	Progress	curves	for	IDH1	WT	(0.01	µM)	and	K224ac	(1	µM)	variant	were	measured	by	monitoring	the	change	in	fluorescence	(ex.		=	350	nm,	em	=	450	nm)	of	the	cofactor	being	reduced	from	NADP+	to	NADPH.		Isocitrate	and	NADP+	were	at	starting	concentrations	of	200	µM	and	75	µM,	respectively.		IDH1	WT	(black)	progressed	at	 a	 rate	 of	 0.077	 F.U./sec,	 reaching	 completion	 in	 less	 than	 2000	 seconds	 and	 had	 a	 steady	 NADPH	fluorescent	signal	through	the	remaining	time	course.		IDH1	K224ac	(red)	progressed	at	a	slower	rate	(0.012	F.U./sec).	 	 At	 2000	 seconds,	 5	 µM	HDAC8	was	 added	 to	 this	 reaction	 (blue).	 	We	had	 expected	 to	 see	 that	addition	of	HDAC8	rescued	IDH1	activity,	but	in	contrast	we	observed	that	by	3000	seconds,	the	rate	of	IDH1	catalysis	 had	 plateaued.	 	 At	 4000	 and	 5000	 seconds,	 5	 µM	 and	 50	 µM	 SAHA	were	 added	 to	 the	 reaction,	respectively	 (green	 and	 pink).	 	 After	 the	 addition	 of	 SAHA,	 the	 fluorescence	 begins	 to	 increase,	 consistent	with	restored	IDH1	activity.		 	
Covalent	inhibition	of	HDAC8	HDAC	inhibitors	play	important	roles	both	as	therapeutics	in	clinical	settings	and	as	biochemical	 tools	 in	basic	 research.	 	Here	we	have	 introduced	 the	 first	dual-mode	HDAC	proinhibitor,	 SAHA-TAP.	 	 In	 collaboration	with	 the	Cohen	 lab,	we	demonstrated	 that	 this	molecule	 covalently	 modifies	 the	 active	 site	 of	 HDAC8	 at	 Cys153	 with	 its	 TAP	 moiety,	
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inactivating	the	enzyme.		Additionally,	upon	thiol-induced	cleavage	of	the	TAP	moiety,	the	competitive	 inhibitor	 SAHA	 is	 released.	 	We	 have	 demonstrated	 that	 SAHA-TAP	 inhibits	HDAC8	in	a	time	dependent	manner,	via	a	two-step	mechanism.		We	hypothesize	that	the	first	 step	 is	 the	 rapid	 binding	 of	 SAHA-TAP	 to	 HDAC8,	 followed	 by	 slow,	 irreversible	inactivation	through	the	covalent	linkage	at	Cys153.		We	also	demonstrate	that	SAHA-TAP	shows	an	improvement	in	plasma	stability	over	its	parent	compound,	SAHA.	These	 results	 are	 encouraging	 for	 the	 development	 of	 additional	 covalent	 HDAC	inhibitors.	 	 SAHA-TAP	 is,	 like	 SAHA,	 a	 pan-HDAC	 inhibitor.	 	 The	 covalently	 modified	residue,	Cys153,	 is	highly	conserved	among	HDAC	isozymes.	 	The	synthesis	of	SAHA-TAP	does	not	require	modifications	to	the	cap	or	linker	regions	of	SAHA,	and	upon	cleavage	of	the	TAP	moiety,	 the	parent	compound	SAHA	 is	 released.	 	 It	would	be	exciting	 to	see	 this	synthetic	 approach	 used	 on	 other	 hydroxamate-based	 HDAC	 inhibitors,	 like	 the	 HDAC8-specific	inhibitor	PCI-34051	(Fig.	6.2).		
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Figure	6.2:	HDACi	structures	A	comparison	of	(A)	the	pan-HDAC	inhibitor	SAHA,	(B)	the	HDAC8-specific	inhibitor	PCI-34051,	and	(C)	the	prodrug	SAHA-TAP.		
Conclusion		 In	 the	 five	 years	 that	 I’ve	 been	 working	 on	 HDACs,	 I	 have	 witnessed	 significant	advancements	 in	 our	 understanding	 of	 the	 biological	 roles	 these	 enzymes	 play.		Researchers	 continue	 to	 link	 misregulation	 of	 this	 PTM	 to	 disease	 phenotypes,	 like	 the	Cornelia	de	Lange	syndrome.		As	the	biological	importance	of	acetylation	grows,	we	need	to	strengthen	 the	 biochemical	 foundation	 upon	which	 our	 understanding	 of	 the	 function	 of	these	 important	 enzymes	 is	 based.	 	 In	 the	work	 presented	 here,	we	 have	made	 exciting	discoveries,	 like	 the	 determination	 that	HDAC8	 catalyzes	 deacetylation	 of	 recombinantly	expressed,	 singly	 acetylated	 IDH1.	 	 The	 methods	 and	 techniques	 described	 in	 this	document	will	continue	to	be	used	as	tools	to	study	HDAC-catalysis.	
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Appendix	1	
	
Table	A1.1:	chip	round	1	HDAC8	hits	
Protein UNIPROT I.D. Acetylated
RDH16 O75452 Yes
PPP1R12B O60237
RABL3 Q5HYI8 Yes
TCHHL1 Q5QJ38 Yes
CRIP1 P50238 Yes
XAGE2 Q96GT9
ADD1 P35611
FHL3 Q13643
AKR1C2 P52895 Yes
FLAD1 Q8NFF5
C1QTNF9B B2RNN3
BCAR1 P56945 Yes
HSPA1L P34931 Yes
MLIP Q5VWP3
ZNF277 E7EW13
RFK Q969G6 Yes
PRKG2 Q13237
AAMP Q13685
PPIL3 Q9H2H8
LOC653486 Q8TD33
IDH1 O75874 Yes
MS4A3 Q96HJ5
PTEN P60484 Yes
AKR1D1 P51857 Yes
KCNK10 P57789
RPA3 P35244 			
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Table	A1.2:	chip	round	2	HDAC8	hits	identified	in	at	least	2	of	3	analysis	methods	
Protein UNIPROT I.D. Acetylated
ZFYVE16 Q7Z3T8
PFKP Q01813 Yes
PRPF38A Q8NAV1 Yes
RNF121 Q9H920
BOLL Q8N9W6 Yes
RPS19BP1 Q86WX3
TTR P02766
EMD P50402
APPL2 Q8NEU8
ASAP2 O43150 Yes
DTNBP1 Q96EV8 Yes
EIF4B P23588 Yes
KLC2 Q9H0B6 Yes
MAGEA9 P43362
P4HB P07237 Yes
PRDX4 Q13162 Yes
PRMT2 P55345
PSMC3 P17980 Yes
TCOF1 Q13428 Yes 										
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Table	A1.3:	chip	round	2	HDAC8	hits	identified	in	1	of	3	analysis	methods	
Protein Accession 
Number 
RSAD2 NM_080657.4 
NME7 NM_197972.1 
PLCD1 NM_006225.1 
-- BC029877.1 
PRKCDBP BC011585.1 
SHCBP1 NM_024745.2 
LOC400201 XM_378449.1 
RFX4 NM_032491.3 
GPATCH3 BC007767.2 
PLEKHG5 BC015231.1 
VWA8 NM_001009814.1 
TPD52L3 NM_033516.4 
TSPAN4 NM_001025239.1 
QARS NM_005051.1 
PEPD BC028295.1 
BZW1 BC026303.1 
PPM1D NM_003620.2 
MYOC NM_000261.1 
DCD NM_053283.2 
API5 BC017709 
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GALNT3 BC056246.1 
SAV1 NM_021818.2 
ECHDC1 BC003549.1 
CCDC53 NM_016053.1 
FGD2 NM_173558.2 
NOS1AP NM_014697.1 
ITIH3 NM_002217.3 
IGKC BC029444.1 
Sim1 Sim1 
THEMIS2 BC081568.1 
SYN3 BC075065.2 
HSPA13 NM_006948.4 
PLEKHA8 BC053990.1 
SMYD5 NM_006062.1 
APIP BC017594.2 
BBX NM_020235.2 
BLVRA NM_000712.3 
C11orf16 BC027865.1 
C16orf70 NM_025187.3 
CTSS BC002642.2 
DDHD1 NM_030637.1 
DKK1 NM_012242.2 
ERP27 NM_152321.1 
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ESM1 NM_007036.3 
FAM9C NM_174901.3 
GABPB2 NM_144618.1 
GAGE8 NM_012196.1 
IFIT5 NM_012420.1 
ISCA2 NM_194279.1 
ITFG2 BC013399.2 
KRTAP19-5 NM_181611.1 
LCN8 NM_178469.3 
LETM2 BC029541.1 
ND BC024211.2 
ND NM_022406.1 
ND NM_003363.2 
ND BC021720.2 
ND NM_018025.2 
ND NM_024726.3 
NUAK2 NM_030952.1 
PCLO BC001304.1 
POMK NM_032237.2 
RASSF1 NM_170713.1 
SCIN NM_033128.1 
SLC10A1 NM_003049.1 
SLC39A6 BC039498.1 
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SNAP47 BC018760.1 
SSU72 NM_014188.2 
STXBP2 BC002869.2 
TAPBP NM_172208.1 
TSPAN4 NM_001025239.1 
TXNDC8 NM_001003936.1 
VSTM2L BC033818.1 
WDR34 BC011874.2 
ZFP64 BC012759.2 
ZFP92 ZFP92 
ZIM2 NM_015363.3 
ZNF641 BC018090.1 
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Table	A1.4:	chip	round	2	HDAC11	hits	*This	entry	 is	 for	an	uncharacterized	gene	product	 from	brain	 tissue,	 and	 the	 supplied	 identification	 is	 the	NCBI	Accession	Number.	
Protein UNIPROT I.D. Acetylated	
ZFYVE16 Q7Z3T8 		
GPATCH1 Q9BRR8 Yes	
CCDC6 Q16204 		
IGFLR1 Q9H665 		
UBE3A Q96GR7 		
INO80E Q8NBZ0 		
NIF3L1 Q9GZT8 Yes	
C11orf57 Q6ZUT1 		
ZNF641 Q96N77 Yes	
UIMC1 Q96RL1 Yes	
CHIC2 Q9UKJ5 		
TCAP O15273 		
ZNF175 Q9Y473 		
GOT1 P17174 Yes	
INTU Q9ULD6 Yes	
LUC7L Q9NQ29 Yes	
-- BC029877.1* 		
NEK4 P51957 Yes	
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ZBTB21 Q9ULJ3 Yes	
EIF5 P55010 Yes	
AP3M2 P53677 Yes	
CNP P09543 Yes	
CEBPZ Q03701 Yes	
DNAJB2 P25686 		
C2orf47 Q8WWC4 Yes			
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Appendix	2	
General Experimental Details:  All chemicals were purchased from commercial suppliers 
(Sigma-Aldrich, Acros Organics, TCI America, Fisher Scientific) and were used without further 
purification.  All reactions were carried out under N2 in oven-dried glassware.  E.  Merck silica 
gel (60, particle size 0.040-0.063 mm) was used for flash chromatography, which was 
performed using a CombiFlash Rf 200 automated system from TeledyneISCO (Lincoln, NE, 
USA).  NMR spectra were recorded on a Varian FT 400 MHz NMR instrument.  Small molecule 
mass spectrometry (MS) was performed at the Molecular Mass Spectrometry Facility (MMSF) in 
the Department of Chemistry and Biochemistry at the University of California, San Diego. 
 
 
 
 (2,5-Dimethoxy-3,4,6-trimethylphenyl)methanol (4).  2,5-Dimethoxy-3,4,6-
trimethylbenzaldehyde2 (1.28 g, 6.2 mmol) was dissolved in anhydrous DMF (10 mL).  A 
separate solution of LiAlH4 (0.35 g, 9.23 mmol) in anhydrous DMF (40 mL) was prepared.  The 
first suspension was added to the LiAlH4 suspension slowly over ice, and the reaction was held 
at 0 °C for 1 h.  The reaction was quenched by the addition of MeOH (10 mL) followed by water 
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(15 mL).  The solvent was removed via rotary evaporation, and the resulting residue was 
dissolved in CH2Cl2 (100 mL) and washed with 1 M HCl (2×100 mL).  The organic layer was 
collected, dried over MgSO4, filtered, and concentrated via rotary evaporation.  The resulting 
crude product was purified by silica gel chromatography eluting 30-50% EtOAc in hexanes to 
afford 4 in 85% yield (1.10 g, 5.2 mmol).  1H NMR (400 MHz, CDCl3)  δ 4.73 (d, J = 6.0 Hz, 2H), 
3.74 (s, 3H), 3.65 (s, 3H), 2.32 (s, 3H), 2.20 (s, 3H), 2.18 (s, 3H), 2.04 (t, J = 6.0 Hz, 1H).   
1-(Bromomethyl)-2,5-dimethoxy-3,4,6-trimethylbenzene (5).  4 (0.50 g, 2.4 mmol) was 
dissolved in CH2Cl2 (25 mL) and cooled on ice before the addition of PPh3 (0.81 g, 3.1 mmol) 
and NBS (0.55 g, 3.1 mmol).  After 0.5 h, the solvent was removed via rotary evaporation, and 
the product was purified by silica gel chromatography eluting 5% EtOAc in hexanes to afford 5 
in 85% yield (0.55 g, 2.0 mmol).  1H NMR (400 MHz, CDCl3)  δ 4.65 (s, 2H), 3.82 (s, 3H), 3.65 
(s, 3H), 2.32 (s, 3H), 2.20 (s, 3H), 2.18 (s, 3H). 
2-(Bromomethyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione (6).  5 (0.30 g, 1.1 mmol) 
was dissolved in MeCN (6 mL).  A separate solution of ceric ammonium nitrate (CAN) (1.57 g, 
2.9 mmol) dissolved in H2O (4 mL) was prepared.  This solution was added to the first solution 
slowly.  After 4 h, water (20 mL) was added to the solution and an extraction with CH2Cl2 (3×30 
mL) was preformed.  The organic layer was collected, dried over MgSO4, and concentrated by 
rotary evaporation.  The resulting crude product was purified by silica gel chromatography 
eluting 2% EtOAc in hexanes to afford 6 in 34% yield (0.09 g, 0.4 mmol).  1H NMR (400 MHz, 
CDCl3)  δ 4.32 (s, 2H), 2.09 (s, 3 H), 2.03-2.02 (m, 6H). 
N1-Phenyl-N8-((2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)methoxy)octanediamide 
(SAHA-TAP).  SAHA (0.06 g, 0.2 mmol) was dissolved in MeOH (2 mL).  To this was added 6 
(0.07 g, 0.3 mmol) followed by 40% (w/v) NaOH (0.02 mL) dropwise.  The reaction was held at 
RT for 18 h.  The solvent was then removed via rotary evaporation.  The resulting residue was 
dissolved in H2O (1 mL) and acidified to pH 1 dropwise with 1 M HCl.  An extraction was then 
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preformed with EtOAc (3×15 mL).  The organic layer was collected, dried over MgSO4, filtered, 
and concentrated by rotary evaporation.  The resulting crude product was purified by silica gel 
chromatography eluting 50% EtOAc in hexanes to afford SAHA-TAP in 74% yield (0.08 g, 0.2 
mmol).  1H NMR (400 MHz, CDCl3)  δ (br, 1H, NH), 8.17 (br, 1H, NH), 7.52 (d, J = 7.6 Hz, 2H), 
7.25 (t, J = 7.6 Hz, 2H), 7.04 (t, J = 7.2 Hz, 1 H), 4.83 (s, 2H), 2.29 (t, J = 6.8 Hz, 2H), 2.15 (s, 
3H), 2.04-2.03 (m, 2H), 1.96 (s, 6 H), 1.66-1.58 (m, 4H), 1.31-1.29 (m, 4H).  13C NMR (100 
MHz, CDCl3)  δ 187.72, 186.43, 172.21, 171.61, 146.04, 141.27, 140.87, 138.41, 136.12, 
129.08, 124.29, 120.09, 68,78.  37.46, 33.04, 33.04, 28.76, 28.68, 25.53, 25.23, 12.89, 12.69, 
12.60.  HRMS (ESI) calcd for [C24H30N2O5Na]+: 449.2047; Found: 449.2049. 
 
N1-(Benzyloxy)-N8-phenyloctanediamide (SAHA-OBn).  SAHA (0.05 g, 0.2 mmol) was 
dissolved in MeOH (2 mL).  To this was added benzyl bromide (0.03 mL, 0.3 mmol) followed by 
40% (w/v) NaOH (0.04 mL) dropwise.  The reaction was held at RT for 18 h.  The solvent was 
then removed via rotary evaporation.  The resulting residue was dissolved in H2O (3 mL) and 
acidified to pH 1 dropwise with 1 M HCl.  An extraction was then preformed with EtOAc (3×15 
mL).  The organic layer was collected, dried over MgSO4, filtered, and concentrated by rotary 
evaporation.  The resulting crude product was purified by silica gel chromatography eluting 50-
75% EtOAc in hexanes to afford SAHA-OBn in 46% yield (0.03 g, 0.09 mmol).  1H NMR (400 
MHz, CD3OD)  δ 7.53 (d, J = 8.4 Hz, 2H), 7.41-7.32 (m, 5H), 7.29 (t, J = 7.2 Hz, 1H), 7.07 (td, J1 
= 7.6 Hz, J2 = 1.2 Hz), 4.83 (s, 2H), 2.35 (t, J = 7.6 Hz, 2H), 2.05 (t, J = 7.6 Hz, 2H), 1.68 (p, J = 
7.2 Hz, 2H), 1.59 (p, J = 7.2 Hz, 2H), 1.41-1.29 (m, 4H).  HRMS (ESI) calcd for 
[C21H26N2O3Na]+: 377.1834; Found: 377.1836. 
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 SAHA SAHA-TAP SAHA-OBn 
HDAC-1 34 371 >10,000 
HDAC-2 5 255 >10,000 
HDAC-3 40 149 >10,000 
HDAC-6 11 23 >10,000 
HDAC-8 1337 3842 >10,000 
Table	A2.1:	Supplementary	Table	1.			Apparent	IC50	values	(nM)	of	SAHA,	SAHA-TAP,	and	SAHA-OBn	against	several	HDAC	isoforms	as	determined	using	an	in	vitro	fluorescence	based	assay.	
 
 
Table	A2.2:	Supplementary	Table	2.			Fragment	 Ion	 Table	 (y	 ion	 series)	 of	 the	 monoisotopic	 mass	 for	 the	 tryptic	 fragment	(DEASGFCYLNDAVLGILR)	of	HDAC-8	(WT	and	treated).	 	The	expected	mass	y	ions	12-20	are	highlighted	 in	yellow,	indicative	of	a	covalent	modification	of	Cys153	with	the	SAHA-TAP	promoiety.	 	
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Figure	A2.1:	Supplementary	Figure	1.			Amino	 acid	 sequence	 alignment	 of	 human	 HDAC	 enzymes.	 	 Conserved	 residues	 amongst	 all	 isoforms	 are	highlighted	 in	 yellow,	 and	 the	 only	 Cys	 conserved	 in	 all	 isoforms	 is	 highlighted	 in	 green.	 	 Amino	 acids	involved	in	the	formation	of	the	active	site	pocket	are	indicated	by	the	orange	bar.		Adapted	from	Furumai,	et	al.1	
 
 
Figure	A2.2:	Supplementary	Figure	2.			HPLC	trace	of	SAHA	(black),	SAHA-TAP	(blue),	and	SAHA-TAP	after	incubation	in	HEPES	(50	mM,	pH	7.4)	for	24	h	at	37	°C	(red).		Retention	times	are	10.7	min	for	SAHA	and	14.7	min	for	SAHA-TAP. 
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Figure	A2.3	Supplementary	Figure	3.			Activation	of	SAHA-TAP	by	Cys153	in	HDAC-8.		Cys153	can	be	covalently	modified,	leading	to	release	of	SAHA.	
 
 
 
 
Figure	A2.4:	Supplementary	Figure	4.			MS/MS	fragmentation	spectrum	for	the	WT	HDAC-8	tryptic	fragment,	DEASGFCYLNDAVLGILR.		The	y	series	ions	detected	are	indicated	by	dashed	lines.	
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Figure	A2.5:	Supplementary	Figure	5.			
MS/MS fragmentation spectrum for the SAHA-TAP treated HDAC-8 tryptic fragment, 
DEASGFCYLNDAVLGILR.  The y series ions detected are indicated by dashed lines.  The y12 
ion shows the mass increase expected for covalent attachment of the SAHA-TAP promoiety. 
 
 
Figure	A2.6:	Supplementary	Figure	6.			WT	HDAC8	progress	curves	at	varying	concentrations	of	(a)	SAHA	(0-8	µM)	and	(b)	SAHA-OBn	(0-10	µM).	
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Figure	A2.7:	Supplementary	Figure	7.			Dependence	of	the	Cys153Ala	HDAC8	(2	µM)	initial	rate	on	the	concentration	(0-16	µM)	of	SAHA-TAP.	
 
 
 
Figure	A2.8:	Supplementary	Figure	8.			Cys153Ala	HDAC8	progress	curves	at	varying	concentrations	of	(a)	SAHA	(0-8	µM)	and	(b)	0	( ),	2	( ),	4	( ),	or	10	( )	µM	SAHA-OBn.	
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Figure	A2.9:	Supplementary	Figure	9.			HPLC	 trace	of	 SAHA-TAP	after	 incubation	 in	human	plasma	at	37	 °C	at	0	min	 (green)	 and	120	min	 (blue).		HPLC	trace	of	SAHA	after	incubation	in	human	plasma	at	37	°C	at	0	min	(red)	and	120	min	(black).	
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